[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 719
1. Nakamura M, Kubo N, Morimoto J, Tanaka H, Muguruma K, Amano R, Noda E, Inoue T, Takashima T, Yamada N, Yashiro M, Yamashita Y, Maeda K, Onoda N, Sawada T, Nakata B, Ohira M, Ishikawa T, Hirakawa K: [A case of type 4 gastric cancer with positive peritoneal lavage cytology, which relapsed at the peritoneum at the time of seven years and eight months after resection]. Gan To Kagaku Ryoho; 2010 Nov;37(12):2436-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of type 4 gastric cancer with positive peritoneal lavage cytology, which relapsed at the peritoneum at the time of seven years and eight months after resection].
  • Upper digestive endoscopy showed a giant fold at the greater curvature stomach and diffused edematous gastric mucosa.
  • Abdominal contrast CT demonstrated a significant thickening of the gastric wall and a large number of lymph node swelling.
  • A clinical finding was Stage IIIB (T3N2M0) Type 4 gastric cancer of poorly differentiated adenocarcinoma.
  • [MeSH-major] Adenocarcinoma, Scirrhous / pathology. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21224598.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


2. Yonemura Y, Wu CC, Fukushima N, Honda I, Bandou E, Kawamura T, Kamata T, Kim BS, Matsuki N, Sawa T, Noh SH, East Asia Surgical Oncology Group: Randomized clinical trial of D2 and extended paraaortic lymphadenectomy in patients with gastric cancer. Int J Clin Oncol; 2008 Apr;13(2):132-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized clinical trial of D2 and extended paraaortic lymphadenectomy in patients with gastric cancer.
  • BACKGROUND: The survival of patients with advanced gastric cancer after D2 dissection is still poor.
  • METHODS: Patients enrolled in the study had potentially curable gastric adenocarcinoma at an advanced stage.
  • Seven patients (5.2%) in the D2 and 15 (11.2%) in the D4 group died of causes other than gastric cancer recurrence.
  • CONCLUSION: Prophylactic D4 dissection is not recommended for patients with potentially curable advanced gastric cancer.
  • [MeSH-major] Adenocarcinoma / surgery. Gastrectomy / methods. Lymph Node Excision / methods. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2004 Jul 15;22(14):2767-73 [15199090.001]
  • [Cites] Lancet Oncol. 2006 Apr;7(4):309-15 [16574546.001]
  • [Cites] Lancet. 1996 Apr 13;347(9007):995-9 [8606613.001]
  • [Cites] Surg Today. 1994;24(6):488-93 [7919729.001]
  • [Cites] Surgery. 1998 May;123(5):573-8 [9591011.001]
  • [Cites] Lancet. 1995 Mar 25;345(8952):745-8 [7891484.001]
  • [Cites] J Clin Oncol. 2004 Jun 1;22(11):2069-77 [15082726.001]
  • [Cites] Jpn J Surg. 1981 Mar;11(2):127-39 [7300058.001]
  • [Cites] Minerva Chir. 2002 Oct;57(5):641-7 [12370665.001]
  • [Cites] Arch Surg. 1987 Nov;122(11):1347-51 [3675199.001]
  • [Cites] Gastric Cancer. 1999 Nov;2(3):179-185 [11957093.001]
  • [Cites] Hepatogastroenterology. 2006 May-Jun;53(69):389-94 [16795979.001]
  • [Cites] Gastric Cancer. 2004;7(4):196-201; discussion 201-203 [15616767.001]
  • [Cites] Hepatogastroenterology. 1999 Jul-Aug;46(28):2635-42 [10522056.001]
  • [Cites] Br J Surg. 2005 Jan;92(1):5-13 [15635680.001]
  • [Cites] J Thorac Cardiovasc Surg. 1997 Oct;114(4):544-51 [9338639.001]
  • [Cites] Br J Surg. 2004 Mar;91(3):283-7 [14991627.001]
  • (PMID = 18463957.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] Japan
  •  go-up   go-down


3. Akagi J, Masuda Y, Takai E, Takemoto T, Fukami K, Yagishita Y: [Long-term survival case of advanced gastric cancer with paraaortic lymph node metastasis and peritoneal metastasis from S-1/CDDP combination therapy after reductive operation]. Gan To Kagaku Ryoho; 2008 Feb;35(2):295-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Long-term survival case of advanced gastric cancer with paraaortic lymph node metastasis and peritoneal metastasis from S-1/CDDP combination therapy after reductive operation].
  • A 72-year-old female patient with type 5 gastric cancer in the upper gastric region underwent surgery.
  • Surgical and pathological findings were poorly differentiated adenocarcinoma, INFbeta, pT3(SE), PM (-), DM (-), ly0, v2, sN3 (#7, #9, #16a1-a2), M0, stage IV.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18281768.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


Advertisement
4. Charalabopoulos K, Kotsalos A, Batistatou A, Charalabopoulos A, Peschos D, Vezyraki P, Kalfakakou V, Metsios A, Charalampopoulos A, Macheras A, Agnantis N, Evangelou A: Serum and tissue selenium levels in gastric cancer patients and correlation with CEA. Anticancer Res; 2009 Aug;29(8):3465-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum and tissue selenium levels in gastric cancer patients and correlation with CEA.
  • MATERIALS AND METHODS: In eighty patients who had been operated on for primary gastric cancer, serum Se and carcinoembryonic antigen (CEA) levels were measured preoperatively using a fluorometric and immunoradiometric assay (IRMA), respectively.
  • The serum CEA was 12+/-1.9 U ml(-1) in the gastric cancer patients and 2.1 U ml(-1) in the control group (p<0.001).
  • There was no correlation between serum/tissue Se concentration and disease stage/histological type or gender in the patient group.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / blood. Carcinoembryonic Antigen / blood. Intestinal Neoplasms / metabolism. Selenium / metabolism. Stomach Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. SELENIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19661375.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; H6241UJ22B / Selenium
  •  go-up   go-down


5. Schafmayer C, Jürgens G, Jürgens I, Klomp HJ, Fändrich F, Kahlke V: [Long-term survival of curatively operated gastric cancer: influence of the gender and splenectomy]. Zentralbl Chir; 2007 Dec;132(6):515-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Long-term survival of curatively operated gastric cancer: influence of the gender and splenectomy].
  • [Transliterated title] Langzeitüberleben nach kurativer Magenkarzinomoperation: Bedeutung des Geschlechts und der Splenektomie.
  • BACKGROUND: Despite advances in operative technique long-term survival of curatively operated gastric cancer patients still remains poor with 5-year-survival of 25 %.
  • Thus, the question arises as to how far gender and splenectomy influence the long time-survival after curative gastric cancer surgery.
  • METHODS: In a retrospective analysis of 505 patients with gastric cancer who had been treated between the years 1992 and 2002, a curative resection, i. e.
  • R0, could be performed in 243 patients (48.1 %) with a definite classified tumour stadium according to the UICC (1997).
  • Multivariate analysis revealed only the tumour stage as a predictor for long time-survival in men, whereas in women the extend of lymphadenectomy and sepsis also influenced long time-survival.
  • CONCLUSION: Long time-survival of curatively operated gastric cancer patients is gender dependent in terms of splenectomy.
  • [MeSH-major] Adenocarcinoma / mortality. Adenocarcinoma / surgery. Postoperative Complications / mortality. Splenectomy. Stomach Neoplasms / mortality. Stomach Neoplasms / surgery. Survivors / statistics & numerical data

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18098079.001).
  • [ISSN] 0044-409X
  • [Journal-full-title] Zentralblatt für Chirurgie
  • [ISO-abbreviation] Zentralbl Chir
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


6. Iizuka T, Kikuchi D, Hoteya S, Yahagi N: The acetic acid + indigocarmine method in the delineation of gastric cancer. J Gastroenterol Hepatol; 2008 Sep;23(9):1358-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The acetic acid + indigocarmine method in the delineation of gastric cancer.
  • BACKGROUND AND AIM: For the purpose of precise preoperative diagnosis that ensures complete endoscopic resection, it is important to accurately determine the lateral spread of gastric cancer lesions.
  • This paper reports its usefulness in the determination of lateral spread of gastric cancer before endoscopic submucosal dissection (ESD).
  • METHODS: The present study was conducted in 114 patients who were operated on for an early-stage gastric cancer, after determining the lateral spread of cancerous lesions by the AI method, between September 2005 and December 2006.
  • CONCLUSION: The present study stresses that the AI method should be used to conduct ESD more safely and accurately in patients with well or moderately differentiated adenocarcinoma.
  • [MeSH-major] Acetic Acid. Adenocarcinoma / pathology. Coloring Agents. Gastric Mucosa / pathology. Gastroscopy. Indigo Carmine. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. INDIGO .
  • Hazardous Substances Data Bank. ACETIC ACID .
  • Hazardous Substances Data Bank. Indigotindisulfonate sodium .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18853994.001).
  • [ISSN] 1440-1746
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Coloring Agents; D3741U8K7L / Indigo Carmine; Q40Q9N063P / Acetic Acid
  •  go-up   go-down


7. Dassen AE, Lemmens VE, van de Poll-Franse LV, Creemers GJ, Brenninkmeijer SJ, Lips DJ, Vd Wurff AA, Bosscha K, Coebergh JW: Trends in incidence, treatment and survival of gastric adenocarcinoma between 1990 and 2007: a population-based study in the Netherlands. Eur J Cancer; 2010 Apr;46(6):1101-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trends in incidence, treatment and survival of gastric adenocarcinoma between 1990 and 2007: a population-based study in the Netherlands.
  • BACKGROUND: Survival of gastric cancer in the Western world remains poor.
  • We conducted a retrospective population-based study to evaluate trends in incidence, treatment and outcome of gastric adenocarcinoma.
  • METHODS: All patients diagnosed with gastric adenocarcinoma during 1990-2007 in the Dutch Eindhoven Cancer Registry area were included (n=4,797).
  • Stage distribution worsened over time among patients with cardia (stages I and II: 32% in 1990-1993 and 22% in 2006-2007, p=0.005) and non-cardia (stage IV: 33% in 1990-1993 and 40% in 2006-2007, p=0.0003) cancer.
  • Age and stage had significant influence on survival after stratification for tumour localisation.
  • After adjustments for relevant factors (i.e. stage), the risk of death decreased since the late 90s for patients with a cardia tumour (hazard ratio 0.8, p=0.01).
  • [MeSH-major] Adenocarcinoma. Stomach Neoplasms

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20219351.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  •  go-up   go-down


8. Lerut T, Coosemans W, Decker G, De Leyn P, Moons J, Nafteux P, Van Raemdonck D: Surgical techniques. J Surg Oncol; 2005 Dec 1;92(3):218-29
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Adenocarcinoma of the esophagus and gastroesophageal junction (GEJ) has shown a remarkable increase during recent decades.
  • Most patients are present with advanced stage disease, reflecting transmural growth and metastasis to lymph nodes at the time of diagnosis.
  • It is not known whether performing a three-field lymph node dissection is beneficial for patients with adenocarcinoma of the distal esophagus.
  • [MeSH-major] Adenocarcinoma / surgery. Esophageal Neoplasms / surgery. Esophagectomy / methods. Esophagogastric Junction
  • [MeSH-minor] Anastomosis, Surgical. Gastric Emptying. Humans. Laparotomy. Lymph Node Excision. Postoperative Complications. Survival Rate. Thoracotomy

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Wiley-Liss, Inc.
  • (PMID = 16299783.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 59
  •  go-up   go-down


9. Ilias EJ, Malheiros CA, Kassab P, Castro OA: [Simulation of D1 lymphadenectomy in patients submitted to D2 lymphadenectomy. Prospective study of 57 patients with gastric adenocarcinoma]. Rev Assoc Med Bras (1992); 2006 Jul-Aug;52(4):270-2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Simulation of D1 lymphadenectomy in patients submitted to D2 lymphadenectomy. Prospective study of 57 patients with gastric adenocarcinoma].
  • [Transliterated title] Linfadenectomia no adenocarcinoma gástrico.
  • BACKGROUND: To simulate a D1 lymphadenectomy in 57 patients who had already been submitted to D2 lymphadenectomy, and analyze stage migration using the Japanese Gastric Cancer Association (JGCA) staging system.
  • All patients were re-staged based on the new data, in order to evaluate the stage migration according to the JGCA staging system.
  • In IA, IB and II tumors, there were no changes in the stage after simulation of D1 lymphadenectomy.
  • In ten IIIA tumors, three migrated to stage II and IB; in 21 tumors staged as IIIB, a migration was observed in 18; all stage IV tumors migrated to IIIB after the D1 simulation.
  • CONCLUSION: a) D2 lymphadenectomy is important for the correct staging of gastric cancer;.
  • b) simulation of D1 lymphadenectomy changed the stage of advanced tumors, particularly in stages IIIA, IIIB, and IV;.
  • [MeSH-major] Adenocarcinoma. Gastrectomy. Lymph Node Excision / methods. Stomach Neoplasms

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16967148.001).
  • [ISSN] 0104-4230
  • [Journal-full-title] Revista da Associação Médica Brasileira (1992)
  • [ISO-abbreviation] Rev Assoc Med Bras (1992)
  • [Language] por
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


10. Unal B, Kocer B, Altun B, Surmeli S, Aksaray S, Balci M, Ozlu B, Cengiz O: Serum neopterin as a prognostic indicator in patients with gastric carcinoma. J Invest Surg; 2009 Nov-Dec;22(6):419-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum neopterin as a prognostic indicator in patients with gastric carcinoma.
  • PURPOSE: To evaluate the possible association between serum neopterin level and clinical and laboratory findings and their prognostic value of patients with gastric carcinoma.
  • RESULTS: Mean neopterin levels were 15.26 +/- 11.46 nmol/L in patients with gastric carcinoma and 9.87 +/- 2.90 nmol/L in the control group.
  • Serum neopterin concentrations were significantly higher in patients with gastric carcinoma than in the control group.
  • The number of patients with elevated neopterin level was significantly correlated with stage, gastric wall involvement, the number of metastatic lymph nodes, and the level of serum CRP.
  • CONCLUSIONS: Serum neopterin levels were elevated in patients with advanced gastric cancer and correlated with prognostic parameters and overall survival.
  • Moreover, neopterin measured at the time of diagnosis can be used to predict the survival of gastric carcinoma.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma, Mucinous / diagnosis. Neopterin / blood. Stomach Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20001811.001).
  • [ISSN] 1521-0553
  • [Journal-full-title] Journal of investigative surgery : the official journal of the Academy of Surgical Research
  • [ISO-abbreviation] J Invest Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 670-65-5 / Neopterin; 9007-41-4 / C-Reactive Protein
  •  go-up   go-down


11. Chang HC, Chen YL, Chan CP, Yeh KT, Kuo SJ, Ko CJ, Fang HY: Overexpression of dihydrodiol dehydrogenase as a prognostic marker in resected gastric cancer patients. Dig Dis Sci; 2009 Feb;54(2):342-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of dihydrodiol dehydrogenase as a prognostic marker in resected gastric cancer patients.
  • This study evaluated the correlation between clinicopathological data and DDH expression and the prognostic significance of DDH expression in patients with resected gastric cancer.
  • Between January 1998 and September 2004, we retrospectively enrolled 81 patients who received surgical treatment for gastric cancer.
  • The relationship between DDH expression and clinicopathological data (age, gender, histological type, stage) was analyzed by chi-square analysis.
  • Of patients with overexpressed DDH, 13% had stage I, 24% had stage II, 52% had stage III, and 78% had stage IV tumors.
  • Thus, DDH expression may be useful in identifying high-risk gastric cancer patients and distinguishing future candidates for curative and palliative treatment.
  • [MeSH-major] Adenocarcinoma / enzymology. Biomarkers, Tumor / metabolism. Oxidoreductases / metabolism. Stomach Neoplasms / enzymology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Biochem. 1992 May 1;205(3):1155-62 [1576998.001]
  • [Cites] Chem Biol Interact. 1993 Oct;89(1):1-34 [8221964.001]
  • [Cites] Oncol Rep. 2002 May-Jun;9(3):515-9 [11956619.001]
  • [Cites] Biochem Pharmacol. 1992 Jul 22;44(2):341-9 [1642648.001]
  • [Cites] Oncol Rep. 2004 Oct;12(4):717-23 [15375490.001]
  • [Cites] World J Surg. 2007 Jul;31(7):1458-68 [17516110.001]
  • [Cites] J Biol Chem. 2002 Apr 26;277(17):15035-43 [11842089.001]
  • [Cites] J Gastrointest Surg. 2008 Jun;12(6):1005-14 [17972143.001]
  • [Cites] Biochemistry. 1998 May 12;37(19):6781-90 [9578563.001]
  • [Cites] Int J Cancer. 2008 Feb 1;122(3):603-8 [17943730.001]
  • [Cites] Cancer Chemother Pharmacol. 2004 Oct;54(4):301-7 [15138708.001]
  • [Cites] Clin Cancer Res. 2006 Sep 1;12(17):5112-7 [16951228.001]
  • [Cites] Gastric Cancer. 2004;7(4):196-201; discussion 201-203 [15616767.001]
  • [Cites] Cancer Res. 2001 Mar 15;61(6):2727-31 [11289154.001]
  • [Cites] Int J Cancer. 2004 Aug 20;111(2):246-51 [15197778.001]
  • [Cites] Scand J Gastroenterol. 2007 Sep;42(9):1070-2 [17710672.001]
  • [Cites] Oncol Rep. 2003 Mar-Apr;10(2):271-6 [12579257.001]
  • [Cites] Gynecol Oncol. 2005 Apr;97(1):110-7 [15790446.001]
  • [Cites] Gastric Cancer. 2005;8(2):64-70 [15864711.001]
  • (PMID = 18600452.001).
  • [ISSN] 1573-2568
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 1.- / Oxidoreductases; EC 1.3.1.20 / trans-1,2-dihydrobenzene-1,2-diol dehydrogenase
  •  go-up   go-down


12. Schiesser M, Schneider PM: Surgical strategies for adenocarcinoma of the esophagogastric junction. Recent Results Cancer Res; 2010;182:93-106
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical strategies for adenocarcinoma of the esophagogastric junction.
  • This chapter summarizes the surgical strategies for adenocarcinomas of the distal esophagus, gastric cardia, and subcardial gastric cancer invading the cardia+/-distal esophagus known as adenocarcinomas of the esophagogastric junction (AEG).
  • The different surgical approaches according to the tumor origin, localization, and tumor stage are addressed with particular attention to the extent and type of resection and appropriate lymphadenectomy (LAD).
  • [MeSH-major] Adenocarcinoma / surgery. Esophageal Neoplasms / surgery. Esophagogastric Junction. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20676874.001).
  • [ISSN] 0080-0015
  • [Journal-full-title] Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer
  • [ISO-abbreviation] Recent Results Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  •  go-up   go-down


13. Takada J, Kenno S, Aoki T, Hamada H, Katsuki Y: [A case in which intra-arterial chemotherapy for simultaneous hepatic metastases markedly improved AFP-producing gastric cancer]. Gan To Kagaku Ryoho; 2009 Nov;36(12):2326-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case in which intra-arterial chemotherapy for simultaneous hepatic metastases markedly improved AFP-producing gastric cancer].
  • The prognosis of most hepatic and lymph node metastases in AFP-producing gastric cancer is poor, and despite the use of multimodal therapy, the average survival period is reported to be approximately one year.
  • Described here is one example in which intra-arterial chemotherapy for simultaneous hepatic metastases in AFP-producing gastric cancer achieved a marked improvement.
  • Distal gastrectomy was performed for Type II gastric cancer.
  • L, type 2, 5.5x2.4 cm, tub 2>por 1, pT2 (MP), int, INF b, ly2, v1, pN1, pPM (-), pDM (-), pH1: stage IV.
  • The AFP level before surgery was 801.4 ng/mL and lowered to 65.8 ng/mL after surgery, AFP-producing gastric cancer and simultaneous hepatic metastases (S4, single lesion) was diagnosed based upon imaging examinations.
  • This suggests the possibility that intra-arterial chemotherapy is an effective treatment method for hepatic metastases in AFP-producing gastric cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Stomach Neoplasms / pathology. alpha-Fetoproteins / biosynthesis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20037411.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / alpha-Fetoproteins; 3Z8479ZZ5X / Epirubicin; 50SG953SK6 / Mitomycin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


14. Celikel C, Eren F, Gulluoglu B, Bekiroglu N, Turhal S: Relation of neuroendocrine cells to transforming growth factor-alpha and epidermal growth factor receptor expression in gastric adenocarcinomas: prognostic implications. Pathol Oncol Res; 2007;13(3):215-26
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relation of neuroendocrine cells to transforming growth factor-alpha and epidermal growth factor receptor expression in gastric adenocarcinomas: prognostic implications.
  • The presence of neuroendocrine (NE) cells in gastric adenocarcinoma (GCa) is well documented, however, their significance is controversial.
  • 101 partial or total gastrectomy specimens from patients operated for conventional gastric adenocarcinoma were included in the study.
  • Among histopathologic variables, the presence of NE cells was significantly related to grade, stage and lymph node status.
  • The results of our study suggest that the presence of NE cells may have an effect on the expression of TGF-alpha and EGFR in GCa, and the autocrine mechanism between TGF-alpha and EGFR plays an important role in the prognosis of gastric carcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Neurosecretory Systems / pathology. Receptor, Epidermal Growth Factor / metabolism. Stomach Neoplasms / metabolism. Transforming Growth Factor alpha / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] APMIS. 2002 Feb;110(2):132-9 [12064868.001]
  • [Cites] World J Gastroenterol. 2003 Apr;9(4):858-61 [12679948.001]
  • [Cites] Am J Surg Pathol. 1997 Mar;21(3):327-33 [9060603.001]
  • [Cites] Jpn J Cancer Res. 1990 Jan;81(1):43-51 [2108945.001]
  • [Cites] Cell. 1984 Jun;37(2):357-8 [6327062.001]
  • [Cites] Cancer. 1983 May 1;51(9):1673-81 [6187432.001]
  • [Cites] Am J Surg Pathol. 2006 Aug;30(8):945-53 [16861964.001]
  • [Cites] Cell. 1989 Oct 6;59(1):33-43 [2790960.001]
  • [Cites] Virchows Arch. 2004 Apr;444(4):324-31 [14991403.001]
  • [Cites] Int J Cancer. 1992 May 8;51(2):189-94 [1349007.001]
  • [Cites] Histochem J. 2000 Sep;32(9):551-6 [11127976.001]
  • [Cites] APMIS. 2003 Oct;111(10):931-9 [14616544.001]
  • [Cites] Scand J Gastroenterol. 1992;27(2):155-60 [1561530.001]
  • [Cites] Virchows Arch. 2002 Jan;440(1):85-93 [11942581.001]
  • [Cites] Yale J Biol Med. 1998 May-Aug;71(3-4):325-35 [10461363.001]
  • [Cites] J Neuroendocrinol. 2006 May;18(5):355-60 [16629834.001]
  • [Cites] Cancer. 1988 Sep 15;62(6):1096-104 [3044573.001]
  • [Cites] Histopathology. 1986 Jan;10(1):53-63 [2420694.001]
  • [Cites] Hum Pathol. 1992 Jun;23(6):681-5 [1592392.001]
  • [Cites] Anticancer Res. 1996 Jan-Feb;16(1):283-8 [8615622.001]
  • [Cites] Ann Surg Oncol. 2003 Apr;10(3):234-41 [12679307.001]
  • [Cites] J Cell Biochem. 1986;32(4):293-304 [3543030.001]
  • [Cites] Mod Pathol. 2005 Oct;18(10):1329-35 [15920550.001]
  • [Cites] Annu Rev Biochem. 1984;53:259-92 [6089648.001]
  • [Cites] Mod Pathol. 2004 May;17(5):579-87 [15073595.001]
  • [Cites] J Cancer Res Clin Oncol. 1990;116(2):121-31 [2157713.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2001 Apr;13(4):405-11 [11338071.001]
  • [Cites] Prostate Suppl. 1998;8:74-9 [9690666.001]
  • [Cites] Gastroenterology. 1996 Sep;111(3):783-810 [8780586.001]
  • [Cites] Gastroenterology. 1996 Nov;111(5):1212-23 [8898635.001]
  • [Cites] Pathol Oncol Res. 2004;10(1):47-51 [15029262.001]
  • [Cites] Cancer. 2000 Oct 1;89(7):1418-24 [11013353.001]
  • [Cites] Br J Cancer. 2003 Nov 3;89(9):1766-75 [14583782.001]
  • [Cites] Int J Cancer. 1995 Mar 3;60(5):645-51 [7860139.001]
  • [Cites] Cancer. 1971 Feb;27(2):447-54 [4322466.001]
  • [Cites] Hum Pathol. 1994 Nov;25(11):1114-22 [7959656.001]
  • [Cites] J Pathol. 1993 Feb;169(2):191-201 [8445485.001]
  • [Cites] Oncology. 1992;49(2):157-61 [1574253.001]
  • [Cites] Am J Pathol. 1984 Jun;115(3):458-68 [6375394.001]
  • [Cites] Dig Dis Sci. 2006 Aug;51(8):1371-9 [16868827.001]
  • [Cites] Cancer. 1998 Aug 1;83(3):435-44 [9690535.001]
  • [Cites] Pathol Res Pract. 1993 Mar;189(2):133-7 [8321742.001]
  • (PMID = 17922051.001).
  • [ISSN] 1219-4956
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Chromogranin A; 0 / Gastrins; 0 / Transforming Growth Factor alpha; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


15. Varadhachary G, Ajani JA: Preoperative and adjuvant therapies for upper gastrointestinal cancers. Expert Rev Anticancer Ther; 2005 Aug;5(4):719-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Survival of esophageal, gastrointestinal junction and gastric cancers is poor given that they frequently present with locally advanced or metastatic disease.
  • The incidence of gastrointestinal junction adenocarcinoma is increasing whereas that of squamous cell carcinoma of the esophagus is decreasing.
  • The accuracy of staging has improved with newer diagnostic techniques, including positron emission tomography, endoscopic ultrasound and laparoscopy, and this should be integrated in prospective Phase III clinical trials evaluating neoadjuvant and adjuvant therapies for some esophageal and all gastric carcinomas.
  • Postoperative chemoradiation is favored in the USA for good performance status patients with resected, high-risk gastric or gastroesophageal junction carcinoma (more than Stage IA).
  • The UK-MAGIC trial results, showing survival benefit with perioperative chemotherapy in operable gastric and lower esophageal cancers, probably has an impact on the treatment practice of these cancers in Europe and Asia.
  • Promising results from trials involving preoperative chemoradiation followed by surgery in gastric cancer (pathologic complete response of 20-30%) need to be further evaluated in a Phase III setting and compared with postoperative chemoradiation.
  • Active ongoing research will help us clarify the role of preoperative and adjuvant therapies in esophageal and gastric cancers.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16111471.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 32
  •  go-up   go-down


16. Tan YK, Fielding JW: Early diagnosis of early gastric cancer. Eur J Gastroenterol Hepatol; 2006 Aug;18(8):821-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early diagnosis of early gastric cancer.
  • The prognosis of gastric cancer is closely related to the stage of disease at diagnosis.
  • Early gastric cancer, whereby disease is limited to mucosa and submucosa, confers a survival rate of greater than 90% in 5 years in many centres.
  • Gastric cancer is still a major cause of cancer mortality worldwide.
  • Hence, strategy has been directed to screen symptomatic individuals who are at higher risk of gastric cancer.
  • Most patients with early gastric cancer present with symptoms indistinguishable from benign peptic ulcer disease.
  • Screening for this group of patients improves detection rate of early gastric cancer and therefore its prognosis.
  • There is compelling evidence for the role of H. pylori in the initiation of Correa's cascade (stepwise progression from chronic active gastritis, atrophic gastritis, intestinal metaplasia, dysplasia and finally adenocarcinoma).
  • However, it is not known whether this might effectively prevent gastric cancer in either low or high-risk population.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16825897.001).
  • [ISSN] 0954-691X
  • [Journal-full-title] European journal of gastroenterology & hepatology
  • [ISO-abbreviation] Eur J Gastroenterol Hepatol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 132
  •  go-up   go-down


17. Mousavi SM, Somi MH: Gastric cancer in Iran 1966-2006. Asian Pac J Cancer Prev; 2009 Jul-Sep;10(3):407-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastric cancer in Iran 1966-2006.
  • This literature review was carried out to provide an up-to-date perspective on gastric cancer clinicoepidemiological characteristics, to explain geographical differences, and to define public health priorities for prevention and early detection programs in Iran.
  • Inclusion criteria were published studies on gastric cancer clinical and epidemiological data.
  • The average gastric cancer incidence rates were reported to be 15.2 (8.1 - 49.1) and 6.7(4.9-25.4) per 100,000 in males and females, respectively, with a ratio of 2.3:1 (1.5 - 2.7).
  • More than two thirds of them were diagnosed in stage IV.
  • The trend for gastric cancer cases was increase from 1969 to 2004; antral adenocarcinomawas shifted to cardia adenocarcinoma in this period.
  • The gastric cancer epidemiological aspects have changed during 4 decades; a Western pattern has been started in Iran where the incidence rate of adenocarcinoma of the most proximal cardia region and adjacent gastro-oesophageal junction has increased.
  • Developing a gastric cancer early detection program, investigating gastric cancer risk factors, preventing patient and system delays, and providing national guidelines for treatment and palliation are all recommended.
  • [MeSH-major] Adenocarcinoma / epidemiology. Adenocarcinoma / mortality. Stomach Neoplasms / epidemiology. Stomach Neoplasms / mortality

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19640183.001).
  • [ISSN] 2476-762X
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Thailand
  •  go-up   go-down


18. Saito M, Iwadate M, Higashimoto M, Ono K, Takebayashi Y, Takenoshita S: Expression of phospholipase D2 in human colorectal carcinoma. Oncol Rep; 2007 Nov;18(5):1329-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PLD activity has been reported to be elevated in human breast, gastric, renal cell and colorectal carcinomas, compared with adjacent non-neoplastic tissues.
  • The activity of PLD was also correlated with nuclear grade in breast cancer, tumor size in gastric carcinoma, and nodal involvement and deeper invasion in colorectal carcinoma.
  • Expression level of PLD was significantly correlated with tumor size (P<0.05); it was independent of lymph node metastasis, extent of invasion, pathological classification, distant metastasis and Dukes' stage.
  • [MeSH-minor] Adenocarcinoma, Mucinous / enzymology. Adenocarcinoma, Mucinous / genetics. Adenocarcinoma, Mucinous / pathology. Adult. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / enzymology. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / pathology. Female. Humans. Lymphatic Metastasis / pathology. Male. Middle Aged. Neoplasm Staging. Reverse Transcriptase Polymerase Chain Reaction. Survival Rate

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17914593.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.1.4.- / phospholipase D2; EC 3.1.4.4 / Phospholipase D
  •  go-up   go-down


19. Hsu PK, Shai SE, Wang J, Hsu CP: Esophageal metastasis from occult lung cancer. J Chin Med Assoc; 2010 Jun;73(6):327-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Following esophagectomy, reconstruction with a gastric tube was performed.
  • Pathological examination and immunohisto-chemistry showed infiltration of adenocarcinoma cells with positive thyroid transcription factor 1-staining in the submucosal layer, which indicated metastatic esophageal carcinoma.
  • To the best of our knowledge, this is the first reported case of metastatic esophageal carcinoma from occult lung cancer (AJCC TNM stage TX).

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier. Published by Elsevier B.V. All rights reserved.
  • (PMID = 20603092.001).
  • [ISSN] 1728-7731
  • [Journal-full-title] Journal of the Chinese Medical Association : JCMA
  • [ISO-abbreviation] J Chin Med Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China (Republic : 1949- )
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / TTF1 protein, human
  •  go-up   go-down


21. Ahn JR, Jung M, Kim C, Hong MH, Chon HJ, Kim HR, Jeung HC, Hyung WJ, Lee SS, Chung HC, Noh SH, Rha SY: Prognosis of pN3 stage gastric cancer. Cancer Res Treat; 2009 Jun;41(2):73-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognosis of pN3 stage gastric cancer.
  • PURPOSE: The aim of this study was to determine the prognosis of pN3 stage gastric cancer patients after they have undergone curative resection, and we also wanted to identify the prognostic factors according to the clinico-pathologic features.
  • MATERIALS AND METHODS: Between January 2000 and December 2004, we retrospectively reviewed the medical records of the patients with histologically confirmed pN3 stage gastric cancer.
  • We categorized the pN3 stage patients into 2 groups; one with pN3 only (pN3M0) and the other with pN3 combined with M1 stage (pN3M1) that included peritoneal seeding, hepatic metastasis or para-aortic LN metastasis.
  • RESULTS: Out of 467 patients with stage IV gastric adenocarcinoma who received surgery, 260 patients underwent curative resection and they were pathologically staged as N3.
  • Among these 260 patients, 78 patients were classified as the pN3/M1 stage.
  • The identified predictor for a worse prognosis was an advanced T4 stage (HR: 3.38, 95% CI, 1.4~8.3, p=0.008) for the pN3 patients.
  • CONCLUSION: The survival for the pN3 gastric cancer patients after curative gastrectomy was significantly longer in the pN3/M0 group as compared to that of the pN3/M1 group.
  • An advanced T stage was a predictor for a poor prognosis for the pN3 patients.
  • Therefore, diverse treatment strategies for these heterogeneous pN3 gastric cancer patients are needed for improving their survival.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Surg Oncol. 2007 Feb 1;95(2):118-22 [17262741.001]
  • [Cites] Ann Surg Oncol. 2007 Sep;14(9):2535-42 [17549571.001]
  • [Cites] J Cancer Res Clin Oncol. 2008 Feb;134(2):187-92 [17611776.001]
  • [Cites] N Engl J Med. 2007 Nov 1;357(18):1810-20 [17978289.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Ann Surg Oncol. 2008 Jul;15(7):1959-67 [18369676.001]
  • [Cites] J Gastrointest Surg. 2008 Aug;12(8):1364-9 [18516653.001]
  • [Cites] Arch Surg. 2009 Jan;144(1):38-45; discussion 45 [19153323.001]
  • [Cites] J Surg Oncol. 2009 May 1;99(6):324-8 [19204941.001]
  • [Cites] Crit Rev Oncol Hematol. 2009 Aug;71(2):127-64 [19230702.001]
  • [Cites] World J Surg. 1999 May;23(5):492-7; discussion 497-8 [10085399.001]
  • [Cites] Br J Cancer. 2001 Jan 5;84(1):64-71 [11139315.001]
  • [Cites] Ann Surg Oncol. 2001 Apr;8(3):215-21 [11314937.001]
  • [Cites] Br J Surg. 2002 Nov;89(11):1438-43 [12390389.001]
  • [Cites] Am J Surg. 2004 Apr;187(4):543-6 [15041508.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] J Clin Oncol. 2006 May 10;24(14):2137-50 [16682732.001]
  • (PMID = 19707504.001).
  • [ISSN] 1598-2998
  • [Journal-full-title] Cancer research and treatment : official journal of Korean Cancer Association
  • [ISO-abbreviation] Cancer Res Treat
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2731212
  • [Keywords] NOTNLM ; Advanced gastric cancer / Prognosis / Prognostic factor / Survival / pN3
  •  go-up   go-down


22. Li C, Kim S, Lai JF, Hyung WJ, Choi WH, Choi SH, Noh SH: Advanced gastric carcinoma with signet ring cell histology. Oncology; 2007;72(1-2):64-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advanced gastric carcinoma with signet ring cell histology.
  • BACKGROUND: Gastric signet ring cell carcinoma (SRC) is a histological type based on microscopic characteristics and not on biological behavior.
  • This study compared the clinicopathological features and prognosis of advanced SRC with non-signet ring cell adenocarcinoma (NSRC) of the stomach.
  • METHODS: We reviewed the records of 4,759 consecutive patients diagnosed with advanced gastric adenocarcinoma who were resected surgically from 1987 to 2003.
  • RESULTS: Significant differences were noted in tumor size, Borrmann type, depth of invasion, lymph node metastasis, peritoneal dissemination and TNM stage.
  • CONCLUSIONS: Advanced gastric SRC tends toward deeper tumor invasion and more lymph node and peritoneal metastasis than NSRC.
  • Advanced gastric SRC had a worse prognosis than NSRC.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Signet Ring Cell / pathology. Stomach Neoplasms / pathology


23. Wang YY, Ye ZY, Zhao ZS, Tao HQ, Chu YQ: High-level expression of S100A4 correlates with lymph node metastasis and poor prognosis in patients with gastric cancer. Ann Surg Oncol; 2010 Jan;17(1):89-97
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-level expression of S100A4 correlates with lymph node metastasis and poor prognosis in patients with gastric cancer.
  • BACKGROUND: The present study investigated the clinical significance of S100 calcium binding protein A4 in the development, progression, and metastasis of gastric cancer.
  • METHODS: Tumor tissue, adjacent normal tissue, and lymph node and peritoneal metastases were obtained from patients with gastric cancer, and their gene expression profiles were analyzed by Affymetrix GeneChip HG-U133A2.0 array.
  • The expression of S100A4 was detected by real-time quantitative reverse-transcription polymerase chain reaction (RT-PCR) in gastric tumor tissue and lymph node and peritoneum metastasis.
  • Immunohistochemistry was employed to analyze S100A4 expression in 436 clinicopathologically characterized gastric cancer cases and in corresponding distant metastases from 61 patients.
  • The expression of S100A4 in lymph node and peritoneal metastases was significantly higher than that in gastric tumor tissue.
  • The expression of S100A4 messenger RNA (mRNA) or protein differed significantly among gastric tumor tissue, matched normal gastric mucosa, and lymph node and peritoneal metastases.
  • Further multivariate analysis suggested that depth of invasion, lymph node and distant metastases, tumor-node-metastasis (TNM) stage, and upregulation of S100A4 were independent prognostic indicators for the disease.
  • Expression of S100A4 in gastric cancer is associated significantly with lymph node and distant metastases, and poor prognosis.
  • S100A4 may be a useful marker to predict development, progression, and metastasis of gastric cancer.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Gastric Mucosa / metabolism. S100 Proteins / metabolism. Stomach Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / secondary. Adenocarcinoma / surgery. Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / secondary. Adenocarcinoma, Mucinous / surgery. Adenocarcinoma, Papillary / metabolism. Adenocarcinoma, Papillary / secondary. Adenocarcinoma, Papillary / surgery. Adult. Aged. Aged, 80 and over. Carcinoma, Signet Ring Cell / metabolism. Carcinoma, Signet Ring Cell / secondary. Carcinoma, Signet Ring Cell / surgery. Female. Follow-Up Studies. Gastrectomy. Gene Expression Profiling. Humans. Immunoenzyme Techniques. Lymphatic Metastasis. Male. Middle Aged. Oligonucleotide Array Sequence Analysis. Peritoneal Neoplasms / metabolism. Peritoneal Neoplasms / secondary. Peritoneal Neoplasms / surgery. Prognosis. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Survival Rate

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19820999.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 0 / S100 Proteins; 142662-27-9 / S100A4 protein, human
  •  go-up   go-down


24. Zhou LX, Zhang ZW, Xu ZY: [Surgical treatment and prognosis of gastric stump cancer]. Ai Zheng; 2009 May;28(5):511-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical treatment and prognosis of gastric stump cancer].
  • BACKGROUND AND OBJECTIVE: Gastric stump cancer (GSC) has unique biological behaviors and poor prognosis.
  • Cox multivariate regression analysis showed that clinical stage, pathologic classification, radical resection, peritoneal seeding and liver metastasis were related with the survival of GSC patients.
  • Clinical stage, pathologic classification, radical resection, peritoneal seeding and liver metastasis are independent prognosis factors of GSC.
  • [MeSH-major] Adenocarcinoma / surgery. Gastrectomy / methods. Gastric Stump / surgery. Stomach Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / secondary. Adenocarcinoma, Mucinous / surgery. Adult. Aged. Carcinoma, Signet Ring Cell / pathology. Carcinoma, Signet Ring Cell / secondary. Carcinoma, Signet Ring Cell / surgery. Female. Follow-Up Studies. Humans. Liver Neoplasms / secondary. Male. Middle Aged. Neoplasm Staging. Proportional Hazards Models. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19624880.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


25. Cesana GC, Romano F, Piacentini G, Scotti M, Brenna A, Bovo G, Vaghi M, Aletti G, Caprotti R, Kaufman H, Uggeri F: Low-dose interleukin-2 administered pre-operatively to patients with gastric cancer activates peripheral and peritumoral lymphocytes but does not affect prognosis. Ann Surg Oncol; 2007 Apr;14(4):1295-304
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-dose interleukin-2 administered pre-operatively to patients with gastric cancer activates peripheral and peritumoral lymphocytes but does not affect prognosis.
  • The ability of cancer patients to undergo surgical resection is still the most important prognostic factor for many solid tumors, including gastric adenocarcinoma.
  • The aim of this randomized case-control study is to evaluate the effects of pre-operative low-dose IL-2 treatment on patients with gastric adenocarcinoma who undergo surgery.
  • METHODS: Sixty-eight patients with gastric adenocarcinoma were enrolled in the study and randomized in two groups: 36 patients were pre-treated with IL-2 and 32 underwent surgery without any treatment.
  • A stepwise multivariate analysis revealed that overall survival and relapse-free survival were affected only by stage of tumor and age of patients.
  • CONCLUSIONS: According to our data low-doses of IL-2 administered pre-operatively to patients with gastric cancer activate peripheral and peri-tumoral lymphocytes but did not affect prognosis.
  • [MeSH-major] Adenocarcinoma / immunology. Interleukin-2 / administration & dosage. Lymphocyte Activation / physiology. Lymphocytes, Tumor-Infiltrating / immunology. Stomach Neoplasms / immunology. T-Lymphocytes / immunology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17225981.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interleukin-2
  •  go-up   go-down


26. Wada Y, Yoshida K, Hihara J, Tanabe K, Ukon K: Kidney metastasis of resected early gastric carcinoma: report of a case. Surg Today; 2007;37(3):248-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Kidney metastasis of resected early gastric carcinoma: report of a case.
  • We report a rare case of kidney metastasis of resected early gastric cancer in a 67-year-old man.
  • We performed distal gastrectomy with D2 lymph node dissection for early gastric cancer, which was histologically diagnosed as moderately differentiated adenocarcinoma (T1N0M0, stage IA).
  • However, 1 year 10 months after the operation, we performed partial kidney resection and the lesion was confirmed to be a metastasis of the gastric cancer.
  • This case illustrates the poor prognosis associated with a high preoperative serum CEA level, even if early gastric cancer is resected curatively.
  • [MeSH-major] Adenocarcinoma / secondary. Carcinoembryonic Antigen / blood. Kidney Neoplasms / secondary. Liver Neoplasms / secondary. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 1975 Jul;114(1):30-2 [1142495.001]
  • [Cites] Anticancer Res. 2003 Mar-Apr;23(2C):1701-8 [12820444.001]
  • [Cites] Br J Cancer. 1982 May;45(5):718-27 [7082557.001]
  • [Cites] Jpn J Surg. 1987 Jul;17(4):269-75 [3682435.001]
  • [Cites] Gastric Cancer. 2006;9(2):51-66 [16767357.001]
  • [Cites] Cancer. 1975 Dec;36(6 Suppl):2460-8 [764963.001]
  • [Cites] Gastric Cancer. 2003;6(3):142-5 [14520526.001]
  • [Cites] J Clin Oncol. 2001 Mar 15;19(6):1865-78 [11251019.001]
  • [Cites] Am J Gastroenterol. 1996 Jan;91(1):49-53 [8561143.001]
  • [Cites] World J Surg. 1995 Jan-Feb;19(1):133-7; discussion 137 [7740800.001]
  • (PMID = 17342368.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen
  •  go-up   go-down


27. Sargan I, Motoc A, Vaida MA, Bolintineanu S, Vîscu S: Anatomic and pathological aspects in the pathology of malignant gastric tumors. Rom J Morphol Embryol; 2006;47(2):163-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anatomic and pathological aspects in the pathology of malignant gastric tumors.
  • The geographic area around Timişoara (Banat Region) is situated on the first place in the country as far as the gastric location of cancer is concerned.
  • The authors aimed to deal with the initial stage in the development of gastric cancer, a stage which has been oncologically termed "precancerous damage", and with the neoplastic invasion of the gastric wall.
  • The present paper is based on the 1995-2005 statistics of the IInd Surgical Department of the Timişoara County Hospital, the study group consisting of 802 patients admitted for gastric disorders, 522 of which being later diagnosed with a tumoral pathology.
  • The age for gastric tumoral pathology ranged between 36-88 years in females, and 31-87 years in males.
  • Most gastric carcinomas are adenocarcinoma, 404 (90%) cases--could be classified as follows: 167 cases of tubular adenocarcinoma; 39 cases of papillary adenocarcinoma; 24 cases of mucinous or colloid adenocarcinoma; 141 "signet ring"-cell carcinoma; 33 cases of undifferentiated carcinoma.
  • Attention should be given to precancerous conditions; there was a large number of premalignant or potentially malignant gastric damage: atrophic chronic gastritis (54 cases), intestinal metaplasia (104 cases), and gastric dysplasia (104 cases).
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Biopsy. Female. Helicobacter Infections / pathology. Helicobacter pylori. Humans. Male. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17106525.001).
  • [ISSN] 1220-0522
  • [Journal-full-title] Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
  • [ISO-abbreviation] Rom J Morphol Embryol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


28. Mlkvý P: Multimodal therapy of gastric cancer. Dig Dis; 2010;28(4-5):615-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multimodal therapy of gastric cancer.
  • Adenocarcinoma of the stomach is the 2nd most common cancer worldwide.
  • The 5-year survival rates after curative surgical resection decline from 60-90% in stage I, to 30-50% in stage II and finally drop to only to 10-25% for patients in stage III of this disease.
  • According to certain criteria, early gastric cancer limited to the mucosa or submucosa is indicated for endoscopic mucosal resection.
  • In advanced gastric cancer with surgical approach, the questions of type of resection, extent of lymph node dissection and indication for splenectomy do arise.
  • Chemotherapy is the treatment of choice in stage IV for unresectable disease.
  • Survival rates in resectable gastric cancer are influenced mainly by the depth of invasion through the gastric wall and by the presence or absence of regional lymph node involvement.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 S. Karger AG, Basel.
  • (PMID = 21088412.001).
  • [ISSN] 1421-9875
  • [Journal-full-title] Digestive diseases (Basel, Switzerland)
  • [ISO-abbreviation] Dig Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


29. Liu H, Ubukata H, Tabuchi T, Takemura A, Motohashi G, Nishimura M, Satani T, Hong J, Katano M, Nakada I, Saniabadi AR, Tabuchi T: It is possible that tumour-infiltrating granulocytes promote tumour progression. Oncol Rep; 2009 Jul;22(1):29-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Using immunnostaining, we retrospectively investigated TIGs and FasL in 130 tissue specimens from gastric carcinoma.
  • Further, TIGs were significantly associated with depth of tumour invasion, lymph node metastasis and tumour stage.
  • Calculating the prognostic relevance, in multivariate analysis, TIGs [relative risk (RR)=1.014; 95% CI=1.002-1.027; P=0.015] and tumour stage were statistically significant factors for survival.
  • Our results suggest that TIGs are conveniently measured by the immunostaining method, and possibly serve as an independent factor of prognosis in patients with gastric carcinoma.
  • This is based on the fact that TIGs were significantly associated with tumour stage and shorter survival time.
  • [MeSH-major] Adenocarcinoma / immunology. Granulocytes / immunology. Stomach Neoplasms / immunology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19513501.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / FASLG protein, human; 0 / Fas Ligand Protein
  •  go-up   go-down


30. Lindenmann J, Matzi V, Porubsky C, Maier A, Smolle-Juettner FM: Complete resection of an isolated chest wall metastasis from esophageal carcinoma after transhiatal esophagectomy and gastric pull-up at one and a half-year follow-up. J Thorac Oncol; 2007 Aug;2(8):773-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete resection of an isolated chest wall metastasis from esophageal carcinoma after transhiatal esophagectomy and gastric pull-up at one and a half-year follow-up.
  • METHODS: In February 2004, a 59-year-old male patient was admitted with esophageal adenocarcinoma.
  • A transhiatal esophagectomy and retrosternal gastric pull-up with cervical esophago-gastrostomy were performed.
  • The definitive histopathological staging showed an adenocarcinoma, Union Internationale Contre le Cancer stage I.
  • The surgical biopsy of this lesion confirmed the suspicion of an isolated chest wall metastasis of the resected esophageal adenocarcinoma.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17762347.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Wu Y, Guo E, Yu J, Xie Q, Chen J: High DcR3 expression predicts stage pN2 in gastric cancer. Hepatogastroenterology; 2007 Oct-Nov;54(79):2172-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High DcR3 expression predicts stage pN2 in gastric cancer.
  • METHODOLOGY: This prospective study evaluated the DcR3 tissue status by RT-PCR and its correlation with the lymph node (N) stages in 62 primary gastric cancers.
  • Using ROC analysis, a cut-off level of DcR3 expression at 1.20 was found to be associated with optimal sensitivity and specificity of 62.5% (15/24) and 92.1% (35/38) respectively, in the prediction of stage pN2.
  • Logistic regression analysis for stage pN2 revealed that high DcR3 expression was an independent risk factor.
  • CONCLUSIONS: Gastric cancer patients with high DcR3 expression presented more advanced pN2 disease than those with low DcR3 expression.
  • Preoperative checking DcR3 expression might be an additional approach to imaging modalities for evaluating N stages in gastric cancer to guide the operative procedures.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Receptors, Tumor Necrosis Factor, Member 6b / metabolism. Stomach Neoplasms / metabolism. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Clin Oncol. 2008 Jun;31(3):310 [18546592.001]
  • (PMID = 18251184.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Duplicate Publication; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Receptors, Tumor Necrosis Factor, Member 6b; 0 / TNFRSF6B protein, human
  •  go-up   go-down


32. Isgüder AS, Nazli O, Tansug T, Bozdag AD, Onal MA: Total gastrectomy for gastric carcinoma. Hepatogastroenterology; 2005 Jan-Feb;52(61):302-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Total gastrectomy for gastric carcinoma.
  • BACKGROUND/AIMS: Gastric cancer is one of the most common organ cancers all around the world and surgical resection is essential for treatment.
  • Total gastrectomy is the procedure of choice for treatment of proximal gastric cancer.
  • METHODOLOGY: Thirty-eight gastric cancer patients underwent total gastrectomy in the Third Surgical Clinic of Izmir Ataturk Training and Research Hospital between 1996 and 2001.
  • Age, gender, location of the tumor, histopathological findings, TNM stage, type of anastomosis, operation time, blood transfusions, oral food intake, postoperative hospital stay, morbidity, mortality both early and late, and survival rate were evaluated.
  • Histological types were adenocarcinoma (97.4%), and squamous cell carcinoma (2.6%).
  • TNM stages were: stage la 2.6%, stage II 7.9%, stage IIIa 39.5%, stage IIIb 42.1%, and stage IV 7.9%.
  • Gastric tubes were removed on the fourth postoperative day.
  • 89.5% of our cases were stage III or IV resulting in a low survival rate.
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoma, Squamous Cell / surgery. Gastrectomy. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15783055.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


33. Kostić Z, Cuk V, Ignjatović M, Usaj-Knezević S: [Early complications following radical surgical treatment of patients with gastric adenocarcinoma]. Vojnosanit Pregl; 2006 Mar;63(3):249-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Early complications following radical surgical treatment of patients with gastric adenocarcinoma].
  • BACKGROUND/AIM: Surgical treatment of patients with gastric adenocarcinoma means the total excision of a tumor and the pathways of its spreading with the risk of operational complications as low as possible.
  • The aim of this study was to evaluate the type and frequency of early postoperative complications and mortality after a radical surgical treatment of patients with gastric adenocarcinoma.
  • Three of four deaths occured in patients older than 70 years, with the stage III and IV of the disease, and in all of them total gastrectomy with splenectomy was performed.
  • CONCLUSION: Radical surgical treatment of patients with gastric adenocarcinoma might be done with an acceptable morbidity and mortality if it is performed by the surgeons with the experience in D2 lymphadenectomy technique.
  • [MeSH-major] Adenocarcinoma / surgery. Postoperative Complications. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16605190.001).
  • [ISSN] 0042-8450
  • [Journal-full-title] Vojnosanitetski pregled
  • [ISO-abbreviation] Vojnosanit Pregl
  • [Language] srp
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Serbia and Montenegro
  •  go-up   go-down


34. Silva EM, Begnami MD, Fregnani JH, Pelosof AG, Zitron C, Montagnini AL, Soares FA: Cadherin-catenin adhesion system and mucin expression: a comparison between young and older patients with gastric carcinoma. Gastric Cancer; 2008;11(3):149-59
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cadherin-catenin adhesion system and mucin expression: a comparison between young and older patients with gastric carcinoma.
  • BACKGROUND: Young patients are thought to develop gastric carcinomas with a molecular genetic profile that is distinct from that of gastric carcinomas occurring at a later age.
  • METHODS: The clinicopathological features and overall survival data of 62 young patients (age <or=40 years) with gastric cancer were retrospectively reviewed from hospital records and compared with the data for 453 older patients (age >40 years).
  • Only stage, tumor size, and tumor location persisted as prognostic factors for patients with gastric cancer.
  • CONCLUSION: Biological markers of cellular adhesion and gastric differentiation were differently expressed in young and older patients.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Stomach Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2003 Aug 28;22(36):5716-9 [12944922.001]
  • [Cites] Glycoconj J. 1996 Oct;13(5):693-707 [8909996.001]
  • [Cites] Br J Surg. 2002 Feb;89(2):236-44 [11856141.001]
  • [Cites] Ann Surg Oncol. 2002 Nov;9(9):887-93 [12417511.001]
  • [Cites] Cancer Res. 1998 Sep 15;58(18):4086-9 [9751616.001]
  • [Cites] Ann Surg Oncol. 2000 Aug;7(7):515-9 [10947020.001]
  • [Cites] Cancer Res. 1987 Nov 1;47(21):5715-24 [3664476.001]
  • [Cites] Cancer Res. 1993 Feb 1;53(3):641-51 [7678777.001]
  • [Cites] Hum Mol Genet. 1993 Jun;2(6):803-4 [8353498.001]
  • [Cites] Gastroenterology. 1994 Feb;106(2):353-61 [7905449.001]
  • [Cites] Nature. 1998 Mar 26;392(6674):402-5 [9537325.001]
  • [Cites] Ann Surg. 1988 Nov;208(5):593-6 [2847662.001]
  • [Cites] Ann Surg. 1993 Nov;218(5):583-92 [8239772.001]
  • [Cites] N Engl J Med. 2001 Jun 21;344(25):1904-9 [11419427.001]
  • [Cites] Cancer Res. 2004 Feb 15;64(4):1255-65 [14973074.001]
  • [Cites] Cancer. 1987 Apr 1;59(7):1362-5 [3815307.001]
  • [Cites] Histopathology. 2001 Aug;39(2):141-9 [11493330.001]
  • [Cites] Int J Cancer. 1996 Jun 21;69(3):184-9 [8682585.001]
  • [Cites] J Clin Invest. 1991 Mar;87(3):1037-45 [1999484.001]
  • [Cites] Cancer Lett. 2003 Nov 10;201(1):97-106 [14580691.001]
  • [Cites] Br J Surg. 2003 Jan;90(1):95-101 [12520583.001]
  • [Cites] Hum Mol Genet. 1999 Apr;8(4):607-10 [10072428.001]
  • [Cites] Acta Pathol Microbiol Scand. 1965;64:31-49 [14320675.001]
  • [Cites] Gastroenterology. 1997 Jan;112(1):46-54 [8978342.001]
  • [Cites] J Biol Chem. 2001 May 25;276(21):18327-36 [11278439.001]
  • [Cites] N Engl J Med. 1995 Jul 6;333(1):32-41 [7776992.001]
  • [Cites] Cancer. 1999 Jun 15;85(12):2506-11 [10375095.001]
  • [Cites] J Am Coll Surg. 1999 Jan;188(1):22-6 [9915238.001]
  • [Cites] J Pathol. 1996 Oct;180(2):160-5 [8976874.001]
  • [Cites] J Pathol. 2007 Jan;211(1):45-51 [17117405.001]
  • [Cites] Int J Cancer. 1998 Apr 17;79(2):133-8 [9583726.001]
  • [Cites] World J Gastroenterol. 2005 Jan 7;11(1):22-6 [15609390.001]
  • [Cites] Lab Invest. 1999 Apr;79(4):459-65 [10211998.001]
  • [Cites] Hum Mutat. 1999;14(3):249-55 [10477433.001]
  • [Cites] Hepatogastroenterology. 2001 Nov-Dec;48(42):1552-5 [11813570.001]
  • [Cites] World J Surg. 1989 Mar-Apr;13(2):225-30; discussion 230-1 [2728468.001]
  • [Cites] Lab Invest. 2000 Dec;80(12):1943-9 [11140706.001]
  • [Cites] Br J Cancer. 1999 Dec;81(8):1392-7 [10604738.001]
  • [Cites] Cancer Res. 1995 Jun 15;55(12):2681-90 [7780985.001]
  • [Cites] World J Gastroenterol. 2002 Dec;8(6):987-93 [12439911.001]
  • [Cites] Br J Surg. 1998 Feb;85(2):255-60 [9501830.001]
  • [Cites] Clin Cancer Res. 1998 Nov;4(11):2605-14 [9829723.001]
  • [Cites] J Pathol. 1999 Oct;189(2):180-5 [10547572.001]
  • [Cites] Am J Pathol. 2001 Apr;158(4):1245-51 [11290542.001]
  • [Cites] Cancer. 1996 May 1;77(9):1774-80 [8646673.001]
  • [Cites] J Clin Gastroenterol. 2002 Jul;35(1):35-42 [12080224.001]
  • [Cites] Virchows Arch. 2002 Mar;440(3):304-10 [11889602.001]
  • [Cites] J Surg Oncol. 1999 Aug;71(4):214-9 [10440758.001]
  • [Cites] Am J Surg. 1996 Nov;172(5):473-6; discussion 476-7 [8942547.001]
  • [Cites] Gastroenterology. 1994 Jul;107(1):160-72 [8020658.001]
  • [Cites] Science. 1991 Mar 22;251(5000):1451-5 [2006419.001]
  • [Cites] Cancer Surv. 1994;19-20:55-76 [7534641.001]
  • [Cites] J Histochem Cytochem. 2000 Mar;48(3):377-88 [10681391.001]
  • [Cites] Oncogene. 1995 Oct 5;11(7):1319-26 [7478552.001]
  • [Cites] Cancer. 2001 Jun 1;91(11):1973-82 [11391575.001]
  • [Cites] Mod Pathol. 2006 Apr;19(4):564-72 [16474375.001]
  • [Cites] Nature. 1996 Aug 15;382(6592):638-42 [8757136.001]
  • [Cites] Biochem Biophys Res Commun. 1992 Feb 14;182(3):1376-82 [1371681.001]
  • [Cites] Cancer Res. 1991 Apr 15;51(8):2185-92 [2009537.001]
  • [Cites] J Pathol. 2004 Sep;204(1):75-83 [15307140.001]
  • [Cites] Int J Cancer. 1998 Aug 21;79(4):402-10 [9699534.001]
  • [Cites] Int J Surg Pathol. 2003 Jan;11(1):1-9 [12598910.001]
  • (PMID = 18825309.001).
  • [ISSN] 1436-3291
  • [Journal-full-title] Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  • [ISO-abbreviation] Gastric Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cadherins; 0 / MUC5AC protein, human; 0 / MUC6 protein, human; 0 / Mucin 5AC; 0 / Mucin-1; 0 / Mucin-2; 0 / Mucin-6; 0 / beta Catenin
  •  go-up   go-down


35. Bragantini E, Barbi S, Beghelli S, Moore PS, de Manzoni G, Roviello F, Tomezzoli A, Vindigni C, Baffa R, Scarpa A: Loss of Fhit expression is associated with poorer survival in gastric cancer but is not an independent prognostic marker. J Cancer Res Clin Oncol; 2006 Jan;132(1):45-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Loss of Fhit expression is associated with poorer survival in gastric cancer but is not an independent prognostic marker.
  • Several studies have reported conflicting results regarding correlations of the loss of Fhit expression with clinicopathological parameters in gastric cancer.
  • We investigated the immunohistochemical expression of Fhit in 362 cases of sporadic advanced gastric adenocarcinoma.
  • Absence of Fhit expression also correlated with tumor stage (P<0.001), lymph node involvement (P<0.001), presence of distant metastasis (P=0.033), and increasing histological grade (P=0.005).

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochem Biophys Res Commun. 2001 Jun 15;284(3):850-5 [11396980.001]
  • [Cites] Cancer Res. 1996 Jul 15;56(14):3173-9 [8764101.001]
  • [Cites] Res Commun Mol Pathol Pharmacol. 2002;112(1-4):39-49 [15080495.001]
  • [Cites] Eur J Cancer. 2002 Mar;38(5):728-35 [11916557.001]
  • [Cites] Cancer Res. 1999 Mar 15;59(6):1308-14 [10096564.001]
  • [Cites] Cancer Res. 2001 Feb 15;61(4):1578-84 [11245468.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10250-5 [11517343.001]
  • [Cites] Biochemistry. 1996 Sep 10;35(36):11529-35 [8794732.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1618-24 [10334551.001]
  • [Cites] Acta Pathol Microbiol Scand. 1965;64:31-49 [14320675.001]
  • [Cites] Eur J Cancer. 2004 Jul;40(10 ):1581-8 [15196543.001]
  • [Cites] J Cancer Res Clin Oncol. 2003 Feb;129(2):84-8 [12669232.001]
  • [Cites] Exp Mol Med. 2001 Sep 30;33(3):124-30 [11642547.001]
  • [Cites] Cancer Res. 1997 Apr 15;57(8):1435-7 [9108441.001]
  • [Cites] Clin Cancer Res. 2004 Nov 15;10(22):7607-12 [15569992.001]
  • [Cites] World J Gastroenterol. 2005 Jan 7;11(1):17-21 [15609389.001]
  • [Cites] FASEB J. 2003 Sep;17(12):1768-70 [12958204.001]
  • [Cites] Genes Chromosomes Cancer. 1997 Sep;20(1):98-102 [9290961.001]
  • [Cites] Oncology. 2001;61(3):205-11 [11574776.001]
  • [Cites] Cell. 1996 Apr 5;85(1):17-26 [8620533.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2003 May;15(5):515-23 [12702909.001]
  • [Cites] Br J Cancer. 2004 Feb 9;90(3):672-7 [14760383.001]
  • [Cites] J Pathol. 2003 May;200(1):39-46 [12692839.001]
  • [Cites] Cancer. 2000 Jan 1;88(1):24-34 [10618602.001]
  • [Cites] Cell. 1996 Feb 23;84(4):587-97 [8598045.001]
  • [Cites] J Pathol. 1999 Aug;188(4):378-81 [10440747.001]
  • [Cites] Cancer Res. 1998 Oct 15;58(20):4708-14 [9788626.001]
  • [Cites] Int J Cancer. 1997 Sep 17;72(6):955-8 [9378557.001]
  • (PMID = 16217683.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / fragile histidine triad protein; EC 3.6.- / Acid Anhydride Hydrolases
  •  go-up   go-down


36. Fan YJ, Song X, Li JL, Li XM, Liu B, Wang R, Fan ZM, Wang LD: Esophageal and gastric cardia cancers on 4238 Chinese patients residing in municipal and rural regions: a histopathological comparison during 24-year period. World J Surg; 2008 Sep;32(9):1980-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Esophageal and gastric cardia cancers on 4238 Chinese patients residing in municipal and rural regions: a histopathological comparison during 24-year period.
  • BACKGROUND: Nutrition deficiencies or poverty traditionally have been recognized to be related with increased risk for esophageal cancer (EC) in rural regions at junction of Henan, Hebei, and Shanxi provinces in northern China--the highest incidence area for esophageal squamous cell carcinoma (ESCC) and gastric cardia adenocarcinoma (GCA).
  • However, the histopathological types, staging pattern, and occurrence of ESCC and GCA, especially for esophageal adenocarcinoma (EAC), which have been rarely examined in the Chinese population during the past decades in these areas have not been well characterized to date.
  • Age at diagnosis, tumor stage and site, and histopathological pattern were recorded for each patient from the tumor registry database in these hospitals.
  • Eighty-six percent of ESCC and 90% of GCA in municipal region were diagnosed at middle and advanced stage; similarly, more than 95% of ESCC and GCA in rural region were diagnosed at middle and advanced stage during the 24-year study period.
  • The present results demonstrate the difference in municipal and rural regions of ESCC, ECA, and GCA in histopathological types, and suggest that there may be different etiological factors involved in esophageal and gastric cardia carcinogenesis in these different areas.
  • [MeSH-minor] Adenocarcinoma / epidemiology. Adenocarcinoma / pathology. Adult. Aged. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / pathology. Chi-Square Distribution. China / epidemiology. Female. Humans. Incidence. Male. Middle Aged. Neoplasm Staging. Risk Factors. Rural Population. Urban Population

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hepatogastroenterology. 2001 Sep-Oct;48(41):1231-7 [11677937.001]
  • [Cites] Dig Dis Sci. 1997 Apr;42(4):702-6 [9125635.001]
  • [Cites] J Natl Cancer Inst. 1984 Dec;73(6):1449-53 [6595453.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2004 May;16(5):495-501 [15097043.001]
  • [Cites] J Natl Cancer Inst. 1995 Jan 18;87(2):104-9 [7707381.001]
  • [Cites] Cancer Res. 1994 Aug 15;54(16):4342-6 [8044781.001]
  • [Cites] Z Gastroenterol. 1982 Jul;20(7):361-7 [7051590.001]
  • [Cites] Semin Oncol. 2004 Aug;31(4):513-29 [15297943.001]
  • [Cites] Dis Esophagus. 2006;19(6):477-81 [17069592.001]
  • [Cites] Ecol Dis. 1983;2(4):249-53 [6681155.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1995 Mar;4(2):85-92 [7742727.001]
  • [Cites] Gan To Kagaku Ryoho. 2002 Feb;29 Suppl 1:159-72 [11890101.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 Apr;4(4):398-407 [16616342.001]
  • [Cites] Hum Nutr Clin Nutr. 1982;36(5):337-49 [7174357.001]
  • [Cites] Cancer. 1992 May 1;69(9):2227-31 [1562967.001]
  • [Cites] Nutr Cancer. 1985;7(3):131-43 [3878498.001]
  • [Cites] J Gastroenterol Hepatol. 2000 Mar;15(3):230-8 [10764021.001]
  • [Cites] Am J Gastroenterol. 1998 May;93(5):702-5 [9625112.001]
  • [Cites] Int J Cancer. 1994 Nov 15;59(4):514-9 [7960222.001]
  • [Cites] Crit Rev Oncol Hematol. 1987;7(4):267-87 [3322593.001]
  • [Cites] Dig Dis Sci. 2002 Apr;47(4):735-40 [11991601.001]
  • [Cites] Int J Obes Relat Metab Disord. 1998 Dec;22(12):1164-71 [9877251.001]
  • [Cites] Bull Am Coll Surg. 2002 Jul;87(7):13-5 [17387902.001]
  • [Cites] Cancer Res. 1993 Apr 15;53(8):1783-7 [8467496.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1993 Jan-Feb;2(1):71-8 [8420615.001]
  • [Cites] Eur J Cancer Prev. 1992 Apr;1(3):259-64 [1467771.001]
  • [Cites] Aliment Pharmacol Ther. 2002 Dec;16(12):2037-42 [12452935.001]
  • [Cites] Am Fam Physician. 2006 Jun 15;73(12):2187-94 [16836035.001]
  • [Cites] J Gastroenterol Hepatol. 2004 Sep;19 Suppl 3:S22-5 [15324378.001]
  • [Cites] N Engl J Med. 1999 Mar 18;340(11):825-31 [10080844.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1996 May;5(5):405-6 [9162308.001]
  • [Cites] J Gastroenterol. 2003 Mar;38 Suppl 15:25-30 [12698867.001]
  • [Cites] Ann Ist Super Sanita. 1996;32(1):65-72 [8804186.001]
  • [Cites] Gastroenterology. 1993 Feb;104(2):510-3 [8425693.001]
  • [Cites] Nutr Cancer. 1982;4(2):154-64 [7162996.001]
  • [Cites] Cancer Res. 1980 Aug;40(8 Pt 1):2633-44 [6992989.001]
  • [Cites] Cancer. 1998 Nov 15;83(10):2049-53 [9827707.001]
  • [Cites] Carcinogenesis. 1999 Jan;20(1):77-84 [9934853.001]
  • [Cites] J Gastroenterol. 2003 Mar;38 Suppl 15:3-6 [12698863.001]
  • [Cites] World J Gastroenterol. 2004 Jun 1;10(11):1647-51 [15162542.001]
  • (PMID = 18566857.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


37. Aoyagi K, Kouhuji K, Yano S, Miyagi M, Imaizumi T, Takeda J, Shirouzu K: VEGF significance in peritoneal recurrence from gastric cancer. Gastric Cancer; 2005;8(3):155-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] VEGF significance in peritoneal recurrence from gastric cancer.
  • BACKGROUND: In gastric cancer, the management of peritoneal dissemination in the Peritoneal cavity is extremely important; however, peritoneal dissemination in the final stage of gastric cancer remains untreatable.
  • METHODS: Immunohistochemical staining, using the avidin-biotin peroxidase complex method, was performed on slides of surgical specimens from 40 patients with stage II gastric cancer with serosal invasion, who underwent surgery at our hospital between 1990 and 2000.
  • Of these, seven had macroscopic type-4 scirrhous-type gastric carcinoma.
  • CONCLUSION: These results suggested that VEGF was correlated with peritoneal metastasis from gastric cancer, and that VEGF was a useful indicator of peritoneal recurrence.
  • [MeSH-minor] Adenocarcinoma, Scirrhous / metabolism. Adenocarcinoma, Scirrhous / pathology. Adult. Aged. Female. Humans. Immunoenzyme Techniques. Male. Middle Aged. Neoplasm Invasiveness / pathology. Prognosis. Survival Rate

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1999 Jan 1;85(1):178-87 [9921991.001]
  • [Cites] Cancer Sci. 2003 Aug;94(8):735-40 [12901801.001]
  • [Cites] Clin Cancer Res. 2000 Feb;6(2):622-30 [10690548.001]
  • [Cites] J Biol Chem. 1998 Nov 13;273(46):30336-43 [9804796.001]
  • [Cites] Cancer Res. 1995 Jan 15;55(2):360-8 [7812969.001]
  • [Cites] J Natl Cancer Inst. 1998 Mar 18;90(6):447-54 [9521169.001]
  • [Cites] Int J Cancer. 1997 Mar 4;70(5):612-8 [9052764.001]
  • [Cites] N Engl J Med. 1971 Nov 18;285(21):1182-6 [4938153.001]
  • [Cites] Am J Pathol. 1998 Oct;153(4):1249-56 [9777956.001]
  • [Cites] J Exp Med. 1992 Oct 1;176(4):1165-74 [1383376.001]
  • [Cites] Am J Pathol. 1995 May;146(5):1029-39 [7538264.001]
  • [Cites] Jpn J Cancer Res. 1996 Dec;87(12):1235-44 [9045958.001]
  • [Cites] Science. 1983 Feb 25;219(4587):983-5 [6823562.001]
  • [Cites] Int Surg. 2003 Jan-Mar;88(1):25-33 [12731728.001]
  • [Cites] Ann Surg Oncol. 1999 Jun;6(4):373-8 [10379858.001]
  • [Cites] J Natl Cancer Inst. 1995 Apr 5;87(7):506-16 [7707437.001]
  • [Cites] J Biol Regul Homeost Agents. 2001 Apr-Jun;15(2):140-4 [11501971.001]
  • [Cites] Biochem Biophys Res Commun. 1991 Dec 16;181(2):902-6 [1755866.001]
  • [Cites] J Cell Physiol. 1992 Dec;153(3):557-62 [1447317.001]
  • [Cites] Gene Ther. 2000 Jun;7(12):1027-33 [10871751.001]
  • [Cites] Cancer Res. 1999 Nov 1;59(21):5412-6 [10554007.001]
  • (PMID = 16086118.001).
  • [ISSN] 1436-3291
  • [Journal-full-title] Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  • [ISO-abbreviation] Gastric Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


38. Hao Z, Li X, Qiao T, Li S, Lv Y, Fan D: Downregulated expression of CIAPIN1 may contribute to gastric carcinogenesis by accelerating cell proliferation and promoting cell cycle progression. Cancer Biol Ther; 2009 Jun;8(11):1064-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Downregulated expression of CIAPIN1 may contribute to gastric carcinogenesis by accelerating cell proliferation and promoting cell cycle progression.
  • Our previous studies revealed that cytokine induced apoptosis inhibitor 1 (CIAPIN1), which was reported to be essential in mouse definitive hematopoiesis, was related to multidrug resistance in gastric cancer cells and that the distribution of CIAPIN1 in normal human tissues was similar to the distribution of Ras.
  • This study aimed to explore whether CIAPIN1 plays a role in gastric carcinogenesis.
  • Expression of CIAPIN1 in normal, inflammatory gastric mucosa, gastric precancerous lesions and gastric adenocarcinoma was detected by immunohistochemistry and western blotting and, influence of CIAPIN1 on the proliferation of gastric cancer cells was investigated by ectopic expression of CIAPIN1 and RNA interference (RNAi).
  • Our immunohistochemical results demonstrated that the expression of CIAPIN1 in gastric antral mucosa was progressively reduced along the sequence of normal/inflammatory gastric mucosa-atrophy-intestinal metaplasia-dysplasia-adenocarcinoma.
  • No relationship between the expression level of CIAPIN1 and the clinicopathological parameters such as age, gender, differentiation, TNM stage and the existence of metastasis was found in gastric cancer patients.
  • In in vitro cellular experiments, ectopic expression of CIAPIN1 by cDNA transfection resulted in suppression of cell proliferation and inhibition of cell cycle progression while knockdown of CIAPIN1 with siRNA accelerated cell proliferation and promoted cell cycle progression in SGC7901 and MKN28 gastric cancer cells.
  • These results suggest that downregulated CIAPIN1 expression may contribute to gastric carcinogenesis by accelerating cell proliferation and promoting cell cycle progression.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19471113.001).
  • [ISSN] 1555-8576
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CIAPIN1 protein, human; 0 / Intracellular Signaling Peptides and Proteins; 0 / RNA, Small Interfering
  •  go-up   go-down


39. Zhan YQ, Sun XW, Li W, Chen YB, Xu L, Guan YX, Li YF, Xu DZ: [Multivariate prognostic analysis in gastric carcinoma patients after radical operation]. Ai Zheng; 2005 May;24(5):596-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Multivariate prognostic analysis in gastric carcinoma patients after radical operation].
  • BACKGROUND & OBJECTIVE: Whether received radical operation is an important prognostic factor of gastric carcinoma.
  • This study was to investigate prognostic factors of gastric carcinoma.
  • METHODS: Clinical data of 405 patients with gastric carcinoma, received radical operation from Jan.
  • The 5-year survival rates of patients in pathologic TNM (pTNM) stage I, II, III, and IV were 75.6%, 58.7%, 28.0%, and 18.4%, respectively (P < 0.01).
  • Univariate analysis showed that perioperative chemotherapy, Borrmann type, tumor size, pathologic type, and pTNM stage were prognostic factors of gastric carcinoma.
  • Multivariate analysis showed that pTNM stage, tumor size, and perioperative chemotherapy were independent prognostic factors of gastric carcinoma.
  • CONCLUSIONS: pTNM stage, tumor size, and perioperative chemotherapy are the most significant factors influencing prognosis of gastric carcinoma patients after radical operation.
  • Perioperative chemotherapy contributes to enhance survival rate of gastric carcinoma patients.
  • [MeSH-major] Adenocarcinoma / surgery. Gastrectomy. Stomach Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma, Mucinous / drug therapy. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / surgery. Adult. Aged. Aged, 80 and over. Carcinoma, Signet Ring Cell / drug therapy. Carcinoma, Signet Ring Cell / pathology. Carcinoma, Signet Ring Cell / surgery. Chemotherapy, Adjuvant. Female. Follow-Up Studies. Humans. Life Tables. Male. Middle Aged. Neoplasm Staging. Perioperative Care. Prognosis. Proportional Hazards Models. Survival Rate

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15890105.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


40. Gamboa-Dominguez A, Seidl S, Reyes-Gutierrez E, Hermannstädter C, Quintanilla-Martinez L, Busch R, Höfler H, Fend F, Luber B: Prognostic significance of p21WAF1/CIP1, p27Kip1, p53 and E-cadherin expression in gastric cancer. J Clin Pathol; 2007 Jul;60(7):756-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of p21WAF1/CIP1, p27Kip1, p53 and E-cadherin expression in gastric cancer.
  • BACKGROUND: Gastric carcinoma is characterised by numerous genetic and epigenetic alterations that influence cell cycle progression, apoptosis and DNA repair.
  • AIMS: To evaluate p21(WAF1/CIP1), p27(Kip1), p53 and E-cadherin protein expression, including mutant E-cadherin variants with deletion of exon 8 (del 8) or 9 (del 9), in gastric cancer from Mexican patients.
  • METHODS: Immunohistochemistry for the above-mentioned markers, including mutation-specific E-cadherin antibodies, was carried out in 69 gastric carcinomas; expression levels were correlated with histotype, tumour stage and prognosis.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Neoplasm Proteins / metabolism. Stomach Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pathol. 1999 Oct;189(2):186-93 [10547573.001]
  • [Cites] J Korean Med Sci. 1998 Aug;13(4):369-76 [9741540.001]
  • [Cites] Lab Invest. 1999 Apr;79(4):459-65 [10211998.001]
  • [Cites] Cancer. 1999 Apr 15;85(8):1711-8 [10223564.001]
  • [Cites] Acta Pathol Microbiol Scand. 1965;64:31-49 [14320675.001]
  • [Cites] Hum Pathol. 2005 Jan;36(1):29-35 [15712179.001]
  • [Cites] Am J Pathol. 1999 Dec;155(6):1803-9 [10595908.001]
  • [Cites] Am J Pathol. 2000 Feb;156(2):585-94 [10666388.001]
  • [Cites] Anticancer Res. 2000 May-Jun;20(3A):1787-92 [10928108.001]
  • [Cites] Cancer. 2000 Oct 15;89(8):1684-91 [11042561.001]
  • [Cites] Cancer. 2000 Dec 1;89(11):2247-57 [11147595.001]
  • [Cites] Verh Dtsch Ges Pathol. 2000;84:43-9 [11217448.001]
  • [Cites] Histopathology. 2001 Dec;39(6):603-10 [11903579.001]
  • [Cites] J Pathol. 2002 Aug;197(5):567-74 [12210074.001]
  • [Cites] Oncology. 2002;63(4):353-61 [12417790.001]
  • [Cites] J Surg Oncol. 2002 Dec;81(4):167-75; discussion 175-6 [12451619.001]
  • [Cites] Int J Cancer. 2003 Mar 10;104(1):60-5 [12532420.001]
  • [Cites] Am J Clin Pathol. 1991 Sep;96(3):330-3 [1877529.001]
  • [Cites] Hum Mol Genet. 1993 Jun;2(6):803-4 [8353498.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Mar 1;91(5):1858-62 [8127895.001]
  • [Cites] Br J Cancer. 1994 May;69(5):943-6 [8180028.001]
  • [Cites] Cancer Res. 1994 Jul 15;54(14):3845-52 [8033105.001]
  • [Cites] Jpn J Cancer Res. 1996 Aug;87(8):843-8 [8797891.001]
  • [Cites] Jpn J Cancer Res. 1996 Nov;87(11):1153-9 [9045944.001]
  • [Cites] Hepatogastroenterology. 1997 Mar-Apr;44(14):546-53 [9164535.001]
  • [Cites] Nat Med. 1997 Jun;3(6):593 [9176477.001]
  • [Cites] Cancer. 1997 Jun 1;79(11):2067-72 [9179052.001]
  • [Cites] Int J Epidemiol. 1997 Dec;26(6):1166-71 [9447395.001]
  • [Cites] Cancer. 1998 Apr 1;82(7):1238-43 [9529014.001]
  • [Cites] Dig Dis Sci. 1998 May;43(5):964-70 [9590408.001]
  • [Cites] J Cell Biol. 1998 Jul 27;142(2):557-71 [9679152.001]
  • [Cites] Hum Mutat. 1998;12(4):226-37 [9744472.001]
  • (PMID = 17483253.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDKN1A protein, human; 0 / Cadherins; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Neoplasm Proteins; 0 / Tumor Suppressor Protein p53; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27
  • [Other-IDs] NLM/ PMC1995786
  •  go-up   go-down


41. Novotny AR, Schuhmacher C, Busch R, Kattan MW, Brennan MF, Siewert JR: Predicting individual survival after gastric cancer resection: validation of a U.S.-derived nomogram at a single high-volume center in Europe. Ann Surg; 2006 Jan;243(1):74-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predicting individual survival after gastric cancer resection: validation of a U.S.-derived nomogram at a single high-volume center in Europe.
  • -derived nomogram for individual prediction of disease-specific gastric cancer survival at a European institution.
  • For gastric cancer, Kattan et al, at Memorial Sloan-Kettering Cancer Center, New York, NY, developed a nomogram, allowing to predict individual patient risk of tumor-related death after R0 resection from basic patient-related variables.
  • The accuracy of the nomogram when applied to patients after having undergone R0 gastric cancer resection at a European high-volume center was investigated.
  • METHODS: Clinical data from patients who underwent R0 gastric cancer resection at Klinikum rechts der Isar, Technical University of Munich, Germany and fitted the respective derivation criteria were used for external validation (n = 862).
  • RESULTS: The bootstrap-corrected concordance index was 0.77 and was superior when compared with the predictive ability of International Union Against Cancer tumor stage (P < 0.008).
  • Nomogram predictions showed the trend to underestimate survival in stage II/III disease of the MRI patients.
  • [MeSH-major] Adenocarcinoma / mortality. Gastrectomy / mortality. Nomograms. Stomach Neoplasms / mortality

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer. 1999 Jul;35(7):1059-64 [10533448.001]
  • [Cites] Acta Pathol Microbiol Scand. 1965;64:31-49 [14320675.001]
  • [Cites] J Cancer Res Clin Oncol. 2000 Apr;126(4):233-7 [10782897.001]
  • [Cites] Ann Surg Oncol. 2000 Jun;7(5):346-51 [10864341.001]
  • [Cites] Ann Surg Oncol. 2000 Aug;7(7):515-9 [10947020.001]
  • [Cites] Br J Cancer. 2001 Apr 6;84(7):878-80 [11286464.001]
  • [Cites] Int J Cancer. 2001 Jun 15;92(6):832-8 [11351303.001]
  • [Cites] N Engl J Med. 2001 Sep 6;345(10):725-30 [11547741.001]
  • [Cites] Cancer. 2001 Sep 15;92(6):1427-34 [11745219.001]
  • [Cites] Hepatogastroenterology. 2001 Nov-Dec;48(42):1552-5 [11813570.001]
  • [Cites] Ann Surg Oncol. 2002 Oct;9(8):771-4 [12374660.001]
  • [Cites] J Pathol. 2003 May;200(1):39-46 [12692839.001]
  • [Cites] Langenbecks Arch Surg. 2003 Sep;388(4):245-9 [12861416.001]
  • [Cites] J Clin Oncol. 2003 Oct 1;21(19):3647-50 [14512396.001]
  • [Cites] Surgery. 2003 Oct;134(4):720-7; discussion 727-9 [14605635.001]
  • [Cites] J Gastrointest Surg. 2004 Mar-Apr;8(3):240-4 [15019915.001]
  • [Cites] Jpn J Surg. 1981 Mar;11(2):127-39 [7300058.001]
  • [Cites] JAMA. 1982 May 14;247(18):2543-6 [7069920.001]
  • [Cites] Surg Gynecol Obstet. 1986 Mar;162(3):229-34 [3952614.001]
  • [Cites] Chirurg. 1987 Jan;58(1):25-32 [3829805.001]
  • [Cites] Arch Surg. 1989 Mar;124(3):314-8 [2919965.001]
  • [Cites] World J Surg. 1989 Jan-Feb;13(1):118-23; discussion 123 [2471364.001]
  • [Cites] Hepatogastroenterology. 1989 Feb;36(1):7-12 [2744714.001]
  • [Cites] Arch Surg. 1989 Sep;124(9):1061-4 [2774908.001]
  • [Cites] Cancer Res. 1991 Feb 1;51(3):1034-8 [1670998.001]
  • [Cites] Br J Surg. 1991 Jul;78(7):825-7 [1873712.001]
  • [Cites] Chirurg. 1992 Aug;63(8):656-61 [1395862.001]
  • [Cites] Cancer. 1993 Dec 1;72(11):3179-84 [7902202.001]
  • [Cites] Cancer Res. 1994 Jun 1;54(11):2900-7 [8187075.001]
  • [Cites] Cancer. 1995 Mar 15;75(6 Suppl):1503-7 [7889482.001]
  • [Cites] Int J Cancer. 1995 Feb 20;64(1):32-6 [7665246.001]
  • [Cites] Am J Pathol. 1995 Sep;147(3):593-600 [7677173.001]
  • [Cites] Jpn J Cancer Res. 1995 Jul;86(7):617-21 [7559076.001]
  • [Cites] Stat Med. 1996 Feb 28;15(4):361-87 [8668867.001]
  • [Cites] Br J Surg. 1996 Aug;83(8):1144-7 [8869330.001]
  • [Cites] Chirurg. 1996 Sep;67(9):877-88 [8991768.001]
  • [Cites] Ann Surg. 1997 Jun;225(6):678-83; discussion 683-5 [9230808.001]
  • [Cites] Hepatogastroenterology. 1997 Nov-Dec;44(18):1641-5 [9427036.001]
  • [Cites] Br J Surg. 1997 Dec;84(12):1651-64 [9448610.001]
  • [Cites] Nat Med. 1998 Jul;4(7):844-7 [9662379.001]
  • [Cites] Ann Surg. 1998 Oct;228(4):449-61 [9790335.001]
  • [Cites] Br J Cancer. 1999 Feb;79(3-4):611-9 [10027338.001]
  • [Cites] Cancer. 1999 Mar 1;85(5):1033-8 [10091785.001]
  • [Cites] J Surg Oncol. 1999 Aug;71(4):214-9 [10440758.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3810-5 [10577853.001]
  • (PMID = 16371739.001).
  • [ISSN] 0003-4932
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Validation Studies
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1449962
  •  go-up   go-down


42. Komuro Y, Watanabe T, Hosoi Y, Matsumoto Y, Nakagawa K, Suzuki N, Nagawa H: Prognostic significance of Ku70 protein expression in patients with advanced colorectal cancer. Hepatogastroenterology; 2005 Jul-Aug;52(64):995-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The expression of Ku70 has been reported to be related to cell proliferation in a human gastric cancer cell line.
  • No significant correlation was seen between Ku expression pattern and the clinical parameters except depth of invasion. pTNM stage, histopathological grade and Ku70 were significant variables for prognosis of survival in the multivariate analysis.
  • CONCLUSIONS: This is the first report correlating reduced survival with elevated expression of Ku protein in colorectal adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Antigens, Nuclear / metabolism. Colorectal Neoplasms / metabolism. DNA-Binding Proteins / metabolism

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16001615.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antigens, Nuclear; 0 / DNA-Binding Proteins; 0 / Ku autoantigen
  •  go-up   go-down


43. Yu J, Cheng YY, Tao Q, Cheung KF, Lam CN, Geng H, Tian LW, Wong YP, Tong JH, Ying JM, Jin H, To KF, Chan FK, Sung JJ: Methylation of protocadherin 10, a novel tumor suppressor, is associated with poor prognosis in patients with gastric cancer. Gastroenterology; 2009 Feb;136(2):640-51.e1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Methylation of protocadherin 10, a novel tumor suppressor, is associated with poor prognosis in patients with gastric cancer.
  • We analyzed its epigenetic inactivation, biological effects, and prognostic significance in gastric cancer.
  • RESULTS: PCDH10 was silenced or down-regulated in 94% (16 of 17) of gastric cancer cell lines; expression levels were restored by exposure to demethylating agents.
  • Re-expression of PCDH10 in MKN45 gastric cancer cells reduced colony formation in vitro and tumor growth in mice; it also inhibited cell proliferation (P < .01), induced cell apoptosis (P < .001), and repressed cell invasion (P < .05), up-regulating the pro-apoptosis genes Fas, Caspase 8, Jun, and CDKN1A; the antiproliferation gene FGFR; and the anti-invasion gene HTATIP2.
  • PCDH10 methylation was detected in 82% (85 of 104) of gastric tumors compared with 37% (38 of 104) of paired nontumor tissues (P < .0001).
  • Kaplan-Meier survival curves showed that PCDH10 methylation was associated significantly with shortened survival in stage I-III gastric cancer patients.
  • CONCLUSIONS: PCDH10 is a gastric tumor suppressor; its methylation at early stages of gastric carcinogenesis is an independent prognostic factor.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / genetics. Cadherins / genetics. Cadherins / metabolism. DNA Methylation / physiology. Stomach Neoplasms / diagnosis. Stomach Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19084528.001).
  • [ISSN] 1528-0012
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cadherins; 0 / PCDH10 protein, human
  •  go-up   go-down


44. Sirak I, Petera J, Hatlova J, Vosmik M, Melichar B, Dvorak J, Zoul Z, Tycova V, Lesko M, Hajduch M: Epidermal growth factor receptor as a predictor of tumor response to preoperative chemoradiation in locally advanced gastric carcinoma. Strahlenther Onkol; 2008 Nov;184(11):592-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidermal growth factor receptor as a predictor of tumor response to preoperative chemoradiation in locally advanced gastric carcinoma.
  • PURPOSE: The purpose of our study was a retrospective evaluation whether the intensity of epidermal growth factor receptor (EGFR) expression predicts tumor response to preoperative chemoradiotherapy in patients with locally advanced gastric carcinoma.
  • PATIENTS AND METHODS: Thirty-six patients with gastric adenocarcinoma (cT2-4 or N+) were studied.
  • Preoperative treatment consisted of 30-45 Gy of gastric irradiation with continuous 5-fluorouracil and weekly cisplatin.
  • Tumor response was defined as a reduction of at least one T-stage level and/or finding of intense tumor regression in histopathologic examination.
  • CONCLUSION: EGFR may represent a molecular marker predictive for poor response to preoperative chemoradiotherapy in locally advanced gastric carcinoma.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Receptor, Epidermal Growth Factor / metabolism. Stomach Neoplasms / radiotherapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19016018.001).
  • [ISSN] 0179-7158
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, Epidermal Growth Factor; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


45. Mirarchi M, De Raffele E, Lega S, Calculli L, Vaccari S, Cola B: [Synchronous adenocarcinoma of the sigmoid colon and multifocal intraductal papillary mucinous neoplasm of the pancreas in an elderly patient]. Chir Ital; 2009 May-Jun;61(3):357-67
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Synchronous adenocarcinoma of the sigmoid colon and multifocal intraductal papillary mucinous neoplasm of the pancreas in an elderly patient].
  • [Transliterated title] Adenocarcinoma del colon e neoplasia papillare intraduttale mucinosa multifocale sincrona del pancreas in un paziente anziano: caso clinico e revisione della letteratura.
  • A 78-year-old man presented with rectal bleeding which led to the diagnosis of a stenosing adenocarcinoma of the sigmoid colon.
  • A two-stage procedure was planned: an R0 sigmoid resection was undertaken first with an uneventful postoperative course.
  • Forty-five days later a pancreaticoduodenectomy was performed and the postoperative course was again uneventful apart from delayed gastric emptying.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Papillary / pathology. Carcinoma, Pancreatic Ductal / pathology. Neoplasms, Multiple Primary / pathology. Pancreatic Neoplasms / pathology. Sigmoid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19694240.001).
  • [ISSN] 0009-4773
  • [Journal-full-title] Chirurgia italiana
  • [ISO-abbreviation] Chir Ital
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


46. Nakajo A, Natsugoe S, Hokita S, Ishigami S, Takatori H, Arigami T, Uenosono Y, Aridome K, Aikou T: Successful treatment of advanced gastric cancer by surgical resection following combination chemotherapy with oral S-1 and biweekly paclitaxel. Gastric Cancer; 2007;10(1):58-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of advanced gastric cancer by surgical resection following combination chemotherapy with oral S-1 and biweekly paclitaxel.
  • We report on the successful treatment of advanced gastric cancer by surgical resection following neoadjuvant chemotherapy.
  • Meticulous examination, however, revealed the presence of gastric cancer with ascites and large lymph node metastasis adjacent to the pancreas.
  • The tumor was pathologically diagnosed as pT2, pN0, P0, M0, CY0, and p-stage II.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Stomach Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anticancer Drugs. 1996 Feb;7(2):137-49 [8740718.001]
  • [Cites] Gastric Cancer. 2003;6 Suppl 1:50-7 [12775021.001]
  • [Cites] Oncology. 2001;61(1):16-22 [11474243.001]
  • [Cites] Gastric Cancer. 2004;7(2):128-33 [15224201.001]
  • [Cites] Int J Clin Oncol. 2005 Feb;10(1):40-4 [15729600.001]
  • [Cites] Jpn J Clin Oncol. 2004 Jun;34(6):342-5 [15333687.001]
  • [Cites] Gastric Cancer. 2003;6 Suppl 1:45-9 [12775020.001]
  • [Cites] Anticancer Drugs. 1996 Jul;7(5):548-57 [8862723.001]
  • [Cites] Gastric Cancer. 1998 Dec;1(1):10-24 [11957040.001]
  • [Cites] Int J Clin Oncol. 2002 Oct;7(5):326-9 [12402069.001]
  • [Cites] Cancer Chemother Pharmacol. 1997;39(3):205-11 [8996521.001]
  • [Cites] Oncology. 2000 Apr;58(3):191-7 [10765119.001]
  • [Cites] Eur J Cancer. 2003 Nov;39(16):2328-33 [14556924.001]
  • [Cites] Eur J Cancer. 1998 Oct;34(11):1715-20 [9893658.001]
  • [Cites] Br J Cancer. 2003 Dec 15;89(12):2207-12 [14676796.001]
  • [Cites] Cell. 1981 Jan;23(1):61-71 [6111398.001]
  • [Cites] Cancer Chemother Pharmacol. 2006 Jun;57(6):736-40 [16163539.001]
  • (PMID = 17334720.001).
  • [ISSN] 1436-3291
  • [Journal-full-title] Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  • [ISO-abbreviation] Gastric Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


47. Ishii HH, Gobe GC, Ebihara Y: p53 is an indicator of tumor progression in early but not advanced gastric carcinomas. Hepatogastroenterology; 2007 Oct-Nov;54(79):2159-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p53 is an indicator of tumor progression in early but not advanced gastric carcinomas.
  • BACKGROUND/AIMS: p53 plays an important role in the development of gastric carcinomas through its effect on apoptosis.
  • This project assessed its value in early and advanced stage gastric carcinomas.
  • METHODOLOGY: The characteristics of positive staining for p53 was evaluated in 202 gastric adenocarcinomas classified into early stage (T1) (127 cases) and advanced stage (T2, 3 and 4) (75 cases) using the tumor-node-metastasis classification.
  • RESULTS: The mucosa of early stage and both mucosa and subserosa of advanced cancers were examined. p53-positive early stage cancers had more apoptosis but also more proliferation than p53-negatives (P<0.05), perhaps indicating conferral of a growth advantage.
  • CONCLUSIONS: p53 may be useful as an indicator of development and progression in early stage gastric cancers but this is not the case for advanced stage gastric cancers.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Stomach Neoplasms / metabolism. Tumor Suppressor Protein p53 / metabolism
  • [MeSH-minor] Apoptosis / physiology. Cell Proliferation. Disease Progression. Gastric Mucosa / metabolism. Humans. Immunohistochemistry. Ki-67 Antigen / metabolism. Neoplasm Staging. Prognosis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18251181.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


48. Fanelli MF, Silva MJ, de Paiva TF Jr, Chinen LT, Guimarães AP, Gimenes DL, Pinheiro ED, Rinck JA Jr, Nicolau UR, Sanches SM, Melo CA, Dettino AL, Cruz MR, de Melo LM, Formiga MN, de Lima VC: Factors correlated with peritoneal carcinomatosis and survival in patients with gastric cancer treated at a single institution in Brazil. Int J Clin Oncol; 2009 Aug;14(4):326-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Factors correlated with peritoneal carcinomatosis and survival in patients with gastric cancer treated at a single institution in Brazil.
  • BACKGROUND: Gastric cancer is the second leading cause of death due to cancer worldwide and is particularly prevalent in Brazil.
  • Promising new therapeutic agents have already shown activity in some gastrointestinal malignancies and their role in gastric cancer will need to be evaluated.
  • Determining the prognostic factors of survival for patients with gastric cancer can help in identifying patients with a worse prognosis after treatment with the current chemotherapeutic regimens.
  • METHODS: A retrospective chart review of 186 patients diagnosed with gastric cancer and treated at a single institution in Brazil from January 1994 to December 2004 was carried out.
  • The prognostic factors for poor survival were tumor stage T3 or T4 (hazard ratio [HR], 1.87; 95% CI, 1.09 to 3.22) and visceral metastasis (HR, 4.98; 95% CI, 3.02 to 8.20).
  • [MeSH-major] Adenocarcinoma / mortality. Adenocarcinoma / therapy. Peritoneal Neoplasms / mortality. Peritoneal Neoplasms / therapy. Stomach Neoplasms / mortality. Stomach Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1993 Sep 30;329(14 ):987-94 [8141877.001]
  • [Cites] World J Surg. 1995 Jul-Aug;19(4):496-500 [7676690.001]
  • [Cites] Ann Oncol. 2007 May;18(5):886-91 [17298958.001]
  • [Cites] Gastric Cancer. 1998 Mar;1(2):125-133 [11957056.001]
  • [Cites] Am J Surg. 1983 Feb;145(2):226-33 [6824136.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3412-20 [15809451.001]
  • [Cites] Med Sci Monit. 2006 May;12(5):CR221-9 [16641880.001]
  • [Cites] Cancer Chemother Pharmacol. 2008 Feb;61(2):301-7 [17429626.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Apr 1;64(5):1401-9 [16472935.001]
  • [Cites] J Clin Oncol. 1984 Apr;2(4):305-10 [6707718.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23 ):2335-42 [15175435.001]
  • [Cites] J Clin Oncol. 2005 May 1;23(13):3094-103 [15860869.001]
  • [Cites] Eur J Cancer. 2001 Sep;37(13):1674-80 [11527695.001]
  • [Cites] N Engl J Med. 2002 Aug 15;347(7):472-80 [12181401.001]
  • [Cites] Semin Oncol. 1985 Mar;12(1):21-31 [3975644.001]
  • [Cites] Int J Cancer. 2004 Jun 10;110(2):155-69 [15069676.001]
  • [Cites] Oncology. 2007;72(1-2):64-8 [18004078.001]
  • [Cites] J Clin Oncol. 2004 Jun 15;22(12):2395-403 [15197201.001]
  • [Cites] Gastric Cancer. 2000 Aug 4;3(1):9-18 [11984703.001]
  • [Cites] Jpn J Clin Oncol. 2004 Nov;34(11):654-9 [15613554.001]
  • [Cites] J Clin Oncol. 2006 May 10;24(14):2137-50 [16682732.001]
  • [Cites] Ann Oncol. 2004 Feb;15(2):338-45 [14760131.001]
  • [Cites] Nat Clin Pract Oncol. 2005 Feb;2(2):98-107 [16264882.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2530-40 [10561319.001]
  • [Cites] Ann Surg Oncol. 2008 May;15(5):1464-9 [18340495.001]
  • [Cites] Cancer. 2006 Dec 1;107(11):2576-80 [17075877.001]
  • [Cites] Ann Surg Oncol. 2006 Jun;13(6):843-50 [16614885.001]
  • [Cites] J Natl Cancer Inst. 2006 Apr 19;98(8):529-34 [16622122.001]
  • [Cites] Br J Surg. 2007 Jun;94(6):737-42 [17330827.001]
  • [Cites] N Engl J Med. 2004 Jul 22;351(4):337-45 [15269313.001]
  • [Cites] Lancet. 2006 Oct 14;368(9544):1329-38 [17046465.001]
  • [Cites] Nat Rev Cancer. 2005 Aug;5(8):591-602 [16056258.001]
  • [Cites] Lancet Oncol. 2001 Sep;2(9):533-43 [11905707.001]
  • [Cites] World J Surg. 1984 Jun;8(3):308-14 [6464487.001]
  • [Cites] Cancer. 2007 Nov 15;110(10):2186-90 [17896785.001]
  • (PMID = 19705243.001).
  • [ISSN] 1437-7772
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


49. Khor TS, Brown I, Kattampallil J, Yusoff I, Kumarasinghe MP: Duodenal adenocarcinoma arising from a pyloric gland adenoma with a brief review of the literature. BMJ Case Rep; 2010;2010
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Duodenal adenocarcinoma arising from a pyloric gland adenoma with a brief review of the literature.
  • Histologic examination of the polyp showed features of a pyloric gland adenoma (PGA) demonstrating the full spectrum of progression from low- to high-grade dysplasia and finally invasive adenocarcinoma.
  • The carcinoma showed gastric-type differentiation highlighted by its mucin immunohistochemistry profile and was of advanced stage with lymph node metastasis.
  • [MeSH-major] Adenocarcinoma / pathology. Adenoma / pathology. Duodenal Neoplasms / pathology. Gastric Mucosa. Neoplasms, Multiple Primary / pathology. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Virchows Arch. 2004 Mar;444(3):224-30 [14758553.001]
  • [Cites] Virchows Arch. 1996 Jul;428(4-5):223-7 [8764930.001]
  • [Cites] Histopathology. 1999 Jul;35(1):38-43 [10383712.001]
  • [Cites] BMC Genomics. 2007;8:345 [17908304.001]
  • [Cites] Virchows Arch. 1999 Oct;435(4):452-7 [10526011.001]
  • [Cites] Virchows Arch. 2005 May;446(5):542-5 [15838648.001]
  • [Cites] Virchows Arch. 2003 Apr;442(4):317-21 [12715167.001]
  • [Cites] Am J Surg Pathol. 2005 Nov;29(11):1442-8 [16224210.001]
  • [Cites] Gastric Cancer. 2006;9(3):177-84 [16952035.001]
  • [Cites] Am J Surg Pathol. 2009 Feb;33(2):186-93 [18830123.001]
  • [Cites] Virchows Arch. 2002 Jun;440(6):655-9 [12070607.001]
  • [Cites] Hum Pathol. 2003 Feb;34(2):156-65 [12612884.001]
  • [Cites] Virchows Arch. 2005 May;446(5):537-41 [15838649.001]
  • (PMID = 22802482.001).
  • [ISSN] 1757-790X
  • [Journal-full-title] BMJ case reports
  • [ISO-abbreviation] BMJ Case Rep
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3028104
  •  go-up   go-down


50. Roessler K, Mönig SP, Schneider PM, Hanisch FG, Landsberg S, Thiele J, Hölscher AH, Dienes HP, Baldus SE: Co-expression of CDX2 and MUC2 in gastric carcinomas: correlations with clinico-pathological parameters and prognosis. World J Gastroenterol; 2005 Jun 7;11(21):3182-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Co-expression of CDX2 and MUC2 in gastric carcinomas: correlations with clinico-pathological parameters and prognosis.
  • CDX2 represents a transcription factor for various intestinal genes (including MUC2) and thus an important regulator of intestinal differentiation, which could previously be identified in gastric carcinomas and intestinal metaplasia.
  • METHODS: Formalin-fixed and paraffin-embedded tissues from 190 gastric carcinoma patients were stained with monoclonal antibodies recognizing CDX2 and MUC2, respectively.
  • CDX2 correlated with a lower pT and pN stage in the subgroups of intestinal and stage I cancers and was associated with MUC2 positivity.
  • CONCLUSION: CDX2 and MUC2 play an important role in the differentiation of normal, inflamed, and neoplastic gastric tissues.
  • According to our results, loss of CDX2 may represent a marker of tumor progression in early gastric cancer and carcinomas with an intestinal phenotype.
  • [MeSH-major] Adenocarcinoma / metabolism. Homeodomain Proteins / metabolism. Mucins / metabolism. Stomach Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15929165.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDX2 protein, human; 0 / Homeodomain Proteins; 0 / MUC2 protein, human; 0 / Mucin-2; 0 / Mucins
  • [Other-IDs] NLM/ PMC4316046
  •  go-up   go-down


51. Moghimi-Dehkordi B, Safaee A, Ghiasi S, Zali MR: Survival in gastric cancer patients: univariate and multivariate analysis. East Afr J Public Health; 2009 Apr;6 Suppl(1):41-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival in gastric cancer patients: univariate and multivariate analysis.
  • In recent years, cancer morbidity and mortality increased in our country and especially gastric cancer has second order among all cancers.
  • The aim of this study was to analysis the survival of patients diagnosed with gastric cancer and the factors which modify prognosis.
  • METHODS: Retrospective study of overall patients diagnosed with gastric cancer registered in the cancer registry center of Research Center for Gastroenterology and Liver Disease (RCGLD), Shahid Beheshti University, M.C, Tehran, Iran, between Dec.
  • With univariate analysis, Age at Diagnosis, surgery treatment, type of first treatment, pathologic stage, tumor size, histology type of tumor, extent of wall penetration and pathologic distant metastasis were significant prognostic factors related to overall survival time.
  • [MeSH-major] Adenocarcinoma / mortality. Carcinoma, Signet Ring Cell / mortality. Stomach Neoplasms / mortality

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20084985.001).
  • [ISSN] 0856-8960
  • [Journal-full-title] East African journal of public health
  • [ISO-abbreviation] East Afr J Public Health
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Tanzania
  •  go-up   go-down


52. Matsuda S, Takahashi M, Watanabe J, Yabuno T, Mochizuki Y, Kito F, Kunisaki C: [A case report of bi-weekly docetaxel and S-1 combination chemotherapy for gastric cancer with multiple liver metastases and esophageal invasion]. Gan To Kagaku Ryoho; 2010 Jul;37(7):1353-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case report of bi-weekly docetaxel and S-1 combination chemotherapy for gastric cancer with multiple liver metastases and esophageal invasion].
  • A 61-year-old man with the chief complaint of pressure with swallowing was referred to our hospital with type 3 cardiac gastric cancer.
  • He was diagnosed as unresectable advanced gastric cancer UE-circ, type-3, c-T3N2H1P0M1, Stage IV.
  • A biopsy revealed adenocarcinoma (tub2-por1).
  • Biweekly DOC/S-1 therapy can be novel antitumor therapy which can be conducted safely in an outpatient setting for advanced gastric cancer.

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20647726.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Taxoids; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 15H5577CQD / docetaxel; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


53. Röcken C, Röhl FW, Diebler E, Lendeckel U, Pross M, Carl-McGrath S, Ebert MP: The angiotensin II/angiotensin II receptor system correlates with nodal spread in intestinal type gastric cancer. Cancer Epidemiol Biomarkers Prev; 2007 Jun;16(6):1206-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The angiotensin II/angiotensin II receptor system correlates with nodal spread in intestinal type gastric cancer.
  • We aimed to substantiate the putative significance of angiotensin II receptor type 1 (AT1R) and type 2 (AT2R) for gastric cancer biology by investigating the correlation of their expression with various clinicopathologic variables and patient survival.
  • Local expression of AT1R, AT2R, and angiotensin-converting enzyme (ACE) was investigated by immunohistochemistry in tumor and corresponding nontumor specimens obtained from 100 patients with gastric cancer, and compared with the ACE insertion/deletion gene polymorphism.
  • AT1R was significantly more prevalent (P < 0.001) in intestinal type gastric cancer than in diffuse type gastric cancer.
  • In intestinal type gastric cancer, its expression correlated with the N category (P = 0.009) and the International Union Against Cancer tumor stage (P = 0.024).
  • AT1R+ intestinal type gastric cancers had a larger number of lymph node metastases (P = 0.026), a higher International Union Against Cancer tumor stage (P = 0.032), and a shorter survival time (P = 0.009) than AT1R- tumors.
  • Irrespective of the genotype, AT1R+ gastric cancers had a relative risk of lymph node metastases of 4.40 (95% confidence interval, 1.30-14.86).
  • Our study shows that AT1R and AT2R are expressed locally in gastric cancer and that the combination of AT1R expression and ACE I/D gene polymorphism correlates with nodal spread in intestinal type gastric cancer.
  • [MeSH-major] Adenocarcinoma / pathology. Angiotensin II / metabolism. Genetic Predisposition to Disease. Peptidyl-Dipeptidase A / genetics. Receptors, Angiotensin / metabolism. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17548686.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Angiotensin; 11128-99-7 / Angiotensin II; EC 3.4.15.1 / Peptidyl-Dipeptidase A
  •  go-up   go-down


54. Tang LP, Cho CH, Hui WM, Huang C, Chu KM, Xia HH, Lam SK, Rashid A, Wong BC, Chan AO: An inverse correlation between Interleukin-6 and select gene promoter methylation in patients with gastric cancer. Digestion; 2006;74(2):85-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An inverse correlation between Interleukin-6 and select gene promoter methylation in patients with gastric cancer.
  • BACKGROUND: Both serum IL-6 levels and CpG island methylation have been shown to have prognostic significance in gastric cancer, it was suggested that an important link existed between IL-6 and methylation of cancers.
  • AIM: To investigate the prognostic value of IL-6 serum level and the association between serum IL-6 levels and CpG island methylation at p16, DAPK, MGMT and E-cadherin in patients with gastric cancer.
  • PATIENTS AND METHODS: Methylation status was assessed by MSP in 75 surgical specimens of gastric adenocarcinoma.
  • Serum IL-6 levels were also associated with TNM stage (p = 0.001), depth of tumor invasion (p = 0.002), lymphatic invasion (p = 0.01), vascular invasion (p = 0.008), metastasis (p = 0.002) and signet cell histology (p = 0.001).
  • CONCLUSION: IL-6 is of prognostic value for patients of gastric cancer.
  • Low serum IL-6 levels were associated with p16 or DAPK gene methylation in patients with gastric cancer.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17139167.001).
  • [ISSN] 0012-2823
  • [Journal-full-title] Digestion
  • [ISO-abbreviation] Digestion
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / Cadherins; 0 / Interleukin-6; 0 / Tumor Suppressor Protein p14ARF; 0 / Tumor Suppressor Proteins; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 2.7.11.1 / Death-Associated Protein Kinases; EC 2.7.11.17 / Calcium-Calmodulin-Dependent Protein Kinases; EC 6.5.1.- / DNA Repair Enzymes
  •  go-up   go-down


55. Kim HH, Hyung WJ, Cho GS, Kim MC, Han SU, Kim W, Ryu SW, Lee HJ, Song KY: Morbidity and mortality of laparoscopic gastrectomy versus open gastrectomy for gastric cancer: an interim report--a phase III multicenter, prospective, randomized Trial (KLASS Trial). Ann Surg; 2010 Mar;251(3):417-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Morbidity and mortality of laparoscopic gastrectomy versus open gastrectomy for gastric cancer: an interim report--a phase III multicenter, prospective, randomized Trial (KLASS Trial).
  • METHODS: Patient eligibility criteria were pathologically-proven adenocarcinoma, 20 to 80 years of age, preoperative stage I, no history of other cancer, chemotherapy, or radiotherapy.
  • The time was decided on the hypothesis that the morbidity of this trial was not significantly different from that of previous reports on open gastric cancer surgeries (17%-20%).

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20160637.001).
  • [ISSN] 1528-1140
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00452751
  • [Publication-type] Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] United States
  •  go-up   go-down


56. Zhao P, Li Y, Lu Y: Aberrant expression of CD133 protein correlates with Ki-67 expression and is a prognostic marker in gastric adenocarcinoma. BMC Cancer; 2010;10:218
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant expression of CD133 protein correlates with Ki-67 expression and is a prognostic marker in gastric adenocarcinoma.
  • BACKGROUND: The relationships between the expression of CD133, Ki-67 and prognosis in gastric adenocarcinoma are unknown and needs exploring.
  • METHODS: The samples of gastric adenocarcinoma from 336 Chinese patients with follow-up were analyzed for CD133 and Ki-67 protein expressions by immunohistochemical method.
  • RESULTS: CD133 was expressed in up to 57.4% (193/336) of this group of gastric carcinoma.
  • CD133 was positive corresponded with the tumour size, grade, infiltrative depth and clinical stage (all P < 0.05).
  • The expression of CD133 has a positive correlation with that of Ki-67 (r = 0.188, P = 0.001) in gastric adenocarcinoma.
  • CONCLUSIONS: It is suggested that CD133 may play an important role in the evolution of gastric adenocarcinoma and should be considered as a potential marker for the prognosis.
  • [MeSH-major] Adenocarcinoma / immunology. Antigens, CD / analysis. Biomarkers, Tumor / analysis. Glycoproteins / analysis. Ki-67 Antigen / analysis. Peptides / analysis. Stomach Neoplasms / immunology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Asian Continental Ancestry Group. China. Female. Gastric Mucosa / immunology. Gastric Mucosa / pathology. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Staging. Predictive Value of Tests. Prognosis. Proportional Hazards Models. Risk Assessment. Time Factors. Up-Regulation. Young Adult

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2000 Jan 1;60(1):18-21 [10646844.001]
  • [Cites] Br J Cancer. 2008 Oct 21;99(8):1285-9 [18781171.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8 [12629218.001]
  • [Cites] Cell Cycle. 2004 Apr;3(4):414-5 [15004528.001]
  • [Cites] J Clin Pathol. 2004 Sep;57(9):965-9 [15333659.001]
  • [Cites] Blood. 1997 Dec 15;90(12):5013-21 [9389721.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):396-401 [15549107.001]
  • [Cites] Rocz Akad Med Bialymst. 2004;49 Suppl 1:64-6 [15638377.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Curr Opin Oncol. 2007 Jan;19(1):61-4 [17133114.001]
  • [Cites] Nature. 2006 Dec 7;444(7120):687-8 [17151644.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):111-5 [17122771.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):106-10 [17122772.001]
  • [Cites] Laryngoscope. 2007 Mar;117(3):455-60 [17334305.001]
  • [Cites] J Neurooncol. 2007 Nov;85(2):149-57 [17516028.001]
  • [Cites] Clin Cancer Res. 2008 Jan 1;14(1):123-9 [18172261.001]
  • [Cites] Ann Surg Oncol. 2008 Feb;15(2):638-48 [17932721.001]
  • [Cites] Br J Cancer. 2008 Apr 22;98(8):1389-97 [18349830.001]
  • [Cites] J Clin Invest. 2008 Jun;118(6):2021-4 [18497883.001]
  • [Cites] J Clin Invest. 2008 Jun;118(6):2111-20 [18497886.001]
  • [Cites] Br J Cancer. 2008 Jul 8;99(1):100-9 [18542072.001]
  • [Cites] Int J Clin Pract. 2008 Aug;62(8):1212-8 [18479363.001]
  • [Cites] Cancer Sci. 2008 Aug;99(8):1578-83 [18754869.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13427-32 [18765800.001]
  • [Cites] J Exp Clin Cancer Res. 2008;27:85 [19108713.001]
  • [Cites] Cancer Lett. 2009 Mar 18;275(2):185-93 [19026485.001]
  • [Cites] World J Gastroenterol. 2009 May 14;15(18):2258-64 [19437567.001]
  • [Cites] Expert Opin Ther Targets. 2009 Jul;13(7):823-37 [19530986.001]
  • [Cites] Eur J Cancer. 2009 Jul;45(11):2034-40 [19403300.001]
  • [Cites] BMC Cancer. 2009;9:221 [19583859.001]
  • [Cites] J Transl Med. 2009;7:56 [19583834.001]
  • [Cites] Cancer Treat Rev. 2009 Aug;35(5):403-8 [19369008.001]
  • [Cites] Histopathology. 2009 Sep;55(3):284-93 [19723143.001]
  • [Cites] Cancer Invest. 2009 Oct;27(8):844-50 [19626493.001]
  • [Cites] J Pathol. 2009 Dec;219(4):427-34 [19621338.001]
  • [Cites] Int J Cancer. 2010 Feb 15;126(4):950-8 [19676044.001]
  • [Cites] Nature. 2001 Nov 1;414(6859):105-11 [11689955.001]
  • (PMID = 20487522.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / AC133 antigen; 0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / Glycoproteins; 0 / Ki-67 Antigen; 0 / Peptides
  • [Other-IDs] NLM/ PMC2891633
  •  go-up   go-down


57. Ma J, Zhang L, Ru GQ, Zhao ZS, Xu WJ: Upregulation of hypoxia inducible factor 1alpha mRNA is associated with elevated vascular endothelial growth factor expression and excessive angiogenesis and predicts a poor prognosis in gastric carcinoma. World J Gastroenterol; 2007 Mar 21;13(11):1680-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Upregulation of hypoxia inducible factor 1alpha mRNA is associated with elevated vascular endothelial growth factor expression and excessive angiogenesis and predicts a poor prognosis in gastric carcinoma.
  • AIM: To investigate the implication of the hypoxia inducible factor HIF-1alpha mRNA in gastric carcinoma and its relation to the expression of vascular endothelial growth factor (VEGF) protein, tumor angiogenesis invasion/metastasis and the patient's survival.
  • METHODS: In situ hybridization was used to examine expression of HIF-1alpha mRNA, and immunohistochemical staining was used to examine expression of VEGF protein and CD34 in 118 specimens from patients with gastric carcinoma.
  • Positive expressions of HIF-1alpha and VEGF in stage T3-T4 tumors and those with vessel invasion, lymph node metastasis and distant metastasis were dramatically stronger than stage T1-T2 cases and those without vessel invasion, lymph node metastasis and distant metastasis.
  • The mean microvascular density (MVD) in stage T3-T4 tumors and those with vessel invasion, lymph node metastasis and distant metastasis was significantly higher than stage T1-T2 tumors and those without vessel invasion, lymph node metastasis and distant metastasis.
  • CONCLUSION: Overexpression of HIF-1alpha is found in gastric carcinoma.
  • HIF-1alpha may induce the angiogenesis in gastric carcinoma by upregulating the transcription of VEGF gene, and take part in tumor invasion and metastasis.
  • They can be used as prognostic markers of gastric cancer in clinical practice.
  • [MeSH-major] Adenocarcinoma / metabolism. Carcinoma, Signet Ring Cell / metabolism. Hypoxia-Inducible Factor 1, alpha Subunit / physiology. Neovascularization, Pathologic / physiopathology. Stomach Neoplasms / metabolism. Up-Regulation. Vascular Endothelial Growth Factor A / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2000 Sep 1;60(17):4873-80 [10987301.001]
  • [Cites] Endocr Relat Cancer. 2006 Dec;13 Suppl 1:S61-75 [17259560.001]
  • [Cites] Oncology. 2002;62(2):157-66 [11914602.001]
  • [Cites] Clin Cancer Res. 2002 Jun;8(6):1831-7 [12060624.001]
  • [Cites] Zhonghua Yi Xue Za Zhi. 2002 May 25;82(10):708-11 [12133473.001]
  • [Cites] Biochim Biophys Acta. 2002 Oct 11;1578(1-3):73-83 [12393189.001]
  • [Cites] Oncology. 2003;64(1):61-73 [12457033.001]
  • [Cites] Int J Cancer. 2003 Jun 10;105(2):176-81 [12673675.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Jun 6;92(12):5510-4 [7539918.001]
  • [Cites] FASEB J. 1999 Jan;13(1):9-22 [9872925.001]
  • [Cites] Histopathology. 2005 Jan;46(1):31-6 [15656883.001]
  • [Cites] Exp Mol Pathol. 2005 Apr;78(2):123-30 [15713437.001]
  • [Cites] J Urol. 2005 May;173(5):1762-6 [15821583.001]
  • [Cites] Di Yi Jun Yi Da Xue Xue Bao. 2005 Aug;25(8):1034-6 [16109571.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):770-4 [16424008.001]
  • [Cites] Clin Colorectal Cancer. 2006 Jan;5(5):350-3 [16512994.001]
  • [Cites] BMC Cancer. 2006;6:26 [16438736.001]
  • [Cites] Curr Opin Hematol. 2006 May;13(3):169-74 [16567961.001]
  • [Cites] Cancer Res. 1999 Nov 15;59(22):5830-5 [10582706.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Dec 29;266(3):718-22 [10603309.001]
  • [Cites] Anat Rec. 2000 Jun 15;261(3):126-35 [10867630.001]
  • [Cites] Am J Pathol. 2000 Aug;157(2):411-21 [10934146.001]
  • [Cites] Cancer Res. 2000 Sep 1;60(17):4693-6 [10987269.001]
  • [Cites] World J Gastroenterol. 2006 Jul 7;12(25):3970-6 [16810742.001]
  • [Cites] J Surg Oncol. 2006 Aug 1;94(2):149-54 [16847924.001]
  • [Cites] Clin Cancer Res. 2006 Sep 1;12(17):5112-7 [16951228.001]
  • [Cites] Oncogene. 2006 Oct 5;25(45):6123-7 [16682946.001]
  • [Cites] Eur Urol. 2006 Dec;50(6):1272-7 [16814458.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Dec;15(12):2332-5 [17164353.001]
  • [Cites] Biochem Biophys Res Commun. 2002 Mar 8;291(4):908-14 [11866451.001]
  • (PMID = 17461470.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / HIF1A protein, human; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / RNA, Messenger; 0 / Vascular Endothelial Growth Factor A
  • [Other-IDs] NLM/ PMC4146946
  •  go-up   go-down


58. Lee DY, Park CS, Kim HS, Kim JY, Kim YC, Lee S: Maspin and p53 protein expression in gastric adenocarcinoma and its clinical applications. Appl Immunohistochem Mol Morphol; 2008 Jan;16(1):13-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Maspin and p53 protein expression in gastric adenocarcinoma and its clinical applications.
  • OBJECTIVES: To investigate the role of maspin and p53 expression in the progression of gastric cancer, and its value as a prognostic indicator.
  • MATERIALS AND METHODS: The expression of maspin and p53 in 152 cases of gastric cancer was detected by immunohistochemistry and compared with the clinicopathologic tumor parameters.
  • The relationship between maspin and p53 expression was also analyzed in the gastric cancers.
  • Two patterns of immunostaining for maspin were seen in the maspin-positive gastric cancer cases: cytoplasm-only staining (67.0%, 73 of 109 cases) and staining of both cytoplasm and nucleus (33.0%, 36 of 109 cases).
  • Maspin expression showed a negative association with histologic grade, depth of invasion, metastasis, and TNM stage (all P<0.05).
  • p53 expression showed an association with node metastasis, and TNM stage (both P<0.05).
  • In univariate log-rank analysis, loss of maspin expression, histologic grade, distant metastasis, and TNM stage were associated with patient survival.
  • However, in multivariate analysis TNM stage and regional node metastasis were the only independent prognostic factors.
  • Maspin expression is inversely correlated with mutant p53 expression in gastric cancer, which suggests that maspin expression is regulated by the p53 pathway.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18091326.001).
  • [ISSN] 1541-2016
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / SERPIN-B5; 0 / Serpins; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


59. Miura T, Yamada S, Maruyama G, Nakamura J, Miura T, Yanagi M, Takahashi T: [A pregnant woman with inoperable advanced gastric cancer who received systemic anti-cancer chemotherapy after the non-full term fetus delivery by cesarean section]. Nihon Shokakibyo Gakkai Zasshi; 2009 Oct;106(10):1500-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A pregnant woman with inoperable advanced gastric cancer who received systemic anti-cancer chemotherapy after the non-full term fetus delivery by cesarean section].
  • Examinations revealed an advanced gastric cancer with multiple liver, bone, lymph node metastasis and mesenteric dissemination, thus she was transferred to our division at 27 weeks and 1 day-gestation.
  • The association of pregnancy and gastric cancer is rare but such cases are often in an advanced clinical stage, with bad prognosis.
  • Upper gastrointestinal endoscopy when gastric cancer is suspected is recommended in any pregnant woman with long-term morning sickness.
  • [MeSH-major] Adenocarcinoma / drug therapy. Cesarean Section. Pregnancy Complications, Neoplastic / drug therapy. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cesarean Section.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19834298.001).
  • [ISSN] 0446-6586
  • [Journal-full-title] Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology
  • [ISO-abbreviation] Nihon Shokakibyo Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 26
  •  go-up   go-down


60. Miyasaka Y, Nagai E, Ohuchida K, Nakata K, Hayashi A, Mizumoto K, Tsuneyoshi M, Tanaka M: CD44v6 expression in intraductal papillary mucinous neoplasms of the pancreas. Pancreas; 2010 Jan;39(1):31-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The IPMNs were divided into 4 groups according to the grade of atypia (adenoma, borderline IPMN, noninvasive carcinoma, and invasive carcinoma) and 5 subtypes according to histological phenotype (gastric, intestinal, pancreatobiliary, oncocytic, and unclassified).
  • RESULTS: Whereas normal ductal epithelium did not express CD44v6, CD44v6 expression was observed from the early stage of IPMNs and up-regulated in the progression of IPMNs to invasive carcinoma.
  • [MeSH-major] Adenocarcinoma, Mucinous / metabolism. Antigens, CD44 / biosynthesis. Carcinoma, Pancreatic Ductal / metabolism. Pancreatic Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19952968.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / CD44v6 antigen
  •  go-up   go-down


61. Klinge U, Ackermann D, Lynen-Jansen P, Mertens PR: The risk to develop a recurrence of a gastric cancer-is it independent of time? Langenbecks Arch Surg; 2008 Mar;393(2):149-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The risk to develop a recurrence of a gastric cancer-is it independent of time?
  • MATERIALS AND METHODS: To test, whether the incidence for developing a recurrence may be considered as remaining constant over time, we analysed survival data of 446 patients with gastric cancer, operated from 1975-2001 in the Surgical Department of the RWTH Aachen.
  • RESULTS: All survival curves, even after sub-grouping according to UICC stage, show a monotonous decline without any apparent S-shape.
  • The impact of TNM and UICC stage to predict the survival in patients is estimated by Cox regression, for estimation the risk for death a logistic regression is performed.
  • Whereas the presence of metastasis lowers the prognosis significantly with a hazard ratio of 1.57 and an odds ratio of 7.56, respectively, a significant relevance for the UICC stage, the tumour size or the lymph node status cannot be proven.
  • [MeSH-major] Adenocarcinoma / mortality. Adenocarcinoma / surgery. Neoplasm Recurrence, Local / mortality. Postoperative Complications / mortality. Stomach Neoplasms / mortality. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Rev Cancer. 2005 Sep;5(9):744-9 [16148886.001]
  • [Cites] Cancer Res. 2003 Apr 15;63(8):1727-30 [12702551.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 1998 Apr;3(2):201-13 [10819528.001]
  • [Cites] Biochemistry (Mosc). 2005 Sep;70(9):1055-64 [16266279.001]
  • [Cites] Cancer Cell Int. 2005 Mar 02;5(1):5 [15743536.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3035-9 [15833829.001]
  • [Cites] Cancer Res. 2005 Mar 1;65(5):1755-60 [15753371.001]
  • [Cites] Ann Surg. 2004 Nov;240(5):808-16 [15492562.001]
  • [Cites] Am J Pathol. 2005 Nov;167(5):1405-10 [16251424.001]
  • [Cites] Cancer Biol Ther. 2002 Sep-Oct;1(5):571-81 [12496492.001]
  • [Cites] Radiother Oncol. 2001 Dec;61(3):233-46 [11730992.001]
  • [Cites] J Pathol. 1999 Jan;187(1):61-81 [10341707.001]
  • [Cites] Ann Surg. 2005 Feb;241(2):247-55 [15650634.001]
  • [Cites] Cancer. 1953 Sep;6(5):963-8 [13094644.001]
  • [Cites] J Am Coll Surg. 2005 Oct;201(4):503-10 [16183487.001]
  • [Cites] Nat Rev Cancer. 2003 Jun;3(6):453-8 [12778135.001]
  • [Cites] Cell. 2006 Jan 27;124(2):263-6 [16439202.001]
  • [Cites] Theor Biol Med Model. 2006 Oct 17;3:37 [17044918.001]
  • (PMID = 18175141.001).
  • [ISSN] 1435-2451
  • [Journal-full-title] Langenbeck's archives of surgery
  • [ISO-abbreviation] Langenbecks Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


62. Repiso A, Gómez-Rodríguez R, López-Pardo R, Lombera MM, Romero M, Aranzana A, Abad S, Rodríguez-Merlo R, López L, Carboles JM: Usefulness of endoscopic ultrasonography in preoperative gastric cancer staging: diagnostic yield and therapeutic impact. Rev Esp Enferm Dig; 2010 Jul;102(7):413-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Usefulness of endoscopic ultrasonography in preoperative gastric cancer staging: diagnostic yield and therapeutic impact.
  • OBJECTIVES: To evaluate the diagnostic yield of endoscopic ultrasonography in loco-regional staging of gastric cancer in our medium and to determine the impact of this technique on later therapeutic management.
  • MATERIAL AND METHODS: This is a retrospective study carried out on patients histologically diagnosed with gastric adenocarcinoma who had been referred for endoscopic ultrasonographic examination.
  • RESULTS: Forty-six patients with gastric adenocarcinoma were included in the study (a reference exploration was available in 36 cases).
  • Diagnostic precision was 70% in stage T, while in stages T1, T2, T3 y T4 was 100, 38, 82, and 100%, respectively.
  • Diagnostic precision was 72% for stage N (N0: 58%; Nx 88%).
  • CONCLUSIONS: Endoscopic ultrasonography is a useful technique for loco-regional staging of gastric adenocarcinoma, which may have important implications in the therapeutic management of these patients.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20617861.001).
  • [ISSN] 1130-0108
  • [Journal-full-title] Revista española de enfermedades digestivas : organo oficial de la Sociedad Española de Patología Digestiva
  • [ISO-abbreviation] Rev Esp Enferm Dig
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


63. Dalal KM, Woo Y, Galanis C, Gonen M, Tang L, Allen P, DeMatteo R, Fong Y, Coit DG: Detection of micrometastases in peritoneal washings of pancreatic cancer patients by the reverse transcriptase polymerase chain reaction. J Gastrointest Surg; 2007 Dec;11(12):1598-605; discussion 1605-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Pancreatic cancer patients with positive (+) peritoneal cytology have a prognosis similar to stage IV patients.
  • METHODS: Peritoneal washes were obtained prospectively from 35 consecutive patients with pancreatic adenocarcinoma undergoing staging laparoscopy and 16 patients undergoing laparoscopy for benign disease.
  • [MeSH-major] Adenocarcinoma / pathology. Pancreatic Neoplasms / pathology. Peritoneum / pathology


64. Nagata Y, Eguchi S, Takatsuki M, Enjoji A, Ichikawa T, Hayashi T, Kanematsu T: Experience of gastric cancer in a patient who had received a living-donor liver transplantation. Gastric Cancer; 2007;10(3):187-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Experience of gastric cancer in a patient who had received a living-donor liver transplantation.
  • A 57-year-old woman had previously undergone a living-donor liver transplantation (LDLT) for end-stage liver disease related to hepatitis B virus.
  • In the course of postoperative surveillance, she was incidentally found to have gastric cancer by an endoscopic examination 2 years after the liver transplantation.
  • A gastric resection was the treatment choice, and the results were successful.
  • The tumor, which was moderately differentiated adenocarcinoma, was limited to the mucosal layer, with no metastasis.
  • This is the first reported case of a gastric cancer after LDLT.
  • [MeSH-major] Adenocarcinoma / etiology. Hepatitis B / complications. Liver Failure / therapy. Liver Transplantation / adverse effects. Stomach Neoplasms / etiology
  • [MeSH-minor] Female. Gastrectomy. Gastric Mucosa / pathology. Helicobacter Infections / complications. Helicobacter pylori / isolation & purification. Humans. Immunosuppressive Agents / adverse effects. Immunosuppressive Agents / therapeutic use. Living Donors. Middle Aged


65. Perrone G, Ruffini PA, Catalano V, Spino C, Santini D, Muretto P, Spoto C, Zingaretti C, Sisti V, Alessandroni P, Giordani P, Cicetti A, D'Emidio S, Morini S, Ruzzo A, Magnani M, Tonini G, Rabitti C, Graziano F: Intratumoural FOXP3-positive regulatory T cells are associated with adverse prognosis in radically resected gastric cancer. Eur J Cancer; 2008 Sep;44(13):1875-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intratumoural FOXP3-positive regulatory T cells are associated with adverse prognosis in radically resected gastric cancer.
  • We investigated the clinical significance of tumour-infiltrating FOXP3-positive regulatory T cells (Tregs) in radically resected (R0) gastric cancer.
  • From a single-institution database, tumors of 110 patients who underwent R0 resection for stage II-III disease were studied for FOXP3-positive Tregs by immunohistochemistry.
  • Tregs were significantly higher in gastric carcinomas than in normal tissue (P = 0.0001).
  • Multivariate analysis showed association between adverse relapse-free survival and grading 3, stage III, VELIPI and Tregs count >or=6 (P = 0.02).
  • Adverse overall survival was associated with grading 3, stage III, VELIPI and Tregs count >or=6 (P = 0.006).
  • FOXP3-positive Tregs may be a novel marker for identifying high-risk gastric cancer patients.
  • [MeSH-major] Adenocarcinoma / metabolism. Forkhead Transcription Factors / metabolism. Stomach Neoplasms / metabolism. T-Lymphocytes, Regulatory / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18617393.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / FOXP3 protein, human; 0 / Forkhead Transcription Factors
  •  go-up   go-down


66. Sakurai Y, Kamoshida S, Furuta S, Sunagawa R, Inaba K, Isogaki J, Komori Y, Uyama I, Tsutsumi Y: Levels and expressions of orotate phosphoribosyltransferase in gastric carcinoma and normal gastric mucosa tissues. Gastric Cancer; 2007;10(4):234-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Levels and expressions of orotate phosphoribosyltransferase in gastric carcinoma and normal gastric mucosa tissues.
  • METHODS: Levels of OPRT were examined in 97 gastric carcinoma tissues and 65 normal gastric mucosa tissues obtained from patients with gastric carcinoma.
  • The relation between OPRT levels and clinicopathological variables was evaluated, and correlations of OPRT with thymidylate synthase and dihydropyrimidine dehydrogenase levels in gastric carcinoma tissues were evaluated.
  • RESULTS: Although OPRT levels were high in well-differentiated and localized carcinomas, they were not correlated with other clinicopathological variables or with the pathological stage of gastric carcinoma.
  • Levels of OPRT were significantly higher in gastric carcinoma tissue than in normal gastric mucosa.
  • In samples of gastric carcinoma tissues and normal gastric mucosa tissues obtained simultaneously from 24 patients, no correlation was found between OPRT levels in gastric carcinoma and levels in normal gastric mucosa.
  • CONCLUSION: These results suggest that the OPRT level is significantly higher in gastric carcinoma tissue than in normal gastric mucosa and that the OPRT level in gastric carcinoma is a novel variable that is independent of the levels of other previously known enzymes related to 5-fluorouracil (FU) metabolism.
  • [MeSH-major] Adenocarcinoma / enzymology. Gastric Mucosa / enzymology. Orotate Phosphoribosyltransferase / metabolism. Stomach Neoplasms / enzymology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1986 Jan;46(1):20-8 [2415245.001]
  • [Cites] Oncol Rep. 2005 Oct;14(4):987-92 [16142362.001]
  • [Cites] Oncol Rep. 1997 Nov-Dec;4(6):1189-94 [21590220.001]
  • [Cites] Gan To Kagaku Ryoho. 2005 May;32(5):653-8 [15918566.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Mar;85(6):1754-8 [3279416.001]
  • [Cites] Cancer. 1992 Sep 1;70(5):1030-7 [1515980.001]
  • [Cites] Br J Surg. 2002 Aug;89(8):1035-42 [12153632.001]
  • [Cites] Gastric Cancer. 2003;6 Suppl 1:2-8 [12775012.001]
  • [Cites] Cancer. 2004 Feb 15;100(4):723-31 [14770427.001]
  • [Cites] Anticancer Drugs. 1996 Jul;7(5):548-57 [8862723.001]
  • [Cites] Cancer Res. 1996 Jun 1;56(11):2602-6 [8653704.001]
  • [Cites] Gan To Kagaku Ryoho. 2005 Jul;32(7):1017-22 [16044965.001]
  • [Cites] Int J Clin Oncol. 2003 Apr;8(2):72-8 [12720098.001]
  • [Cites] Cancer. 1991 Nov 1;68(9):1903-9 [1717130.001]
  • [Cites] Br J Cancer. 2007 Jan 29;96(2):277-83 [17211470.001]
  • [Cites] Gastric Cancer. 1998 Dec;1(1):10-24 [11957040.001]
  • [Cites] Gastric Cancer. 2004;7(4):196-201; discussion 201-203 [15616767.001]
  • [Cites] Oncol Rep. 1997 Jul-Aug;4(4):685-90 [21590122.001]
  • [Cites] Br J Surg. 1989 Jun;76(6):535-40 [2758258.001]
  • [Cites] Cancer Sci. 2006 Jun;97(6):492-8 [16734727.001]
  • [Cites] Gastric Cancer. 2005;8(2):78-85 [15864714.001]
  • [Cites] Oncol Rep. 2004 May;11(5):973-9 [15069534.001]
  • [Cites] Anticancer Drugs. 2004 Feb;15(2):85-106 [15075664.001]
  • [Cites] Cancer. 2007 Jan 1;109(1):33-40 [17133415.001]
  • (PMID = 18095079.001).
  • [ISSN] 1436-3291
  • [Journal-full-title] Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  • [ISO-abbreviation] Gastric Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; EC 1.3.1.2 / Dihydrouracil Dehydrogenase (NADP); EC 2.1.1.45 / Thymidylate Synthase; EC 2.4.2.10 / Orotate Phosphoribosyltransferase; U3P01618RT / Fluorouracil
  •  go-up   go-down


67. Cunningham SC, Kamangar F, Kim MP, Hammoud S, Haque R, Iacobuzio-Donahue C, Ashfaq R, Kern SE, Maitra A, Heitmiller RE, Choti MA, Lillemoe KD, Cameron JL, Yeo CJ, Montgomery E, Schulick RD: MKK4 status predicts survival after resection of gastric adenocarcinoma. Arch Surg; 2006 Nov;141(11):1095-9; discussion 1100
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MKK4 status predicts survival after resection of gastric adenocarcinoma.
  • HYPOTHESIS: Lack of expression of the tumor-suppressor gene MKK4 is significantly correlated with poor survival after resection of gastric adenocarcinoma.
  • PATIENTS: Patients operated on because of gastric adenocarcinoma between 1983 and 1995.
  • Given the small size (7%) of the MKK4-negative group (as expected, given the 5%-10% incidence of genetic loss in carcinomas), a Cox proportional hazards analysis was performed, adjusting for age, sex, and tumor stage.
  • CONCLUSIONS: The lack of expression of the tumor-suppressor gene MKK4 in resected gastric adenocarcinoma is robustly associated with poor survival.
  • This finding may provide a useful prognostic tool in patients with gastric adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / enzymology. MAP Kinase Kinase 4 / genetics. Stomach Neoplasms / enzymology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17116802.001).
  • [ISSN] 0004-0010
  • [Journal-full-title] Archives of surgery (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch Surg
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA62924
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.12.2 / MAP Kinase Kinase 4
  •  go-up   go-down


68. Baldus SE, Mönig SP, Zirbes TK, Thakran J, Köthe D, Köppel M, Hanisch FG, Thiele J, Schneider PM, Hölscher AH, Dienes HP: Lewis(y) antigen (CD174) and apoptosis in gastric and colorectal carcinomas: correlations with clinical and prognostic parameters. Histol Histopathol; 2006 05;21(5):503-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lewis(y) antigen (CD174) and apoptosis in gastric and colorectal carcinomas: correlations with clinical and prognostic parameters.
  • Therefore, we tried to elucidate its clinicopathological relevance in a series of 160 gastric and 215 colorectal carcinomas by immunohistochemical detection of Le(y) and visualization of apoptotic cells applying the in-situ-end labelling (ISEL) method, followed by semiquantitative scoring of the specimens.
  • In both gastric as well as colorectal carcinomas, between 40 and 50% of the cases were Le(y) reactive.
  • In colorectal cancers, Le(y) was associated with increased tumor staging, showing the strongest positivity in stage IV.
  • [MeSH-major] Adenocarcinoma / immunology. Apoptosis. Carcinoma, Signet Ring Cell / immunology. Colorectal Neoplasms / immunology. Lewis Blood-Group System / analysis. Stomach Neoplasms / immunology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16493580.001).
  • [ISSN] 1699-5848
  • [Journal-full-title] Histology and histopathology
  • [ISO-abbreviation] Histol. Histopathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Lewis Blood-Group System; 0 / Lewis Y antigen
  •  go-up   go-down


69. Yoshida I, Sakurai Y, Komori Y, Tonomura S, Masui T, Shoji M, Nakamura Y, Imazu H, Uyama I, Ochiai M: Successful downstaging by S-1-based chemotherapy followed by surgical resections for gastric carcinoma with extensive distant lymph node metastasis - report of two cases and a review of cases with surgical resection after downstaging by S-1-based chemotherapy. Hepatogastroenterology; 2005 May-Jun;52(63):978-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful downstaging by S-1-based chemotherapy followed by surgical resections for gastric carcinoma with extensive distant lymph node metastasis - report of two cases and a review of cases with surgical resection after downstaging by S-1-based chemotherapy.
  • We report two cases of gastric carcinoma with successful downstaging using S-1-based chemotherapy followed by surgical resection, which enabled us to confirm the histological effect of chemotherapy.
  • After the successful downstaging of these metastatic gastric carcinomas evaluated by imaging analyses, the patients underwent surgical resections.
  • These cases provide further evidence, suggesting that S-1-based chemotherapy enabled downstaging of stage IV gastric carcinoma associated with distant extensive lymph node metastasis and consequently the following possible curative resections.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antimetabolites, Antineoplastic / therapeutic use. Gastrectomy. Lymphatic Metastasis. Neoadjuvant Therapy. Oxonic Acid / therapeutic use. Pyridines / therapeutic use. Stomach Neoplasms / drug therapy. Tegafur / therapeutic use

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15966245.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


70. Carboni F, Lorusso R, Santoro R, Lepiane P, Mancini P, Sperduti I, Santoro E: Adenocarcinoma of the esophagogastric junction: the role of abdominal-transhiatal resection. Ann Surg Oncol; 2009 Feb;16(2):304-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of the esophagogastric junction: the role of abdominal-transhiatal resection.
  • The surgical strategy for adenocarcinoma of the esophagogastric junction is still controversial.
  • The aim of this study was to evaluate surgical results of the abdominal-transhiatal approach for 100 consecutively operated type II and III cardia adenocarcinoma, to clarify clinicopathological differences between these tumors, and to define prognostic factors.
  • A prospectively maintained database identified 100 consecutively operated patients with Siewert type II and III cardia adenocarcinoma.
  • Concerning clinicopathological characteristics, only the incidence of T1-2 stage was significantly higher in Siewert II type (P = .006).
  • Pathologic T and N stage and R status were independent prognostic factors by multivariate analysis, and Siewert type showed a trend toward significance.
  • True carcinoma of the cardia may be a distinct clinical entity with a more aggressive natural history than subcardial gastric carcinoma.
  • [MeSH-major] Adenocarcinoma / surgery. Digestive System Surgical Procedures. Esophagogastric Junction / surgery. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Surg Oncol. 2009 Jul;16(7):2074-5; author reply 2076 [19365623.001]
  • (PMID = 19050964.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


71. Ahn HS, Kim JW, Yoo MW, Park DJ, Lee HJ, Lee KU, Yang HK: Clinicopathological features and surgical outcomes of patients with remnant gastric cancer after a distal gastrectomy. Ann Surg Oncol; 2008 Jun;15(6):1632-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological features and surgical outcomes of patients with remnant gastric cancer after a distal gastrectomy.
  • BACKGROUND: The incidence of gastric cancer in the remnant stomach after distal gastrectomy is increasing.
  • The aim of this study was to evaluate the clinicopathological features and surgical outcomes of remnant gastric cancer (RGC).
  • The 45 RGCs occurring after distal gastrectomy for initial gastric cancer had a shorter interval and were more frequently located at the non-anastomotic site than those following benign lesions (P <0.001 and P = 0.010).
  • An early stage of the initial gastric cancer, no symptoms at diagnosis, curative resection, tumor size smaller than 6 cm, and an early TNM stage of the RGC were associated with longer survival; the initial gastric disease, the interval and the location of RGC were not.
  • CONCLUSION: The successful curative resection and an early stage of the RGC led to good outcomes.
  • In considering the different latency periods of the two initial gastric diseases, appropriate follow-up programs should be developed.
  • [MeSH-major] Adenocarcinoma / surgery. Gastrectomy. Gastric Stump / surgery. Neoplasm Recurrence, Local / surgery. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18379851.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


72. Guo E, Chen L, Xie Q, Chen J, Tang Z, Wu Y: Serum HDL-C as a potential biomarker for nodal stages in gastric cancer. Ann Surg Oncol; 2007 Sep;14(9):2528-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum HDL-C as a potential biomarker for nodal stages in gastric cancer.
  • BACKGROUND: Although changes in lipid profile have been documented in gastrointestinal cancers, the specific relationship between serum lipid levels and lymph node (N) stages in gastric cancer remains uncertain.
  • METHODS: Preoperative serum lipid concentrations were retrospectively examined in 501 patients who underwent curative resection for primary gastric cancer.
  • RESULTS: The serum high-density lipoprotein cholesterol (HDL-C) levels in gastric cancer patients correlated well with N stages.
  • By receiver operating characteristic analysis, the combination of serum HDL-C concentration and TC/HDL-C ratio led to a sensitivity of 70.0% and a specificity of 51.0% in predicting stage pN(2-3).
  • When patients' lipid levels were stratified by means of histological differentiation, the significant correlation of serum HDL-C levels with nodal stages was only detected in differentiated gastric cancer.
  • CONCLUSIONS: For gastric cancer patients, preoperative low serum HDL-C concentration or high TC/HDL-C ratio might be a potential biomarker of advanced pN(2-3) stages, especially for those with the histologically differentiated type.
  • [MeSH-major] Adenocarcinoma / blood. Cholesterol, HDL / blood. Stomach Neoplasms / blood

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17597347.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cholesterol, HDL; 0 / Cholesterol, LDL; 0 / Triglycerides
  •  go-up   go-down


73. Alakus H, Grass G, Hennecken JK, Bollschweiler E, Schulte C, Drebber U, Baldus SE, Metzger R, Hölscher AH, Mönig SP: Clinicopathological significance of MMP-2 and its specific inhibitor TIMP-2 in gastric cancer. Histol Histopathol; 2008 08;23(8):917-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological significance of MMP-2 and its specific inhibitor TIMP-2 in gastric cancer.
  • Since in a previous study we showed that the expression of MMP-2 correlates with clinicopathological parameters in gastric cancer, we have now investigated a possible correlation of MMP-2 and TIMP-2 expression with survival in gastric cancer, as well as the possible association of TIMP-2 with clinicopathological parameters.
  • Tissue samples were obtained from 116 gastric cancer patients who underwent gastrectomy with extended lymphadenectomy.
  • High epithelial MMP-2 immunoreactivity was significantly associated with tumor stage and poor survival using the Kaplan-Meier log-rank statistical method (log-rank statistics).
  • TIMP-2 showed no association with survival in gastric cancer, but the intensity of TIMP-2 staining in tumor cells correlated significantly with tumor differentiation based on the WHO and Lauren and Ming classifications, as well as with presence of distant metastasis.
  • Our results show that high epithelial MMP-2 expression in gastric cancer is associated with poor survival, although it is not an independent prognostic factor, and that aggressive forms of gastric cancer are associated with low TIMP-2 expression.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Biomarkers, Tumor / metabolism. Matrix Metalloproteinase 2 / metabolism. Stomach Neoplasms / metabolism. Stomach Neoplasms / pathology. Tissue Inhibitor of Metalloproteinase-2 / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18498066.001).
  • [ISSN] 1699-5848
  • [Journal-full-title] Histology and histopathology
  • [ISO-abbreviation] Histol. Histopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 127497-59-0 / Tissue Inhibitor of Metalloproteinase-2; EC 3.4.24.24 / Matrix Metalloproteinase 2
  •  go-up   go-down


74. Abete M, Ronchetti V, Casano A, Pescio G: [Pancreatic fistula after pancreaticoduodenectomy: risk factors and treatment]. Minerva Chir; 2005 Apr;60(2):99-110
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Indications for surgery were pancreatic head adenocarcinoma (70%), ampullary adenocarcinoma (16.6%), duodenal adenocarcinoma (6.6%) and chronic pancreatitis (6.6%).The personal method of reconstruction after PD consisting of a double Roux-en-Y on the same jejunal loop without interruption of the mesentery and a third anatomical Roux-en-Y to reconstitute the alimentary tract.
  • The gastric stump was anastomosed with the jejunum as a Billroth II-type reconstruction in older patients.
  • Nowadays pancreaticojejunostomy remains the standard technique; pancreaticogastrostomy, occlusion of the pancreatic duct and two-stage pancreaticojejunostomy must be reserved to selected cases.

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Pancreatic Diseases.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15973216.001).
  • [ISSN] 0026-4733
  • [Journal-full-title] Minerva chirurgica
  • [ISO-abbreviation] Minerva Chir
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article; Multicenter Study
  • [Publication-country] Italy
  •  go-up   go-down


75. Cho WJ, Shin JM, Kim JS, Lee MR, Hong KS, Lee JH, Koo KH, Park JW, Kim KS: miR-372 regulates cell cycle and apoptosis of ags human gastric cancer cell line through direct regulation of LATS2. Mol Cells; 2009 Dec 31;28(6):521-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] miR-372 regulates cell cycle and apoptosis of ags human gastric cancer cell line through direct regulation of LATS2.
  • Previously, we have reported tissue- and stage-specific expression of miR-372 in human embryonic stem cells and so far, not many reports speculate the function of this microRNA (miRNA).
  • In this study, we screened various human cancer cell lines including gastric cancer cell lines and found first time that miR-372 is expressed only in AGS human gastric adenocarcinoma cell line.
  • [MeSH-major] Adenocarcinoma / metabolism. MicroRNAs / metabolism. Protein-Serine-Threonine Kinases / metabolism. Stomach Neoplasms / metabolism. Tumor Suppressor Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19937137.001).
  • [ISSN] 0219-1032
  • [Journal-full-title] Molecules and cells
  • [ISO-abbreviation] Mol. Cells
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MicroRNAs; 0 / RNA, Small Interfering; 0 / Tumor Suppressor Proteins; EC 2.7.1.11 / LATS2 protein, human; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  •  go-up   go-down


76. Ajani JA, Mansfield PF, Crane CH, Wu TT, Lunagomez S, Lynch PM, Janjan N, Feig B, Faust J, Yao JC, Nivers R, Morris J, Pisters PW: Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome. J Clin Oncol; 2005 Feb 20;23(6):1237-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome.
  • We evaluated paclitaxel-based induction chemotherapy and chemoradiotherapy in patients with localized gastric or gastroesophageal adenocarcinoma to determine its feasibility, impact on the R0 resection rate, type of pathologic response, OS, and DFS.
  • PATIENTS AND METHODS: Patients with operable, localized gastric, or gastroesophageal adenocarcinoma were eligible.
  • Most carcinomas were proximal (83%) and pretreatment stage EUST3 (85%).
  • No pretreatment parameter (sex, cancer location, baseline T stage, or baseline N stage) predicted the type of postsurgery pathologic response, OS, or DFS.
  • [MeSH-major] Adenocarcinoma / therapy. Chemotherapy, Adjuvant. Paclitaxel / administration & dosage. Radiotherapy, Adjuvant. Stomach Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15718321.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] P88XT4IS4D / Paclitaxel
  •  go-up   go-down


77. Reid-Lombardo KM, Gay G, Patel-Parekh L, Ajani JA, Donohue JH, Gastric Patient Care Evaluation Group from the Commission on Cancer: Treatment of gastric adenocarcinoma may differ among hospital types in the United States, a report from theNational Cancer Data Base. J Gastrointest Surg; 2007 Apr;11(4):410-9; discussion 419-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of gastric adenocarcinoma may differ among hospital types in the United States, a report from theNational Cancer Data Base.
  • We wanted to determine if there were differences in the treatment of patients with gastric cancer between community cancer centers and teaching hospitals in the United States.
  • Data from the 2001 Gastric Cancer Patient Care Evaluation Study of the National Cancer Data Base comprising 6,047 patients with gastric adenocarcinoma treated at 691 hospitals were assessed.
  • Adjusted for cancer stage, chemotherapy and radiation therapy were utilized with equal frequency at all types of treatment centers.
  • [MeSH-major] Adenocarcinoma / therapy. Hospitals, Community / statistics & numerical data. Hospitals, Teaching / statistics & numerical data. Stomach Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2001 Jul 19;345(3):181-8 [11463014.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):7114-24 [16192595.001]
  • [Cites] N Engl J Med. 2002 Apr 11;346(15):1128-37 [11948273.001]
  • [Cites] Eur J Surg Oncol. 2002 Jun;28(4):401-5 [12099650.001]
  • [Cites] J Gastrointest Surg. 2003 Nov;7(7):879-83 [14592661.001]
  • [Cites] Cancer. 2000 Feb 15;88(4):921-32 [10679663.001]
  • [Cites] Ann Ital Chir. 1999 Nov-Dec;70(6):829-30 [10804656.001]
  • [Cites] Ann Surg. 2000 Sep;232(3):362-71 [10973386.001]
  • [Cites] JAMA. 2000 Dec 20;284(23):3028-35 [11122590.001]
  • [Cites] Cancer Sci. 2003 Nov;94(11):998-1002 [14611678.001]
  • [Cites] Jpn J Clin Oncol. 2004 Jun;34(6):352-6 [15333689.001]
  • [Cites] Chirurg. 1994 Apr;65(4):298-306 [8020350.001]
  • [Cites] Lancet. 1995 Mar 25;345(8952):745-8 [7891484.001]
  • [Cites] Lancet. 1996 Apr 13;347(9007):995-9 [8606613.001]
  • [Cites] Eur J Surg Oncol. 1996 Jun;22(3):205-10 [8654596.001]
  • [Cites] J Am Coll Surg. 1996 Dec;183(6):616-24 [8957465.001]
  • [Cites] Jpn J Clin Oncol. 2005 Feb;35(2):103-5 [15709097.001]
  • [Cites] Br J Surg. 2005 Sep;92(9):1103-9 [16106493.001]
  • [Cites] Br J Surg. 2002 Jan;89(1):123 [11851682.001]
  • (PMID = 17436123.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1852379
  •  go-up   go-down


78. Lee J, Lee K, Kim W: Duodenal stump cancer after Billroth-II distal gastrectomy for gastric cancer. Gastric Cancer; 2009;12(2):118-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Duodenal stump cancer after Billroth-II distal gastrectomy for gastric cancer.
  • However, metachronous or even recurrent cancer at the duodenal stump following Billroth II type distal gastrec tomy for gastric cancer is extremely rare and, to our knowledge, has not yet been reported.
  • A 68-year-old man underwent Billroth II distal gastrectomy with D2 lymph node dissection for an advanced gastric cancer.
  • At that time the tumor stage was T2bN3M0, with 44 of 78 retrieved lymph nodes showing metastasis.
  • A polypoid tumor that bled easily when touched was found at the end of the afferent loop of the duodenal stump by gastrofiberscopic examination, and it was proven to be an adenocarcinoma by endoscopic biopsy.
  • [MeSH-major] Adenocarcinoma / pathology. Duodenal Neoplasms / pathology. Gastroenterostomy. Neoplasms, Second Primary / pathology

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Gastroenterol. 2002 May-Jun;34(5):533-5 [11960064.001]
  • [Cites] J Surg Oncol. 2008 Aug 1;98(2):106-10 [18452218.001]
  • [Cites] Br J Surg. 1994 Oct;81(10):1472-4 [7820475.001]
  • [Cites] Radiographics. 2006 Jan-Feb;26(1):143-56 [16418249.001]
  • [Cites] Am J Surg. 2008 Jul;196(1):19-22 [18417082.001]
  • [Cites] Surgery. 1999 Feb;125(2):195-201 [10026754.001]
  • [Cites] Surg Today. 2000;30(8):735-8 [10955739.001]
  • [Cites] Am Surg. 1995 Apr;61(4):371-6 [7893109.001]
  • [Cites] Cancer. 2001 Sep 15;92(6):1427-34 [11745219.001]
  • [Cites] Br J Surg. 2000 Feb;87(2):236-42 [10671934.001]
  • [Cites] Oncology. 2003;65(2):113-7 [12931016.001]
  • [Cites] Arch Surg. 2000 Sep;135(9):1070-4; discussion 1074-5 [10982512.001]
  • [Cites] Clin Radiol. 2003 Mar;58(3):215-21 [12639527.001]
  • (PMID = 19562467.001).
  • [ISSN] 1436-3291
  • [Journal-full-title] Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  • [ISO-abbreviation] Gastric Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


79. Fry LC, Mönkemüller K, Malfertheiner P: Prevention of gastric cancer: a challenging but feasible task. Acta Gastroenterol Latinoam; 2007 Jun;37(2):110-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevention of gastric cancer: a challenging but feasible task.
  • Despite its declining incidence gastric cancer still ranks as the second most common malignancy of the digestive tract, accounting for 10% of cancer deaths worldwide.
  • At the time of the diagnosis less than 15% of the patients are in the stage of early cancer, the only stage in which a definite cure of gastric cancer is possible.
  • Therefore the challenges are either early detection or even better prevention of gastric cancer. H. pylori has become recognized as the major risk factor for gastric adenocarcinoma.
  • Epidemiological, biological, histomorphologic, molecular-genetic, epidemiological evidence and more recently few clinical trails have shown that H. pylori eradication has the potential to prevent the development of gastric cancer.
  • Currently H. pylori eradication is an indication for the prevention of gastric cancer in patients and groups of individuals with strongly increased risk, but further investigations are still required before an implementation of a general and global policy to eradicate H. pylori for the prevention of gastric cancer can be instituted.
  • At present time, the main challenge remains to find out at what point mucosal abnormalities are no longer reversible and gastric cancer development cannot be prevented despite H. pylori eradication.
  • [MeSH-major] Adenocarcinoma / prevention & control. Helicobacter Infections / complications. Helicobacter pylori. Stomach Neoplasms / prevention & control

  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17684942.001).
  • [ISSN] 0300-9033
  • [Journal-full-title] Acta gastroenterologica Latinoamericana
  • [ISO-abbreviation] Acta Gastroenterol. Latinoam.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Argentina
  • [Number-of-references] 49
  •  go-up   go-down


80. Siedlar M, Szaflarska A, Szczepanik A, Ruggiero I, Frankenberger M, Szatanek R, Czupryna A, Popiela T, Zembala M: Depressed tumor necrosis factor alpha and interleukin-12p40 production by peripheral blood mononuclear cells of gastric cancer patients: association with IL-1R-associated kinase-1 protein expression and disease stage. Int J Cancer; 2005 Mar 10;114(1):144-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Depressed tumor necrosis factor alpha and interleukin-12p40 production by peripheral blood mononuclear cells of gastric cancer patients: association with IL-1R-associated kinase-1 protein expression and disease stage.
  • Our study investigated the ability of peripheral blood mononuclear cells (PBMCs) isolated from patients with different clinical stages of gastric cancer to produce proinflammatory (tumor necrosis factor alpha [TNFalpha], interleukin 12p40 [IL-12p40] and interleukin 6 [IL-6]) and antiinflammatory (interleukin-10 [IL-10]) cytokines after stimulation with lipopolysaccharide (LPS) or tumor cells, and its correlation with IL-1R-associated kinase-1 (IRAK-1) protein expression.
  • The data showed that TNF production by tumor cell-stimulated PBMCs obtained from patients with advanced gastric cancer was significantly depressed in comparison to the control group.
  • These findings may suggest that in advanced gastric cancer (at least in some cancer patients) diminished IRAK-1 protein expression may be a novel mechanism responsible for or facilitating downregulation of innate immune response to tumor cells.
  • [MeSH-minor] Adenocarcinoma / metabolism. Antigens, CD14 / metabolism. Case-Control Studies. Cell Line, Tumor. Down-Regulation. Gene Expression Regulation, Neoplastic. Humans. Interleukin-1 Receptor-Associated Kinases. Interleukin-10 / metabolism. Interleukin-12 Subunit p40. Interleukin-6 / metabolism. Lipopolysaccharides. Neoplasm Staging. Pancreatic Neoplasms / metabolism. Receptors, IgG / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15523691.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD14; 0 / Interleukin-12 Subunit p40; 0 / Interleukin-6; 0 / Lipopolysaccharides; 0 / Protein Subunits; 0 / Receptors, IgG; 0 / Tumor Necrosis Factor-alpha; 130068-27-8 / Interleukin-10; 187348-17-0 / Interleukin-12; EC 2.7.- / Protein Kinases; EC 2.7.11.1 / Interleukin-1 Receptor-Associated Kinases
  •  go-up   go-down


81. Migita K, Watanabe A, Sakamoto C, Nakamura T, Ohyama T, Ishikawa H, Yamamoto K: [A case of multiple bone metastases from gastric cancer treated with combination chemotherapy of S-1 and CDDP]. Gan To Kagaku Ryoho; 2007 Jun;34(6):929-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of multiple bone metastases from gastric cancer treated with combination chemotherapy of S-1 and CDDP].
  • We report a case of multiple bone metastases from gastric cancer treated with combination chemotherapy of S-1 and CDDP.
  • A 54-year-old man underwent distal gastrectomy for gastric cancer (Stage II) in March 2003.
  • Combination chemotherapy of S-1 and CDDP is considered effective treatment for prolonging survival in cases of gastric cancer with bone metastases.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / drug therapy. Bone Neoplasms / secondary. Stomach Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17565259.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


82. Kojima T, Yoshikawa K, Saga S, Yamada T, Kure S, Matsui T, Uemura T, Fujimitsu Y, Sakakibara M, Kodera Y, Kojima H: Detection of elevated proteins in peritoneal dissemination of gastric cancer by analyzing mass spectra data of serum proteins. J Surg Res; 2009 Jul;155(1):13-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of elevated proteins in peritoneal dissemination of gastric cancer by analyzing mass spectra data of serum proteins.
  • In the current study, a similar approach was employed to analyze the serum of patients with various stages of gastric cancer.
  • METHODS: Control serum specimens from patients with gastritis (n = 19) and those with gastric cancer (Stage I: n = 6, Stage II or III: n = 6, Stage IV: n = 6, total: n = 18) were collected and analyzed by the Protein Chip biomarker system (Bio-Rad, Japan), a platform for SELDI-TOF-MS, and protein profiles were obtained and compared.
  • RESULTS: nine proteins were significantly over-expressed (P < 0.05, Student t-test) in patients with gastric cancer compared to patients with gastritis.
  • Employing one data mining method, CART (classification and regression trees), gastric cancer patients with peritoneal dissemination were successfully separated from those who had no peritoneal seeding.
  • CONCLUSION: A validation study with a larger number of samples is mandatory; however, the detected peaks here might be candidates for biomarkers of peritoneal dissemination and/or gastric cancer.
  • [MeSH-major] Adenocarcinoma / blood. Peritoneal Neoplasms / blood. Protein Array Analysis. Stomach Neoplasms / blood

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19394641.001).
  • [ISSN] 1095-8673
  • [Journal-full-title] The Journal of surgical research
  • [ISO-abbreviation] J. Surg. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


83. Chou NH, Chen HC, Chou NS, Hsu PI, Tseng HH: Expression of altered retinoblastoma protein inversely correlates with tumor invasion in gastric carcinoma. World J Gastroenterol; 2006 Nov 28;12(44):7188-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of altered retinoblastoma protein inversely correlates with tumor invasion in gastric carcinoma.
  • AIM: To investigate the clinical and pathological significance of altered retinoblastoma (Rb) encoding protein (pRb) in gastric carcinoma.
  • METHODS: Expression of altered pRb was analyzed in 91 patients with gastric adenocarcinoma by immunohistochemistry.
  • RESULTS: Sixty-five percent (59/91) of the tumors were positively stained and the staining in tumor nuclei of gastric carcinoma ranged 0%-90%.
  • Moreover, strong expression of altered pRb was found in 35% (6/17), 24% (5/21), 17% (8/46) and 0% (0/7) of T1, T2, T3 and T4 gastric carcinomas, respectively.
  • In terms of prognostic significance, univariate analysis showed that poor differentiation [41 (66.1%) vs 34 (42.5%) P = 0.051], advanced tumor stage (P < 0.001) and weakly altered pRb expression [17 (80.5%) vs 58 (49.6%) P=0.044] were associated with worse prognosis in these patients.
  • However, multivariate analysis revealed that advanced tumor stage was the only independent poor prognostic factor (P < 0.001).
  • CONCLUSION: the mutation of Rb gene is frequent in gastric carcinoma.
  • The expression of altered pRb inversely correlates with tumor invasion and is not an independent prognostic marker in gastric adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Retinoblastoma Protein / metabolism. Stomach Neoplasms / pathology

  • Genetic Alliance. consumer health - Retinoblastoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 1990 Oct;87(19):7762-6 [2217208.001]
  • [Cites] J Clin Invest. 1990 Apr;85(4):988-93 [2180983.001]
  • [Cites] Science. 1991 Nov 22;254(5035):1138-46 [1659741.001]
  • [Cites] Oncogene. 1991 Dec;6(12):2305-9 [1766677.001]
  • [Cites] Oncogene. 1992 Jan;7(1):101-8 [1741157.001]
  • [Cites] J Natl Cancer Inst. 1992 Aug 19;84(16):1251-6 [1640484.001]
  • [Cites] Int J Cancer. 1993 Mar 12;53(5):781-4 [8449603.001]
  • [Cites] J Natl Cancer Inst. 1994 May 4;86(9):695-9 [8158700.001]
  • [Cites] Int J Cancer. 1994 Jul 15;58(2):161-7 [8026875.001]
  • [Cites] Br J Cancer. 1994 Nov;70(5):1018-24 [7947078.001]
  • [Cites] Br J Cancer. 1994 Dec;70(6):1252-7 [7526887.001]
  • [Cites] Am J Pathol. 1995 Sep;147(3):545-60 [7677168.001]
  • [Cites] Int J Cancer. 1996 Feb 8;65(4):442-5 [8621224.001]
  • [Cites] Br J Cancer. 1997;75(1):87-93 [9000603.001]
  • [Cites] J Clin Oncol. 1997 Nov;15(11):3301-12 [9363859.001]
  • [Cites] Int J Cancer. 1999 Dec 22;84(6):604-8 [10567906.001]
  • [Cites] Int J Cancer. 1999 Dec 22;84(6):618-22 [10567909.001]
  • [Cites] Nature. 1986 Oct 16-22;323(6089):643-6 [2877398.001]
  • [Cites] Science. 1987 Mar 13;235(4794):1394-9 [3823889.001]
  • [Cites] Science. 1987 Jun 26;236(4809):1657-61 [2885916.001]
  • [Cites] Oncogene. 1989 Jun;4(6):725-9 [2543943.001]
  • [Cites] Oncogene. 1989 Jul;4(7):839-43 [2755701.001]
  • [Cites] Oncogene. 1991 Aug;6(8):1343-6 [1886710.001]
  • (PMID = 17131485.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Retinoblastoma Protein
  • [Other-IDs] NLM/ PMC4087784
  •  go-up   go-down


84. Mizukami Y, Kono K, Kawaguchi Y, Akaike H, Kamimura K, Sugai H, Fujii H: Localisation pattern of Foxp3+ regulatory T cells is associated with clinical behaviour in gastric cancer. Br J Cancer; 2008 Jan 15;98(1):148-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Localisation pattern of Foxp3+ regulatory T cells is associated with clinical behaviour in gastric cancer.
  • In the present study, we investigated the prevalence and localisation pattern of Foxp3+ cells in gastric cancer (n=80) by immunohistochemistry, in relation to the clinical outcome of gastric cancer patients.
  • As a result, although the populations of Foxp3+ cells in stage IV were significantly larger than those in stage I (P<0.05), there was no significant difference in survival between the patients with high and low population levels of Foxp3+ cells.
  • [MeSH-minor] Adenocarcinoma, Follicular / immunology. Adenocarcinoma, Follicular / metabolism. Adenocarcinoma, Follicular / pathology. Female. Humans. Immunoenzyme Techniques / methods. Intestinal Neoplasms / immunology. Intestinal Neoplasms / metabolism. Intestinal Neoplasms / pathology. Lymphatic Metastasis. Lymphocytes, Tumor-Infiltrating / metabolism. Male. Middle Aged. Prognosis. Survival Rate

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2005 Dec 1;11(23):8326-31 [16322292.001]
  • [Cites] J Immunol. 2006 Feb 1;176(3):1582-7 [16424187.001]
  • [Cites] Clin Cancer Res. 2006 Jan 15;12(2):465-72 [16428488.001]
  • [Cites] J Exp Med. 2001 Jun 4;193(11):1285-94 [11390435.001]
  • [Cites] J Exp Med. 2001 Jun 4;193(11):1303-10 [11390437.001]
  • [Cites] Cancer Res. 2001 Jun 15;61(12):4766-72 [11406550.001]
  • [Cites] Blood. 2001 Nov 1;98(9):2736-44 [11675346.001]
  • [Cites] J Exp Med. 2002 Jul 15;196(2):247-53 [12119349.001]
  • [Cites] J Immunol. 2002 Sep 1;169(5):2756-61 [12193750.001]
  • [Cites] Clin Cancer Res. 2003 Oct 1;9(12):4404-8 [14555512.001]
  • [Cites] J Immunol. 2004 Apr 15;172(8):4676-80 [15067041.001]
  • [Cites] J Immunol. 2004 May 1;172(9):5213-21 [15100259.001]
  • [Cites] Microbes Infect. 2004 Jul;6(8):745-51 [15207821.001]
  • [Cites] Nat Med. 2004 Sep;10(9):942-9 [15322536.001]
  • [Cites] Int Immunol. 2004 Nov;16(11):1643-56 [15466453.001]
  • [Cites] J Immunol. 1995 Aug 1;155(3):1151-64 [7636184.001]
  • [Cites] Infect Immun. 2005 Jan;73(1):523-31 [15618192.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2457-64 [15781662.001]
  • [Cites] Immunity. 2005 Mar;22(3):329-41 [15780990.001]
  • [Cites] Clin Immunol. 2005 Apr;115(1):3-9 [15870014.001]
  • [Cites] Clin Exp Immunol. 2005 Sep;141(3):549-57 [16045746.001]
  • [Cites] Immunology. 2006 Mar;117(3):289-300 [16476048.001]
  • [Cites] J Immunol. 2006 Apr 1;176(7):4484-91 [16547287.001]
  • [Cites] Dig Dis Sci. 2006 Apr;51(4):677-86 [16614988.001]
  • [Cites] Cancer Immunol Immunother. 2006 Sep;55(9):1064-71 [16328385.001]
  • [Cites] Blood. 2006 Aug 1;108(3):804-11 [16861339.001]
  • [Cites] Immunol Rev. 2006 Aug;212:8-27 [16903903.001]
  • [Cites] Ann Surg Oncol. 2006 Sep;13(9):1252-8 [16952047.001]
  • [Cites] Clin Cancer Res. 2006 Sep 15;12(18):5423-34 [17000676.001]
  • [Cites] Clin Immunol. 2006 Dec;121(3):358-68 [16934529.001]
  • [Cites] Cancer. 2006 Dec 15;107(12):2866-72 [17099880.001]
  • [Cites] Clin Immunol. 2007 Apr;123(1):18-29 [17185041.001]
  • [Cites] J Immunol. 2007 Apr 1;178(7):4089-96 [17371963.001]
  • [Cites] Int Immunol. 2007 Apr;19(4):345-54 [17329235.001]
  • [Cites] Clin Cancer Res. 2007 Apr 1;13(7):2075-81 [17404089.001]
  • (PMID = 18087278.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / FOXP3 protein, human; 0 / Forkhead Transcription Factors
  • [Other-IDs] NLM/ PMC2359685
  •  go-up   go-down


85. Koide A, Maruyama M, Hasegawa K, Miyawaki Y, Tamura N, Ohbu M, Maruyama S, Takashima I, Ebuchi M: [An effective weekly paclitaxel administration for gastric cancer with malignant ascites--a case report]. Gan To Kagaku Ryoho; 2005 Oct;32(11):1752-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [An effective weekly paclitaxel administration for gastric cancer with malignant ascites--a case report].
  • A 71 year-old woman underwent total gastrectomy for advanced gastric cancer of p stage IV (pathological findings: por1 type 3 pT3, pN3 (12p: 1/1, 16b1 int: 3/3, 16b1 lat: 2/2), P1, CY1, H0) in March 2002.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents, Phytogenic / administration & dosage. Ascites / drug therapy. Paclitaxel / administration & dosage. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16315930.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


86. Lazăr D, Tăban S, Sporea I, Dema A, Cornianu M, Lazăr E, Goldiş A, Vernic C: Ki-67 expression in gastric cancer. Results from a prospective study with long-term follow-up. Rom J Morphol Embryol; 2010;51(4):655-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ki-67 expression in gastric cancer. Results from a prospective study with long-term follow-up.
  • AIM: The analysis of immunohistochemical expression of the Ki-67 antigen using the monoclonal antibody MIB1 in 61 patients with gastric cancer, the correlation with clinicopathological factors and the prognosis of the patients.
  • RESULTS: In the gastric carcinomas, we remarked various Ki-67 scores.
  • For a proper grouping of the results, we classified gastric carcinomas into two categories: carcinomas with high MI Ki-67 (≥45%) and carcinomas with low MI Ki-67 (≤45%).
  • The histological forms associated to high Ki-67 values are represented by the anaplastic carcinoma (100% of cases) and papillary adenocarcinoma (60% of cases).We observed a close correlation between the degree of tumor differentiation and the Ki-67 score (p<0.001).
  • The results of our study do not reveal any correlation between the Lauren's Classification of gastric carcinomas, the lymphovascular invasion, the depth of tumor invasion, the TNM stage and the Ki-67 score (p>0.05).

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21103622.001).
  • [ISSN] 1220-0522
  • [Journal-full-title] Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
  • [ISO-abbreviation] Rom J Morphol Embryol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Ki-67 Antigen
  •  go-up   go-down


87. Oshiro Y, Moon Y, Yamamoto Y, Aita K: [A resected case of stage IV gastric cancer successfully treated with TS-1/CDDP as neoadjuvant chemotherapy]. Gan To Kagaku Ryoho; 2006 May;33(5):667-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A resected case of stage IV gastric cancer successfully treated with TS-1/CDDP as neoadjuvant chemotherapy].
  • A resected case of gastric cancer is described.
  • The patient was a 60-year-old woman who presented a type 3 gastric tumor complicated by invasion of the head of the pancreas and liver.
  • TS-1/CDDP therapy is useful for advanced gastric cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / surgery. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Gastrectomy. Stomach Neoplasms / drug therapy. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16685169.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


88. Wang GQ, Wei WQ, Zhang JH: [Natural progression of early stage adenocarcinoma of gastric cardia: a report of seventeen cases]. Ai Zheng; 2007 Nov;26(11):1153-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Natural progression of early stage adenocarcinoma of gastric cardia: a report of seventeen cases].
  • BACKGROUND & OBJECTIVE: The survival time of untreated advanced gastric cardiac adenocarcinoma patients is about 8-9 months.
  • This study was to observe the natural progression of untreated early stage gastric cardiac adenocarcinoma.
  • METHODS: In 1987, at a high risk area of esophageal cancer, 851 patients with a previous cytologic diagnosis of esophageal dysplasia were re-examined by endoscopy, and 43 of them were diagnosed histologically as gastric cardiac adenocarcinoma.
  • Of the 43 patients, 31 had early stage tumors, 12 had advanced tumors.
  • The 17 early stage patients who refused treatment were followed up for 14 years till death.
  • RESULTS: Of the 17 untreated patients, 12 were died of gastric cardiac adenocarcinoma, 5 were died of non-cancer diseases; 13 had survived for over 5 years.
  • CONCLUSIONS: The progression of early stage cardiac cancer to advanced cancer is a very slow and long process, which is very helpful for early diagnosis and choice of therapeutic timing.
  • The therapeutic effect on early stage cardiac cancer should be assessed with consideration of the natural history of this disease.
  • [MeSH-major] Adenocarcinoma / pathology. Cardia / pathology. Disease Progression. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17991310.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


89. Crane SJ, Locke GR 3rd, Harmsen WS, Zinsmeister AR, Romero Y, Talley NJ: Survival trends in patients with gastric and esophageal adenocarcinomas: a population-based study. Mayo Clin Proc; 2008 Oct;83(10):1087-94
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival trends in patients with gastric and esophageal adenocarcinomas: a population-based study.
  • OBJECTIVE: To use a population-based approach to describe survival trends in patients diagnosed as having gastric or esophageal adenocarcinoma.
  • All residents of Olmsted County who were diagnosed as having gastric or esophageal adenocarcinoma from January 1, 1971, through December 31, 2000, were included in the study.
  • RESULTS: From 1971 through 2000, median survival for patients with gastric adenocarcinoma (n=121) decreased from 5.5 months to 3.2 months, whereas median survival for patients with esophageal adenocarcinoma (n=65) increased from 8.5 months to 11.7 months.
  • Decade of diagnosis was not significantly associated with patient survival for either gastric or esophageal adenocarcinoma (P>.05).
  • There was no significant shift in stage of disease at diagnosis during the 30-year period for either gastric or esophageal adenocarcinoma (P>.05).
  • CONCLUSION: No significant change has occurred in the survival rates of this patient population with gastric or esophageal adenocarcinoma, which is representative of the US white population.
  • [MeSH-major] Adenocarcinoma / mortality. Esophageal Neoplasms / mortality. Population Surveillance. Stomach Neoplasms / mortality

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Gastroenterol. 2004 Apr;99(4):582-8 [15089886.001]
  • [Cites] Am J Gastroenterol. 2004 Mar;99(3):419-24 [15056079.001]
  • [Cites] Ann Surg Oncol. 2004 Jul;11(7):641-3 [15197008.001]
  • [Cites] J Chronic Dis. 1987;40(5):373-83 [3558716.001]
  • [Cites] Gan To Kagaku Ryoho. 1988 Apr;15(4 Pt 2-1):929-36 [3389836.001]
  • [Cites] JAMA. 1991 Mar 13;265(10):1287-9 [1995976.001]
  • [Cites] J Clin Epidemiol. 1992 Jun;45(6):613-9 [1607900.001]
  • [Cites] Gastroenterology. 1993 Feb;104(2):510-3 [8425693.001]
  • [Cites] Gastroenterology. 1995 Dec;109(6):1750-6 [7498638.001]
  • [Cites] Mayo Clin Proc. 1996 Mar;71(3):266-74 [8594285.001]
  • [Cites] N Engl J Med. 1996 Aug 15;335(7):462-7 [8672151.001]
  • [Cites] Eur J Cancer. 1998 Dec;34(14 Spec No):2167-75 [10070283.001]
  • [Cites] Eur J Cardiothorac Surg. 1999 May;15(5):626-30 [10386408.001]
  • [Cites] Ann Surg. 1999 Aug;230(2):162-9 [10450729.001]
  • [Cites] J Clin Oncol. 2005 Jul 1;23(19):4330-7 [15781882.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2005 Oct;17(10):1029-35 [16148547.001]
  • [Cites] Scand J Surg. 2005;94(3):191-6 [16259166.001]
  • [Cites] J Surg Oncol. 2005 Dec 1;92(3):239-45 [16299784.001]
  • [Cites] Eur J Cancer. 2006 Jan;42(2):228-33 [16337786.001]
  • [Cites] N Engl J Med. 2006 Jul 6;355(1):11-20 [16822992.001]
  • [Cites] Dis Esophagus. 2006;19(6):448-53 [17069587.001]
  • [Cites] Aliment Pharmacol Ther. 2007 Feb 15;25(4):447-53 [17270000.001]
  • [Cites] Ann Surg Oncol. 2007 Oct;14(10):2687-90 [17653804.001]
  • [Cites] Surg Oncol Clin N Am. 2002 Apr;11(2):235-56 [12424848.001]
  • [Cites] Scand J Gastroenterol. 2002 Dec;37(12):1359-65 [12523583.001]
  • [Cites] Aliment Pharmacol Ther. 2003 Mar 1;17(5):655-64 [12641514.001]
  • [Cites] Am J Surg. 2003 Jun;185(6):538-43 [12781882.001]
  • [Cites] Br J Cancer. 2004 Jan 12;90(1):70-5 [14710209.001]
  • [Cites] Gut. 2004 Jul;53(7):925-30 [15194636.001]
  • (PMID = 18828967.001).
  • [ISSN] 1942-5546
  • [Journal-full-title] Mayo Clinic proceedings
  • [ISO-abbreviation] Mayo Clin. Proc.
  • [Language] eng
  • [Grant] United States / NIAMS NIH HHS / AR / R01 AR030582; United States / NIAMS NIH HHS / AR / R01 AR030582-42
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS73710; NLM/ PMC2597541
  •  go-up   go-down


90. Greengauz-Roberts O, Stöppler H, Nomura S, Yamaguchi H, Goldenring JR, Podolsky RH, Lee JR, Dynan WS: Saturation labeling with cysteine-reactive cyanine fluorescent dyes provides increased sensitivity for protein expression profiling of laser-microdissected clinical specimens. Proteomics; 2005 May;5(7):1746-57
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • LCM has particular value for analysis of early stage tumors, which are often small and intermixed with non-tumor tissue.
  • This was true both with extracts prepared from human papillomavirus E6 and E7-transduced human keratinocytes, a model for early-stage cervical cancer, and with LCM samples.
  • In an experiment comparing LCM clinical samples of gastric adenocarcinoma versus precancerous, spasmolytic polypeptide expressing metaplasia (SPEM) from the same patient, cysteine labeling allowed the identification of more than 1000 discrete protein spots in samples containing 5000 cells.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYSTEINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15761955.001).
  • [ISSN] 1615-9853
  • [Journal-full-title] Proteomics
  • [ISO-abbreviation] Proteomics
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA095941-01; United States / NCI NIH HHS / CA / R21 CA095941; United States / NCI NIH HHS / CA / 1 R21 CA 95941; United States / NCI NIH HHS / CA / R21 CA095941-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Carbocyanines; 0 / Fluorescent Dyes; K848JZ4886 / Cysteine
  •  go-up   go-down


91. Shioiri T, Inoue S, Kusano T, Umekita N, Kitamura M, Warabi M, Kawahara Y: [A case of advanced gastric cancer responding to neoadjuvant TS-1/CDDP chemotherapy]. Gan To Kagaku Ryoho; 2005 Sep;32(9):1327-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of advanced gastric cancer responding to neoadjuvant TS-1/CDDP chemotherapy].
  • Upper gastrointestinal endoscopy and X-ray examination of the stomach revealed type 3 cancer in the gastric antrum, extending to the middle body.
  • It was about 9 cm in diameter, and the biopsy specimen revealed moderately differentiated tubular adenocarcinoma.
  • For this gastric cancer, clinical Stage IIIA (cT3N1HOPOMO), neoadjuvant chemotherapy with TS-1/CDDP was planned.
  • An upper GI series revealed 33% reduction of gastric cancer, and laboratory studies CEA and CA 19-9 showed normal values.
  • TS-1/CDDP chemotherapy produced a high response in this case, and it may be useful as neoadjuvant chemotherapy for advanced gastric cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymph Nodes / pathology. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16184934.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


92. Tajima Y, Yamazaki K, Makino R, Nishino N, Masuda Y, Aoki S, Kato M, Morohara K, Kusano M: Differences in the histological findings, phenotypic marker expressions and genetic alterations between adenocarcinoma of the gastric cardia and distal stomach. Br J Cancer; 2007 Feb 26;96(4):631-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differences in the histological findings, phenotypic marker expressions and genetic alterations between adenocarcinoma of the gastric cardia and distal stomach.
  • Adenocarcinoma of the gastric cardia (C-Ca) is possibly a specific subtype of gastric carcinoma.
  • The purpose of this study was to clarify the differences in the clinicopathological characteristics between C-Ca and adenocarcinoma of the distal stomach (D-Ca), and also the differences in the expressions of gastric and intestinal phenotypic markers and genetic alterations between the two.
  • The phenotypic marker expressions examined were those of human gastric mucin (HGM), MUC6, MUC2 and CD10.
  • Oesophageal invasion by the tumour beyond the oesophago-gastric junction (OGJ) was found in 56.9% of cases with C-Ca; LVI in the area of oesophageal invasion was demonstrated in 61% of these cases.
  • The incidence of undifferentiated-type tumours was significantly higher in cases with advanced-stage C-Ca than in those with early-stage C-Ca (5 vs 36.5%, P=0.0076).
  • A significantly greater frequency of HGM expression in early-stage C-Ca and significantly lower frequency of MUC2 expression in advanced-stage C-Ca was observed as compared with the corresponding values in cases of D-Ca (78.9 vs 52.2%, P=0.0402 and 51.5 vs 84.6%, P=0.0247, respectively).
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Biomarkers, Tumor / genetics. DNA, Neoplasm / genetics. Gene Expression Regulation, Neoplastic / genetics. Stomach Neoplasms / genetics. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Surg. 1994 Jun;129(6):609-14 [8204035.001]
  • [Cites] Gastroenterology. 1993 Feb;104(2):510-3 [8425693.001]
  • [Cites] Gastroenterology. 1995 Sep;109(3):723-34 [7657100.001]
  • [Cites] Gastroenterology. 1995 Sep;109(3):999-1001 [7657131.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):2015-21 [9164213.001]
  • [Cites] Int J Cancer. 1998 Mar 2;75(5):767-73 [9495247.001]
  • [Cites] Int J Cancer. 1999 Feb 19;84(1):28-32 [9988228.001]
  • [Cites] Cancer Res. 1999 Mar 1;59(5):1003-7 [10070955.001]
  • [Cites] Pathol Int. 1999 Jan;49(1):55-61 [10227725.001]
  • [Cites] Acta Pathol Microbiol Scand. 1965;64:31-49 [14320675.001]
  • [Cites] J Clin Oncol. 2005 Feb 1;23(4):874-9 [15681533.001]
  • [Cites] J Cancer Res Clin Oncol. 2006 Jun;132(6):363-75 [16447040.001]
  • [Cites] World J Gastroenterol. 2006 Jun 28;12(24):3803-9 [16804962.001]
  • [Cites] J Natl Cancer Inst. 2006 Oct 18;98(20):1445-52 [17047193.001]
  • [Cites] Mutat Res. 2000 Jul 20;452(1):83-90 [10894894.001]
  • [Cites] Mod Pathol. 2000 Oct;13(10):1055-9 [11048797.001]
  • [Cites] Oncology. 2001;61(1):1-9 [11474241.001]
  • [Cites] Genes Chromosomes Cancer. 2001 Sep;32(1):50-8 [11477661.001]
  • [Cites] Gastroenterology. 2001 Sep;121(3):592-8 [11522743.001]
  • [Cites] Oncology. 2001;61(3):212-20 [11574777.001]
  • [Cites] Cancer. 2001 Oct 15;92(8):2228-33 [11596042.001]
  • [Cites] Int J Cancer. 2002 Feb 10;97(5):562-6 [11807778.001]
  • [Cites] Int J Cancer. 2002 May 20;99(3):336-43 [11992401.001]
  • [Cites] Histopathology. 2002 Jul;41(1):56-64 [12121238.001]
  • [Cites] Am J Pathol. 2002 Aug;161(2):611-8 [12163385.001]
  • [Cites] Gastric Cancer. 2004;7(1):46-53 [15052440.001]
  • [Cites] Clin Cancer Res. 2004 May 1;10(9):3082-90 [15131047.001]
  • [Cites] Br J Cancer. 2004 Oct 4;91(7):1342-8 [15354218.001]
  • [Cites] Gan. 1968 Jun;59(3):251-8 [5726267.001]
  • [Cites] J Histochem Cytochem. 1981 Apr;29(4):577-80 [6166661.001]
  • [Cites] Gastroenterology. 1984 Mar;86(3):461-7 [6693012.001]
  • [Cites] Clin Exp Immunol. 1984 Feb;55(2):319-32 [6365376.001]
  • [Cites] J Clin Pathol. 1985 Sep;38(9):1002-6 [2931454.001]
  • [Cites] Hum Pathol. 1986 May;17(5):482-7 [3699811.001]
  • [Cites] Cancer. 1987 Sep 1;60(5):1094-8 [3607726.001]
  • [Cites] Int J Cancer. 1988 Feb 15;41(2):184-97 [3338870.001]
  • [Cites] Hum Pathol. 1988 Aug;19(8):942-8 [3402983.001]
  • [Cites] Acta Pathol Jpn. 1990 Jul;40(7):494-504 [2220396.001]
  • [Cites] CA Cancer J Clin. 1991 Jan-Feb;41(1):19-36 [1984806.001]
  • [Cites] JAMA. 1991 Mar 13;265(10):1287-9 [1995976.001]
  • [Cites] Hum Pathol. 1991 Nov;22(11):1158-61 [1743701.001]
  • [Cites] Int J Cancer. 1992 Jan 21;50(2):202-7 [1730514.001]
  • [Cites] Cancer. 1992 Mar 1;69(5):1088-93 [1739905.001]
  • [Cites] J Am Coll Surg. 1995 May;180(5):577-82 [7749534.001]
  • (PMID = 17262083.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm
  • [Other-IDs] NLM/ PMC2360051
  •  go-up   go-down


93. Zhong XY, Zhang LH, Jia SQ, Shi T, Niu ZJ, Du H, Zhang GG, Hu Y, Lu AP, Li JY, Ji JF: Positive association of up-regulated Cripto-1 and down-regulated E-cadherin with tumour progression and poor prognosis in gastric cancer. Histopathology; 2008 Apr;52(5):560-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Positive association of up-regulated Cripto-1 and down-regulated E-cadherin with tumour progression and poor prognosis in gastric cancer.
  • The aim was to investigate the expression of Cripto-1 and E-cadherin in relation to clinicopathological features and patient prognosis of gastric cancer.
  • METHODS AND RESULTS: The expression of Cripto-1 and E-cadherin was studied by immunohistochemistry in 118 gastric cancer cases.
  • Either CR+ or E-cad- was associated with lymph node metastasis, liver metastasis and late TNM stage (P < 0.05).
  • Multivariate analysis revealed that CR+/E-cad- was an independent prognostic factor in gastric cancer.
  • CONCLUSIONS: Combined analysis of Cripto-1 and E-cadherin has significant value in evaluating the metastatic potential of gastric cancer and predicting patient prognosis.
  • [MeSH-major] Adenocarcinoma / metabolism. Cadherins / metabolism. Epidermal Growth Factor / metabolism. Membrane Glycoproteins / metabolism. Neoplasm Proteins / metabolism. Stomach Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18312357.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cadherins; 0 / GPI-Linked Proteins; 0 / Intercellular Signaling Peptides and Proteins; 0 / Membrane Glycoproteins; 0 / Neoplasm Proteins; 0 / TDGF1 protein, human; 62229-50-9 / Epidermal Growth Factor
  •  go-up   go-down


94. David S, Kan T, Cheng Y, Agarwal R, Jin Z, Mori Y: Aberrant silencing of the endocrine peptide gene tachykinin-1 in gastric cancer. Biochem Biophys Res Commun; 2009 Jan 16;378(3):605-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant silencing of the endocrine peptide gene tachykinin-1 in gastric cancer.
  • Tachykinin-1 (TAC1) is the precursor protein for neuroendocrine peptides, including substance P, and is centrally involved in gastric secretion, motility, mucosal immunity, and cell proliferation.
  • Here we report aberrant silencing of TAC1 in gastric cancer (GC) by promoter hypermethylation.
  • TAC1 methylation and mRNA expression in 47 primary GCs and 41 noncancerous gastric mucosae (NLs) were analyzed by utilizing real-time quantitative PCR-based assays.
  • There was no significant association between TAC1 methylation and age, gender, stage, histological differentiation, or the presence of Helicobacter pylori.
  • Further studies are indicated to elucidate the functional involvement of TAC1 in gastric carcinogenesis.
  • [MeSH-major] Adenocarcinoma / genetics. Cell Transformation, Neoplastic / genetics. Gene Expression Regulation, Neoplastic. Gene Silencing. Protein Precursors / genetics. Stomach Neoplasms / genetics. Tachykinins / genetics

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19046942.001).
  • [ISSN] 1090-2104
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protein Precursors; 0 / Tachykinins; 0 / protachykinin
  •  go-up   go-down


95. Papadakou M, Xydakis E, Bonios M, Makropoulou E, Boukis C, Kakavoulis T, Karaliotas C, Panagos G: Adjuvant chemotherapy with cisplatin, etoposide, fluorouracil and leucovorin for gastric carcinoma. J BUON; 2006 Jul-Sep;11(3):285-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant chemotherapy with cisplatin, etoposide, fluorouracil and leucovorin for gastric carcinoma.
  • CEFL) combination chemotherapy given as adjuvant treatment to patients with stage III gastric cancer.
  • PATIENTS AND METHODS: A total of 33 patients who had undergone curative resection for stage III gastric adenocarcinoma were enrolled in our adjuvant chemotherapy protocol to receive 6 cycles of CEFL starting within 8 weeks from surgery.
  • Patients with stage IIIA disease had longer RFS that those with stage IIIB (37 vs. 25 months, p>0.05).
  • Mean OS was 35 months (range 4 to 114+), while stage IIIA patients survived longer than IIIB ones (42 vs. 27 months, p>0.05).
  • CONCLUSION: CEFL regimen appears to be an effective adjuvant treatment for patients with stage III gastric carcinoma as it prolongs both RFS and OS.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17309151.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


96. Lee EJ, Park SM, Maeng L, Lee A, Kim KM: Composite glandular-endocrine cell carcinomas of the stomach: clinicopathologic and methylation study. APMIS; 2005 Sep;113(9):569-76
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All but one of the tumors arose in the antrum and two of them were at the early stage.
  • Mucin stains were positive in the adenocarcinoma areas while only the neuroendocrine markers were positive in neuroendocrine tumor components.
  • An additional six gastric large cell neuroendocrine carcinomas showed no methylation.
  • Our results suggest that hypermethylation of tumor suppressor genes is rare in gastric composite and neuroendocrine carcinomas, and prognosis of gastric composite carcinomas appears to be related to the histopathology of neuroendocrine components and tumor stage.
  • [MeSH-major] Adenocarcinoma / pathology. Neuroendocrine Tumors / pathology. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16218931.001).
  • [ISSN] 0903-4641
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  •  go-up   go-down


97. Strong VE, Song KY, Park CH, Jacks LM, Gonen M, Shah M, Coit DG, Brennan MF: Comparison of gastric cancer survival following R0 resection in the United States and Korea using an internationally validated nomogram. Ann Surg; 2010 Apr;251(4):640-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of gastric cancer survival following R0 resection in the United States and Korea using an internationally validated nomogram.
  • OBJECTIVE: To compare disease-specific survival (DSS) between the US and Korea following R0 resection for gastric carcinoma (GC).
  • Although clinicopathological presentations of GC are known to vary widely between Eastern and Western countries, including histology, tumor location, and stage at presentation, it remains unclear whether these factors account for differences in survival.
  • Korean patients had more early stage tumors (42% vs. 28% stage Ia, P < 0.0001) with a higher number of lymph nodes identified (97% vs. 79%, >or=15 lymph nodes, P < 0.0001).
  • CONCLUSIONS: This study demonstrates better survival for GC patients in Korea compared with the US as determined by multivariate analysis with a validated gastric cancer nomogram.
  • [MeSH-major] Adenocarcinoma / mortality. Gastrectomy. Nomograms. Stomach Neoplasms / mortality

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Surg. 2014 May;259(5):e78-9 [23673771.001]
  • (PMID = 20224369.001).
  • [ISSN] 1528-1140
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


98. De Vita F, Giuliani F, Orditura M, Maiello E, Galizia G, Di Martino N, Montemurro F, Cartenì G, Manzione L, Romito S, Gebbia V, Ciardiello F, Catalano G, Colucci G, Gruppo Oncologico Italia Meridionale: Adjuvant chemotherapy with epirubicin, leucovorin, 5-fluorouracil and etoposide regimen in resected gastric cancer patients: a randomized phase III trial by the Gruppo Oncologico Italia Meridionale (GOIM 9602 Study). Ann Oncol; 2007 Aug;18(8):1354-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant chemotherapy with epirubicin, leucovorin, 5-fluorouracil and etoposide regimen in resected gastric cancer patients: a randomized phase III trial by the Gruppo Oncologico Italia Meridionale (GOIM 9602 Study).
  • BACKGROUND: This randomized, multicenter, phase III trial evaluated the efficacy and safety of the combination of epirubicin, leucovorin, 5-fluorouracil and etoposide (ELFE regimen) as adjuvant therapy for radically resected gastric cancer patients.
  • PATIENTS AND METHODS: From June 1996 to June 2001, 228 stage IB-IIIB gastric cancer patients were enrolled.
  • CONCLUSIONS: In radically resected gastric cancer patients, adjuvant chemotherapy with ELFE regimen does not improve OS over surgery alone.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17525087.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; 6PLQ3CP4P3 / Etoposide; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


99. Song HS, Kim IH, Sohn SS, Kwon KY, Lee WS: Prognostic significance of immunohistochemical expression of p53 and retinoblastoma gene protein (pRB) in curatively resected gastric cancer. Korean J Intern Med; 2005 Mar;20(1):1-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of immunohistochemical expression of p53 and retinoblastoma gene protein (pRB) in curatively resected gastric cancer.
  • BACKGROUND: The aim of this study was to determine the prognostic significance of the expression of p53 and retinoblastoma (Rb) gene products in cases of curatively resected gastric adenocarcinoma, by immunohistochemical analysis.
  • METHODS: Between January 1996 and December 2001, 736 curatively resected gastric cancer patients underwent immunohistochemical staining for p53 or Rb proteins (pRb), and we retrospectively analyzed the correlation of our results with the clinical outcomes of these cases.
  • Multivariate Cox regression analysis indicated that tumor stage, tumor size, patient age and pRb expression were the significant prognostic factors with regard to overall survival, and tumor stage and age were both significant factors with regard to relapse-free survival.
  • CONCLUSION: Immunohistochemical staining of retinoblastoma gene products was an independent prognostic factor for the prediction of overall survival in curatively resected gastric cancer patients.
  • [MeSH-major] Adenocarcinoma / genetics. Retinoblastoma Protein / metabolism. Stomach Neoplasms / genetics. Tumor Suppressor Protein p53 / metabolism

  • Genetic Alliance. consumer health - Retinoblastoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hepatogastroenterology. 1997 Mar-Apr;44(14):604-9 [9164544.001]
  • [Cites] Hepatogastroenterology. 1997 Mar-Apr;44(14):546-53 [9164535.001]
  • [Cites] Hepatogastroenterology. 1997 May-Jun;44(15):826-37 [9222700.001]
  • [Cites] Int J Cancer. 1997 Aug 22;74(4):407-15 [9291430.001]
  • [Cites] Oncology. 1998 Nov-Dec;55(6):594-9 [9778629.001]
  • [Cites] Br J Cancer. 1999 Mar;79(7-8):1255-61 [10098768.001]
  • [Cites] Nature. 1986 Oct 16-22;323(6089):643-6 [2877398.001]
  • [Cites] Mol Cell Biol. 1988 Feb;8(2):531-9 [2832726.001]
  • [Cites] Oncogene. 1988 Mar;2(3):283-7 [3281095.001]
  • [Cites] Cell. 1989 Sep 22;58(6):1097-105 [2673543.001]
  • [Cites] Science. 1990 Aug 31;249(4972):1046-9 [2144363.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Mar 1;88(5):1958-62 [1705714.001]
  • [Cites] Cancer Res. 1991 May 15;51(10):2735-9 [1850661.001]
  • [Cites] Crit Rev Oncog. 1991;2(3):211-27 [1888791.001]
  • [Cites] Cancer Res. 1991 Dec 1;51(23 Pt 1):6304-11 [1933891.001]
  • [Cites] Cancer Metastasis Rev. 1992 Sep;11(2):95-103 [1394797.001]
  • [Cites] Br J Surg. 1993 Mar;80(3):325-8 [8472141.001]
  • [Cites] Blood. 1993 Jul 1;82(1):15-21 [8324219.001]
  • [Cites] Int J Cancer. 1993 Jul 9;54(5):759-64 [8392033.001]
  • [Cites] FASEB J. 1993 Jul;7(10):841-5 [8393817.001]
  • [Cites] Am J Surg Pathol. 1994 Dec;18(12):1247-53 [7977948.001]
  • [Cites] Cell. 1995 May 5;81(3):323-30 [7736585.001]
  • [Cites] Cancer. 1995 Sep 1;76(5):720-6 [8625172.001]
  • [Cites] Int J Cancer. 1996 Jun 21;69(3):200-4 [8682588.001]
  • [Cites] Gan To Kagaku Ryoho. 1996 Jun;23 Suppl 2:148-50 [8678558.001]
  • [Cites] Oncogene. 1996 Sep 19;13(6):1335-42 [8808708.001]
  • [Cites] Cancer. 1997 Jun 1;79(11):2067-72 [9179052.001]
  • (PMID = 15906946.001).
  • [ISSN] 1226-3303
  • [Journal-full-title] The Korean journal of internal medicine
  • [ISO-abbreviation] Korean J. Intern. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Retinoblastoma Protein; 0 / Tumor Suppressor Protein p53
  • [Other-IDs] NLM/ PMC3891404
  •  go-up   go-down


100. Koga T, Tokunaga E, Sumiyoshi Y, Oki E, Oda S, Takahashi I, Kakeji Y, Baba H, Maehara Y: Detection of circulating gastric cancer cells in peripheral blood using real time quantitative RT-PCR. Hepatogastroenterology; 2008 May-Jun;55(84):1131-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of circulating gastric cancer cells in peripheral blood using real time quantitative RT-PCR.
  • This study addresses the detection of circulating tumor cells in peripheral blood in patients with gastric cancer using Quantitative RT-PCR.
  • METHODOLOGY: Common mRNA targets for RT-PCR for detection of small numbers of cancer cells in gastric cancer are CK18, CK19, CK20, and CEA.
  • Ten milliliter of peripheral venous blood was taken from 14 healthy Japanese volunteers and 101 patients with gastric cancer.
  • The group of gastric cancer patients included 69 individuals with curative disease on preoperative diagnosis and 32 individuals with a non-curative operation or recurrence of the disease.
  • RESULTS: The number of CK19 and CK20 mRNA copies was significantly increased in patients with a non-curative operation or recurrence of gastric cancer (CK19; p=0.0087, CK20; p=0.0022) compared with healthy volunteers.
  • For CK19, there were 61 (88.4%) negative cases and 8 (11.6%) positive cases in 69 individuals with curative gastric cancer.
  • On postoperative day 14, there was a significant difference between positive and negative cases regarding tumor size, tumor stage, and lymph node metastasis for CK19, and tumor stage and lymph node metastasis for CK20.
  • CONCLUSIONS: Micrometastases of gastric cancer can be detected in circulating peripheral blood using quantitative real-time RT-PCR.
  • [MeSH-major] Adenocarcinoma / genetics. Biomarkers, Tumor / genetics. Carcinoembryonic Antigen / genetics. Keratin-18 / genetics. Keratin-19 / genetics. Neoplasm Recurrence, Local / genetics. Neoplastic Cells, Circulating / pathology. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction. Stomach Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18705345.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; 0 / KRT18 protein, human; 0 / KRT20 protein, human; 0 / Keratin-18; 0 / Keratin-19; 0 / Keratin-20; 0 / RNA, Messenger
  •  go-up   go-down






Advertisement